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ABSTRACT 
 
Estrogen withdrawal after the menopause leads to an increased rate of bone 
remodeling, excessive osteoclast activity and a greater fracture risk.  Hor-
mone replacement therapy (HRT) was prescribed as a treatment for post-
menopausal women to prevent bone loss; however, HRT is associated with 
an elevated incidence of cardiovascular disease, stroke and cancer.  These 
side effects led to an interest in naturally occurring compounds with estrogen-
ic action such as phytoestrogens (PEs), which are non-steroidal-plant derived 
compounds.  The aim of this study describes investigation of the protective 
effect of phytoestrogen molecules (Genistein, Daidzein, Resveratrol, 6-
Gingerol and Fucosterol) in the prevention of reactive oxygen species in-
duced by H2O2 cell death in MLOY4 osteocyte like cell line.  All compounds 
tested significantly (p<0.05) reduced osteocyte apoptosis and decreased re-
active oxygen species activity.  PEs have multiple effects on different bone 
cells, reducing osteoblast apoptosis and inhibiting RANKL inducing osteo-
clast formation.  The protective effect of Genistein, Daidzein and Resveratrol 
was not prevented by estrogen receptor inhibitor ICI 182780, suggesting a 
potential direct antioxidant effect.   Additionally, this study offers evidence for 
bone protection conferred by PEs through demonstrating their potent inhibito-
ry effect on cytokine release and activating antioxidant enzymes such as 
Catalase (CAT).  The antioxidant effect of PEs was thought to be due to their 
similar phenolic structure to estrogen; therefore Genistein and Daidzein were 
modified by masking their hydroxyl groups and tested for their protective ef-
fects on osteocyte apoptosis.  Not all modified compounds protected osteo-
cytes from oxidative stress induced by hydrogen peroxide (H2O2).  This study 
iv 
 
provides novel evidence that PEs have multiple effects on bone cell activity. 
Thus, PEs may not be the only treatment but possible supplementation of 
pharmacological or alternative to pharmacological treatment of post-
menopausal osteoporosis. 
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1. 1 Bone biology 
Bone is a rigid connective tissue whose function is to bear mechanical loads 
upon the body during movement.  Other functions of bone include maintain-
ing plasma calcium homeostasis, and supporting hematopoiesis within the 
bone marrow (Clarke 2008).  Recent studies suggest that in addition to its 
classic roles, bone can also be considered as an endocrine organ.  Evidence 
has been accumulating that FGF23 that is derived from bone cells and oste-
ocalcin, which is derived from osteoblast cells has important roles in regulat-
ing kidney function and glucose metabolism.  Osteocalcin has an endocrine 
action on pancreatic β-cells, stimulating proliferation and insulin production 
(Fukumoto and Martin, 2009).  Bone can be woven or lamellar.  Woven bone 
is immature bone, which is formed very rapidly during growth or fracture heal-
ing.  It is so called because its collagen fibers are loosely arranged in irregu-
lar arrays and therefore also called nonlamellar bone.  Woven bone contains 
more cells per unit area than lamellar bone (Hernandez et al., 2004).  In con-
trast, lamellar bone is mature bone, in which the collagen fibers are arranged 
in a lamellar structure (Hernandez et al., 2004, Ross and Pawlina 2006).  
Lamellar bone is mainly composed of cylindrical units called osteons or Ha-
versian systems, which consist of a central canal surrounded by concentric 
lamellae.  The central canal is called osteonal or Haversian canal and con-
tains blood vessels and nerves (Pawlina Ross and 2006).  Woven bone is 
often replaced by lamellar bone as growth continues (Bandyopadhyay-Ghosh 
2008).  Bone is categorized as being long, short, flat, or irregular according to 
its shape and function.  For instance, long bones such as the femur and ulna 
are tubular in structure and longer than they are wide, and are the major 
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weight-bearing bones of the body.  Short bones are small bones that act as 
shock absorbers and force distributors.  Flat bones protect internal organs 
and consequently contain broad surfaces for muscle attachment to bone.  
Irregular bones such as the vertebra and the skull are termed irregular be-
cause their shape determines their specific functions within the skeleton 
(Clarke 2008).  Skeletal bone is also categorized according to the proportion 
of trabecular and cortical bone, which are the two major types of bone tissue. 
Trabecular bone is a spongy like porous material and is composed of plates 
or rods of bone that are distributed within bone marrow.  The high porosity of 
the plates or rods, known as trabeculae, allows the bone to absorb and dis-
tribute mechanical energy when loaded.  Cortical bone is a dense material 
with approximately 15% porosity (Hamill 2009).  Due to its increased density, 
cortical bone is stiffer and is able to tolerate large tensile and compressive 
loads.  Approximately 80% of the skeleton is made of cortical bone which 
forms the outer protective shell of all bones, whereas the other 20% is tra-
becular bone.  Each type of bone has various ratios of trabecular and cortical 
bone, which in turn is correlated to each bone’s specific mechanical require-
ments.  For instance, vertebral bone is made of 25% cortical bone and 75% 
trabecular bone, and the femoral neck is 50% cortical and 50% trabecular 
bone (Clarke 2008).  Long bones are the primary weight-bearing bones of the 
skeleton and they are structured to transfer loads from the ends of the bone 
to the middle.  Thus, sections of long bone have different trabecular to corti-
cal bone ratios with age to fulfil their respective mechanical requirements. 
The three regions within a long bone are the epiphysis, metaphysis, and di-
aphysis (Fig.1.1).   
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Figure1.1: The basic anatomy of bone. showing the diaphysis (shaft of bones) and epiph-
ysis (ends of bones) with the periosteum membrane and medullary cavity highlighted 
(Umadevi  and Geethalakshmi 2011). 
 
 
The epiphysis is located on either end of a long bone and is covered with ar-
ticular cartilage to protect the bone from friction within an articulating joint.  
The epiphysis is composed mainly of trabecular bone with a thin cortical 
bone outer layer.  Beneath the epiphysis is the metaphysis.  The cone-
shaped metaphysis of long bone is composed of a cartilaginous core that al-
lows the bone to continuously grow via endochondral ossification during 
childhood.  Upon adulthood (18-25 years old) the cartilaginous region ossifies 
and fuses with the epiphysis and diaphysis, thereby stopping bone growth.  
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Like the epiphysis, the metaphysis is mostly composed of trabecular bone 
that is bordered by a thin outer layer of cortical bone.  The diaphysis is a long 
tubular shaft comprised of dense cortical bone, and is filled with bone mar-
row, when loaded, the wide trabecular ends of long bone allows for compres-
sive forces exerted from locomotion to be transferred to the stronger and 
stiffer cortical bone within the diaphysis (Turner 2006).  
The outer layer of bone is a well-vascularized connective tissue known as the 
periosteum.  The periosteum is a fibrous connective tissue sheath that sur-
rounds the outer cortical surface of bone, except at joints where bone is lined 
by articular cartilage, which contains blood vessels, nerve fibers, osteoblasts 
and osteoclasts.  The periosteum is tightly attached to the outer cortical sur-
face of bone by thick collagenous fibers, called Sharpeys’ fibers, which ex-
tend into underlying bone tissue (Clarke 2008).  The periosteum provides os-
teoprogenitor cells to the bone that are essential for appositional bone growth 
and fracture repair.  As a result, the periosteum experiences more bone for-
mation than bone resorption (Turner 2006).  The endosteum is the layer of 
connective tissue lined with bone lining cells that separates the bone from the 
bone marrow compartment within the bone shaft.  The endosteum typically 
experiences more bone resorption than bone formation, as the endosteum 
has a large surface area exposed to the bone marrow space that is the home 
of formation of osteoclast precursor, the haematopoietic origin of osteoclasts, 
the bone resorbing cells.  Bone has a stiff structure to bear loading, resist de-
formation, it is flexible in turn to absorb energy from loading and light enough 
to help in mobility (Bilezikian 2008).  The external layer of bone is a double-
layered membrane (periosteum), which is the external surface of bone 
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(Fig.1.1).  The outer fibrous layer serves as an insertion point for ligaments 
and tendons where as its inner osteogenic layer is more cellular and vascu-
lar.  Cortical and porous trabecular bone lies beneath the periosteum and 
compose the main bone matrix.  The main structural unit of the cortical bone 
is the osteon, concentric rings of lamella or matrix tubules form an osteon. 
They have cylinder shape arranged parallel to the bone long axis to enable 
loading and bending stress (Fig.1.2). 
 
 
 
 
 
 
 
Figure1.2: Cortical and trabecular bone structure. Each osteon consists of concentric 
layers or lamellae of compact tissue that boarders a central canal (the Harversian canal 
which contains bone nervous supply and blood supply). Osteons are connected to each oth-
er by Volkmann’s channels ((Umadevi and Geethalakshmi  2011) 
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Bone tissue is composed of an organic matrix of type I collagen.  It is miner-
alized with an inorganic phase comprising calcium hydroxyapatite crysctals.  
The organic matrix provides flexibility, whereas increasing amounts of miner-
al confer increasing degrees of material stiffness.  The mineralized tissue is 
organized into basic structure units (BSUs) that are the footprint of a remod-
eling event (Follet et al., 2004).  In addition to collagen, there are also non-
collagenous proteins which are synthesized by bone cells and make up 15% 
of bone protein.  Osteoblasts produce several proteins that play an important 
role in bone matrix mineralization including enzymes such as alkaline phos-
phatase, ALP (Xiao et al., 2007).  ALP is an important molecule in mineraliza-
tion of bone formation and  an osteoblastic differentiation marker that is ex-
pressed in the initial phases of the process, in addition, this enzyme is nec-
essary for mineralization and formation of bone and its immobilization on a 
collagen scaffold leads to an increase in the concentration of inorganic phos-
phate in cell culture and increases the rate of osteoblast differentiation 
(Jafary et al., 2017). 
 
 
1.2 Bone Cells 
Bone tissue is continuously remodelled through the action of bone cells, 
which include bone resorption by osteoclasts, bone formation by osteoblasts, 
whereas osteocytes act as mechanosensors, and regulate the bone remodel-
ling process (Florencio-Silvaet al., 2015).  Osteoblasts produce new extracel-
lular matrix and control mineralization.  The lining cells, which are covering 
the entire bone surface, are thought to control the access to the pure bone 
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matrix at the bone surface, which is important for Ca+2-homeostasis and at-
tachment of osteoblasts and osteoclasts (Bonewald and Johnson 2008).  The 
osteocytes are embedded throughout the mineralized matrix and are inter-
connected via cell membrane extensions known as canaliculi and are thought 
to play a pivotal role in mechanosensing and Ca+2, PO4
-2, homeostasis.  In 
the adult skeleton, the osteocytes make up 90-95% of all bone cells com-
pared with 4-6% osteoblasts and 1-2% osteoclasts (Bonewald and Johnson 
2008). 
 
 
1.3 The osteoblast 
Osteoblasts are derived from multipotent marrow stromal stem cells called 
mesenchymal stem cells (MSC) (Aubin and Triffitt, 2002).  They are respon-
sible for matrix secretion and mineralization of bone.  Osteoblasts arise from 
osteoprogenitors found in the bone marrow (Dennis and Charbord 2002), 
periosteum (Ogitaet al., 2008), and pericytes that surround blood vessels 
(Shi and Grothos 2003).  Recent work has found that the osteoblast linage 
comprises the supporting unit for haematopoietic stem cells (HSC), which re-
side in endosteal niches (often called osteoblast niches) in bone marrow to 
exert their function and a small proportion of HSC and mostly haematopoietic 
progenitor cells traffic countiously from BM into circulation and concurrently 
re-home to the BM, leading to the release of small proportion of haematopoi-
etic stem cells and their progenitor from their niches into the blood (Lévesque 
et al., 2010).  Osteoprogenitors with appropriate stimulation undergo prolifer-
ation, differentiation into pre-osteoblasts, and commitment into terminally dif-
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ferentiated osteoblasts.  In addition, osteoblasts contribute to the regulation 
of bone resorption through the expression of receptor activator of nuclear ac-
tivator kB (RANK) ligand (RANKL), which binds to its receptor RANK, on the 
surface of osteoclast progenitor cells, inducing their differentiation and bone 
resorption (Wada et al., 2006).  Osteoblasts also produce the soluble recep-
tor decoy osteoprotegerin (OPG), which can block the interaction of RANK/ 
RANKL through binding to RANKL, therefore, preventing osteoclast differen-
tiation and activation, which in turn can reduce bone resorption (Gori et al., 
2000).  It has been proposed that RANKL / OPG ratio can be regulated by 
several factors, which in turn regulate osteoclastogenesis.  Among these fac-
tors are Vitamin D3 (Simonet et al., 1997), IL-1α, IL-1β, TNF-α, TNF-β, bone 
morphogenic protein (BMP) 2, transforming growth factor β(TGFβ) and 17β-
estradiol all of which increase OPG levels, whereas prostaglandin E2 
(PGE2), parathyroid hormone (PTH) (Khosla 2001), glucocorticoids and insu-
lin-like growth factor-1 (IGF-1) decrease OPG level (Walsh and Choi 2003).  
Recent studies have demonstrated that Protein Kinase B (PKB), extracellular 
signal-regulated kinase 1/2 (ERK1/2) and canonical wingless/integrated 
(WNT) signalling pathways regulate osteoblast proliferation and differentia-
tion.  In response to fibroblast growth factor (FGF) that inhibits osteoblast dif-
ferentiation, the PKB signalling pathway promotes osteoblast survival while 
ERK1/2 strongly regulates osteoblast proliferation (Raucciet al., 2008).  Os-
teoblasts are specialized fibroblasts that secrete osteoid matrix proteins to 
form the foundation of newly formed bone.  Osteoblasts secrete both colla-
genous and non-collagenous proteins such as type 1 collagen, osteocalcin, 
osteopontin, osteonectin, bone sialoprotein, and alkaline phosphatase (Flor-
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encio-Silvaet al., 2015).  Some osteoblasts undergo apoptosis (programmed 
cell death) when the deposition of bone matrix terminates, while others dif-
ferentiate into flattened ‘bone lining cells’ on the bone surface, whereas oth-
ers become trapped in bone matrix known as osteocytes (Marks and Odgren, 
2002; Parfitt, 2002).  Estrogen loss in menopause is known to have a great 
impact on skeletal mass and calcium metabolism, and both osteoblasts and 
osteoclasts express estrogen receptors (Kholsa 2010).  Estrogen promotes 
the differentiation of osteoblasts from mesenchymal stem cells and sup-
presses expression of lipoprotein lipase, a marker of adipocyte differentiation 
(Okazaki et al., 2002, Dang et al., 2002), prolongs the lifespan of the osteo-
blast (Kousteni et al., 2001), increases osteoblast expression of proteins that 
play a role in bone formation (e.g., type I collagen, IGF-1, bone morphogenic 
protein-6) (Kholsa 2010) and inhibits apoptosis in osteoblasts and osteocytes 
(Kousteni et al., 2001).  Estrogen suppresses osteoclast activity via stimula-
tion of osteoclast apoptosis (Nakamura et al., 2007 and reducing osteoblasts 
expression of RANK-L (Eghbali-Fatourechi et al., 2003).  In addition, to the 
direct effects of estrogen on osteoblasts and osteoclasts, estrogen also inhib-
its inflammatory cytokine production from bone marrow stromal and mononu-
clear cells (Kitazawa et al., 1994; 1992, Jilka et al., 1992).  This is an im-
portant bone protective-mechanism because inflammatory cytokines such as 
interleukin (IL)-1, IL-6, and TNF-α are known to be potent stimulators of os-
teoclastogenesis (Strand and Kavanaugh 2004). 
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1.4 The osteoclast 
Osteoclasts are multinucleated cells that are derived from hematopoietic 
stemcells and are responsible for bone resorption.  Differentiation and activa-
tion of osteoclasts are regulated by different factors such as RANKL, OPG, 
TNF-α, IL-1, IL-6, M-CSF, parathyroid hormone and 1,25(OH) D3, which are 
produced by different cell types including osteoblasts and lymphocytes 
(Teitelbaum and Ross 2003).  Activated multinucleated osteoclasts secrete 
hydrogen ions via H+-ATPase proton pumps and chloride channels within 
their ruffled border cell membranes into the resorption pits beneath them to 
lower the pH within the bone-resorbing compartment to a PH of below 4, 
which helps solubilize bone mineral (Ross and Teitelbaum, 2005).  Resorbing 
osteoclasts secrete tartrate-resistant acid phosphatase (TRAP), cathepsin K, 
matrix metalloproteinase-9 (MMP-9), and gelatinase from cytoplasmic lyso-
somes to digest organic matrix, resulting in the formation of saucer-shaped 
Howship’s lacunae on the surface of trabecular bone and resorption tunnels 
in cortical bone.  The resorption phase is completed when the multinucleated 
osteoclasts stop functioning and undergo apoptosis (Reddy 2004). 
 
 
1.4.1 Factors that affect osteoclastogenesis 
1.4.1.1 Receptor activator of NF-kB (RANKL) 
A member of the TNF family of proteins, RANKL also known as osteoproter-
gerin  ligand (OPG-L), exists as a homotrimeric protein and is typically mem-
brane-bound on osteoblastic and activated T cells or is secreted by some 
cells, such as activated T cells (Kearns et al., 2008), being involved in pro-
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moting the survival of dendritic cells and contributing to efficient priming of T 
cells (Akiyamaet al., 2012).  However, the discovery of OPG, which binds 
RANKL and inhibits osteoclastogenesis, identified that RANKL is an essential 
regulator of osteoclastogenesis (Simonet et al., 1997; Yasuda et al., 1998). 
RANKL is a type II transmembrane protein that consists of an intracellular 
domain, a transmembrane domain and an extracellular TNF family homolo-
gous domain. RANKL is expressed as an integral membrane protein, but a 
soluble form of RANKL is produced by cleavage of TNF-related activation in-
duced cytokine (TRANCE) or several metalloproteases (Bezerra et al., 2005). 
In addition, RANKL exists as a homotrimer that binds a cysteine-rich site on 
the extracellular domain of RANK, the specific receptor of RANKL (Lacy et 
al., 2012).  Similar to other members of the TNF receptor superfamily, the 
binding of RANKL to RANK causes receptor clustering to form functional tri-
meric receptors resulting in the activation of signaling molecules in the cells 
(Lacy et al., 2012).  The dimerization of OPG occurs through its carboxyl 
terminal domain, which binds and inhibits RANKL. OPG has a unique C-
terminus domain that binds heparin and TRAIL, a member of the TNF family 
(Lamoureux et al., 2010).  Despite the role of the RANKL/RANK pathway in 
osteoclastogenesis, it has been reported that RANKL plays an important role 
in cell proliferation and differentiation in different cells, particularly in epithelial 
cells in mammary gland lobules during pregnancy and is required for hyper-
plasia of these cells during lactation and thus milk production in mice (Fata et 
al., 2000)).  RANKL is also known to be an important factor of bone damage 
associated with cancer metastasis. 
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RANKL, which was previously reported as a dendritic cell survival factor, was 
identified as a ligand for OPG. Other studies conducted have showed that the 
addition of RANKL to bone marrow culture induces osteoclast differentiation 
in the presence of M-CSF (Jimi et al., 1999).  RANKL and RANK knockout 
mice displayed osteopetrosis; this reveals that RANKL signals are essential 
for in vivo osteoclastogenesis (Kong et al., 1999, Dougall et al., 1999). 
RANKL is also involved in the stimulation of multinucleation from osteoclast 
precursor cells and bone resorption activity of mature osteoclasts (Jimi et al., 
1999).  The survival of mature osteoclasts is regulated by several factors in-
cluding RANKL.  Therefore, RANKL is involved in the differentiation, activa-
tion and survival of osteoclasts. In normal physiology, RANKL regulates bone 
homeostasis by working with OPG. RANKL expression is induced by stimu-
lating osteoblasts with several osteotropic factors such as parathyroid hor-
mone (PTH), Vitamin D3 and IL-6, which enhance osteoclastogenesis 
(Takahashi et al., 1999).  The process of osteoclastogenesis is thought to be 
affected by the membrane-bound RANKL, which is expressed on the surface 
of osteoblasts.  However, recent studies conducted, have shown that high 
expression of RANKL in osteocytes plays an important role in osteoclasto-
genesis, especially in bone remodeling (Nakashima et al., 2011, Xiong et al., 
2011).  Soluble and/or membrane forms of RANKL derived from osteocytes 
are thought to be involved in osteoclastogenesis.  RANKL is also expressed 
in lymphocytes, its expression by T or B-lymphocytes does not play an im-
portant role in bone remodeling under normal physiological conditions 
(Nakashima et al., 2011, Onal et al., 2012); however, RANKL expressed in B-
cells was partially involved in a mouse model of bone loss induced by estro-
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gen deficiency (Onal et al.,2012).  RANKL expression in osteoclast precursor 
cells is stimulated by several factors including M-CSF, TNF-alpha, LPS and 
WNT5A (Arai et al., 1991, Maeda et al., 2012).  Binding of RANKL to RANK 
receptors which are expressed on osteoclast precursor cells induces intracel-
lular signals essential for osteoclast differentiation and activation (Takayanagi 
2007). Signaling through RANK is mediated by recruitment of TRAFs. Among 
the TRAF family of proteins, TRAF6 is essential for RANKL-induced osteo-
clastogenesis (Naito et al., 1999).  TRAF6 activates signaling pathway of NF-
kB and MAPK.  RANKL promotes osteoclast differentiation via activation of 
the NF-kB pathway.  RANK signaling also activates the transcription factor 
AP-1 by inducing its component c-Fos.  Activation of NF-kB and c-Fos leads 
to the induction of NFATc1, which stimulates the expression of osteoclast-
specific genes such as cathepsin K.  RANKL also induces the phosphoryla-
tion of Microphthalmia-associated transcription factor (MITF), which regulates 
the development and function of several cell lineages, including osteoclasts 
and involved in osteoclastogenesis which activates downstream of MAPK 
(Hu et al., 2007).  The transcription factor complex, including transcription 
factors such as NFATc1 and MITF, stimulates the expression of osteoclast-
specific genes such as cathepsin K.  In osteoclastogenesis, the expression of 
NFATc1 is strongly induced via auto amplification in the later stages of differ-
entiation.  Transcriptional activity of NFATc1 is dependent on the localization 
of protein in the nuclei, which is regulated by calcium signaling.  Co-
stimulatory molecules possessing tyrosine-based activation motif-
accomodating adaptors induce calcium signalling in osteoclastogenesis 
(Negishi‐Koga andTakayanagi 2009).  In addition, RANK has a unique cyto-
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plasmic domain that recruits adaptor proteins Gab2 and PLCg2, which also 
induce calcium signalling (Taguchi et al., 2009).  Phosphorylation of PLCg2 
in conjunction with co- stimulatory signals lead to the activation of NFATc1 
(Mao et al.,2006).  NFATc1 also stimulates transcription of the D2 isoform of 
the vacuolar ATPase Vo domain and of the dendritic cell-specific transmem-
brane protein DCSTAMP, which are involved in multinucleation of osteoclasts 
(Lee et al., 2006, Yagi et al., 2005).  Thus, it is generally accepted that 
NFATc1 is involved in the differentiation and multinucleation of osteoclasts. 
 
 
1.4.1.2 Tumor Necrosis Factor -  (TNF-) 
Tumor necrosis factor-α (TNF-α) is a pro-inflammatory cytokine with multi-
functional properties, it belongs to the tumor necrosis factor ligand superfami-
ly, with multi activities such as regulation, differentiation, proliferation and 
apoptosis.  TNF can be found in two different forms (α andβ) with similar bio-
logical effects.  TNF-α plays an important role in modulating the acute in-
flammatory response to injury or infection, however high levels of TNF-α pro-
duction contributes to the development of chronic diseases including bone 
resorption (Azuma et al., 2000).  TNF-α is expressed on T- lymphocytes (Gil-
lespie 2007), and promotes bone loss in different conditions such as post-
menopausal osteoporosis and could be the key regulator of bone loss in 
rheumatoid arthritis (Teitelbaum 2007).  The first mechanism of TNF-α, is 
that it promotes osteoclast formation and activation in the inflamed joint by 
stimulating RANKL, produces RANKL, M-CSF, and IL-1 production by mar-
row stromal cells and by directly stimulating differentiation of osteoclast pre-
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cursors (Lam et al., 2000).  TNF-α and RANKL are synergistic, and minimal 
levels of one markedly enhance the osteoclastogenic capacity of the other 
(Lam et al., 2000).  TNF-α also has effective anti-apoptotic effects on osteo-
clasts, extending their lifetime (Weitzmann and Pacifici, 2005).  The second 
mechanism occurs after exacerbation of inflammatory process, hence TNF-α 
may support osteoclast formation through the activation of transforming 
growth factor (TGF)-β (Teitelbaum 2007).  Studies showed that mice whose 
CD4 cells express a dominant-negative TGF-βII (such that these cells do not 
respond to TGF-β) have a lower bone mineral density (BMD) than wild-type 
animals (Gillespie 2007).  TNF-α attracts monocytes and lymphocytes to the 
site of infection and stimulates apoptosis in different cell types via stimulation 
of cytokine production.  The effect of TNF-α is mediated by transmembrane 
receptor TNFR1 (p55r) and TNFR2 (p75r).  TNFR1 (P55r) contains a death 
domain that can prompt apoptosis, while p75 lacks a death domain (Koba-
yashi et al., 2000).  TNFR1 (p55r) is an important receptor involved in osteo-
clast differentiation and bone resorption, and treatment with anti-p55r anti-
body completely inhibits TNF-α-induced osteoclastogenesis (Kobayashi et 
al., 2000, Azuma et al.,2000).  Activation of a TNF receptor associated death 
domain which is caused by binding of TNF-α to its receptor, stimulates two 
pathways, JNK, protein kinase C and IkB leading to activation of NFκB which 
translocates to the nucleus and induces the transcription of TNFα-responsive 
genes (Kruppa et al., 1992).  TNF-α also has the ability to trigger the Fas ac-
tivated death domain which provokes the apoptotic signaling cascades 
(Nanes 2003).  TNF-α affects bone remodeling by direct and indirect action 
through collaboration with other signal pathways via TNF receptor-associated 
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factor (TRAF) and NF-κB (Kim et al., 2005).  Treatment with TNF-α can in-
duce TRAP positive osteoclast formation on the surface of bone in the ab-
sence of RANKL, suggesting that TNF-α may act independently of the 
RANKL/RANK axis (Kim et al., 2005).  Similarly, TNF-α stimulates osteoclast 
formation in cultures of M-CSF dependent precursors by a TNFR1 dependent 
but RANKL-independent mechanism (Kitauraet al., 2005). In addition, it has 
been shown that TNF-α directly induced human osteoclast formation by a 
RANKL-independent mechanism (Kudo 2002), alsoTNF-α can stimulate os-
teoclast formation in the presence of M-CSF with less effect than RANK, 
while RANKL increased the level of TNF-α m-RNA and induced TNF-α re-
lease from osteoclast progenitors (Zou 2001).  
 
 
1.4.1.3 Interleukin-6 (IL-6) 
IL-6 is a pro-inflammatory cytokine, secreted by T-cells and macrophages, it 
possesses pro anti-inflammatory functions and mediates immune response 
during an infection, and it elevates differentiation of B cells into plasma cells, 
activates cytotoxic T cells, and regulates bone hemostasis.  IL-6 signals 
through soluble IL-6 receptors binding to gp130, which is ubiquitous in all 
cells (Barkhausenet al., 2011).  IL-6 is known as a potent stimulator of osteo-
clast induced bone resorption and subsequent bone loss in the context of 
chronic inflammation (Edwards and Williams 2010).  Animal studies suggest 
that over expression of IL-6 in transgenic mice exhibit severe impairment in 
cortical and trabecular bone with an increase in osteoclastogenesis and de-
creased osteoblastogenesis (De Benedetti et al., 2006).  Estrogen has the 
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ability to inhibit IL-6 production in osteoblast lineage cells (Stein and Yang 
1995).  Moreover, studies conducted on wild type animals showed that estro-
gen deficiency resulted in bone turnover in these animals, but ovariecctomy 
failed to cause any change in bone mass and bone remodeling in IL-6 defi-
cient mice (Poli et al., 1994).  IL-6 is produced by osteoblasts, however the 
biological effect is recognized on osteoclast cells, it regulates RANKL produc-
tion and binding to its receptor on osteoblasts which indirectly promotes os-
teoclastogenesis and bone resorption (Udagawa et al.,1995).  Although the 
direct effects of IL-6 on osteoclasts are inhibitory (Yoshitake et al., 2008, Ax-
mannet al., 2009), IL-6 is thought to contribute to bone loss in osteoporosis, 
which is caused as a result of estrogen deficiency leading to a mild increase 
in pro-inflammatory cytokines (Terauchi 2011; Jilkaet al., 1992).  This finding 
has led to the development of an anti-IL-6 receptor agents (tocilizumab) 
which has been used in patients with moderate to severe rheumatoid arthritis 
(Agarwal 2011).  Studies on indirect mechanism of IL-6 on osteoclast for-
mation have demonstrated that IL-6 stimulates osteoclastogenesis when co-
cultured with osteoblasts with no effects on purified osteoclasts culture (Hat-
tersley et al., 1988).  Further studies suggested that IL-6 receptors are re-
quired on osteoblasts but not on osteoclasts for osteoclastogenesis regula-
tion, though higher levels of IL-6 receptors are found on osteoclastic cells 
(Udagawa et al., 1995).  IL-6 mostly binds to IL-6R and forms a complex with 
gp130 to stimulate the associated intracellular signaling machinery 
(JAK/STAT or MAPK pathway) and subsequent gene expression (Ohsugi 
and Kishimoto 2008).  Osteoclast formation and activity is mainly affected by 
IL-6, which stimulates signaling molecules especially RANKL, produced by 
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osteoblasts (Bellido et al., 1995).  Additionally, IL-6 activity on osteoclasts 
commonly interacts with IL-1, TNF, and IL-6 increases their effect on bone 
resorption by increasing osteoclastic progenitor pool (Devlin et al., 1998).  As 
IL-6 is essential for the differentiation of immature CD4+ T cells to Th17 cells, 
it is an effective osteoclastogenic inducer in chronic inflammation and auto-
immune diseases. 
 
 
1.5 Osteocytes 
Osteocytes are generated from osteoblasts, which become encased in the 
bone matrix they produce and are left within the bone matrix after bone re-
modelling (Manolagaset al., 2006, Seemanet al., 2006).  Osteocytes are situ-
ated in lacunae and are connected to each other by canals called canaliculi 
within the bone matrix (Fig. 1.3).  They also retain nutrient and dispose waste 
through this lacunar-canalculi network (Palumbo et al., 1990b; Zhang et al., 
2006b).  Osteocyte processes are connected via gap junctions which enable 
them to communicate with each other and with bone lining cells (BLCs) at the 
surface of bone (Batra et al., 2011; Ishihara et al., 2008).  Gap junctions are 
facilitated by a group of proteins called connexion (Goodenough et al., 1996). 
Connexin 43 (CX43) is expressed on the cell membrane of osteocytes as 
well as on the cell processes (John et al., 1993).  Osteocytes can sense 
changes in the level of circulatory hormones (Manolagas 2000), induce sig-
nals for bone resorption by activating death signalling pathway through apop-
tosis (Kogianniet al., 2008) and communicate with bone lining cells through 
gap junctions to stabilize bone mineral by  preserving an adequate local ionic 
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environment (Cowin 2001).  It has been suggested that osteocytes act as the 
sensor for mechanical loading of bone and transmit signals to the bone cells 
at the surface of the bone to control bone remodelling (Bonewald 2011). 
 
Figure 1.3: Scanning Electron Microscopy (SEM) image of osteocyte-canalicular  
system. From 4 month old mouse long bone that shows an osteocyte lacuna connecting 
 with bone lining cells through a network of canaliculi toward the bone surface  
(Pajevic 2009). 
 
 
1.6 Osteocyte function 
1.6.1 Blood-calcium/phosphate homeostasis 
Osteocytes play an important role in the metabolism and maintenance of 
bone.  The bone tissue may utilize two advantages that this unique network 
offers:  
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1) Intracellular communication system between osteocytes and bone lining 
cells by a gap junction based network and an extracellular communication 
system between located osteocytes within the bone and the bone surface via 
hemichannels.  
2) The communication area of cell-bone surface between osteocytes and 
bone lining cells, that is about twice as large as the communication area be-
tween the osteoblasts and bone lining cells at the bone surface (Johnson, 
1966).  
Osteocytes might be responsible for blood-calcium homeostasis; later obser-
vations supported this theory (Palumbo et al., 1990a, Sissonset al., 1990). 
Osteoblasts and osteoclasts transport calcium into and out of bone (Marotti 
et al., 1992), however the osteocytes may aid the circulation of calcium into 
and out of the bone tissue (Bonucci et al., 1990).  Thus, osteocytes may play 
a key functional role in the regulation of blood-calcium homeostasis.  Osteo-
cytes also regulate phosphate and bio-mineralization through molecules such 
as PHEX, DMP-1 and FGF-23 (Bonewald 2007), which  are expressed by 
osteocytes (Thompson et al., 2002).  Both DMP1 and PHEX appear to down 
regulate FGF-23 expression, which, in turn, allows reabsorption of phosphate 
by the kidney, thereby maintaining sufficient circulating phosphate to pre-
serve normal bone mineral content.  In the absence of either DMP1or Phex, 
FGF-23 is elevated in the osteocyte and in the circulation, leading to phos-
phate excretion by the kidney, thereby reducing circulating phosphate.  
Therefore, it has been proposed that the osteocyte lacunocanalicular network 
can function as an endocrine system, targeting distant organs such as kidney 
(Feng et al., 2006). 
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1.6.2 The osteocyte as a mechanosensor 
Osteocytes reside in a fluid-filled widely spaced lacuna and are connected 
via cellular processes contained within channels called canaliculi.  Osteo-
cytes have been proposed to act as the mechanosensor in bone through 
their ability to detect the mechanical strain and load generated factors such 
as fluid flow, streaming and pressure through a connected network (Bone-
wald 2011).  They may also sense load, such as through the cell body, the 
dendritic processes, or bending of Cilia (Bonwald 2006).  It has been pro-
posed that the osteocyte senses load only through its processes (Han et al., 
2004) or through both the cell body and the processes (Nicolella et al., 2008). 
However, a recent study has shown that osteocyte dendritic processes sence 
mechanical loading, which is likely to be transmitted through the glycocalyx, 
leading to the opening of hemichannels on the cell body (Burra et al., 2010).  
This suggests the role of dendrites and the glycocalyx in transducing me-
chanical signals and in the regulation of the opening of hemichannels (Burra 
et al., 2010).  In addition, it has been proposed that the osteocyte senses 
load through cilia.  Primary cilia are sensory, microtubule-based organelles 
that grow from the centrosome and project from the cell surface in many ver-
tebrate tissues including bone cells and they might regulate homeostasis in 
diverse tissues by allowing mechanical signals to alter cellular activity via tis-
sue-specific pathways (Xiao et al., 2006; Malone et al., 2007).  Mechanical 
signals sensed by osteocytes are converted to chemical signals, and the 
lacuno-canalicular network plays a critical role in conveying these signals to 
osteoblasts, osteoclasts, and bone-lining cells (Klein-Nulend et al., 2005). 
Rapid anabolic signals that are released within seconds after loading in oste-
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ocytes include nitric oxide (NO), prostaglandins, and other small molecules 
such as ATP. NO, a short-lived free radical that inhibits resorption and pro-
motes bone formation is generated within seconds in both osteoblasts and 
osteocytes in response to mechanical strain (Bakkeret al., 2001).  Primary 
osteocytes and primary calvarial bone cells have also been shown to release 
prostaglandins in response to fluid flow treatment, and a number of studies 
have suggested that osteocytes are the primary source of these load-induced 
prostaglandins (Ajubiet al., 1999).  In vivo studies have shown that new bone 
formation induced by loading can be blocked by the prostaglandin inhibitor, 
indomethacin (Forwood 1996), and agonists of the prostaglandin receptors 
have been shown to increase new bone formation (Hagino et al., 2005).  NO 
is a mechanical mediator that appears to be released around the same time 
as PGE2 from osteocytes (Klein-Nulend et al., 1995) and endothelial NO syn-
thase is found in osteocytes (Zaman et al., 1999).  In bone, NO inhibits re-
sorption and promotes bone formation. Both osteoblasts and osteocytes re-
lease NO in response to mechanical strain or fluid-flow shear stress (Bakker 
et al., 2001).  ATP and intracellular calcium can also be released from osteo-
cytes in response to extracellular calcium or mechanical stimulation (Genetos 
et al., 2005; Kamioka et al., 1995); additionally, osteocytes are considered to 
be the most sensitive bone cells to mechanical loading because of their dis-
tribution throughout the bone matrix and their ability to respond to strain with 
biochemicals such as nitic oxide and prostaglandins (Skerry et al., 1989).  
Many studies have also confirmed the rapid changes in metabolic activity of 
osteocytes after mechanical loading; this confirms the mechanosensory role 
of osteocytes in bone (Dallas and Bonewald, 2010, Lee et al., 2002).  
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1.6.3 Bone remodeling 
Bone remodelling is a metabolic process, which regulates the structure or 
remodelling function of bone during adult life (Boydet al., 2003).  Bone mod-
eling is a periodic replacement of old bone by new which is responsible for 
the complete regeneration of the adult skeleton approximately every 10 years 
(Manolagas and Weinstein 1999).  Bone remodeling confers repair of micro-
architectural damage and maintenance of calcium homoeostasis and acid–
base balance.  It results from the synchronized action of bone cells in the 
bone remodelling unit (BRU).  Bone remodeling occurs in both cortical and 
cancellous bone but is much greater in surface area within cancellous bone, 
the process predominates within this compartment (Peel 2009).  Bone re-
modeling occurs via the activity of a functional group of cells called the basic 
multicellular unit (BMU), which consists of the osteoclasts resorbing bone, 
the osteoblasts forming bone, the osteocytes within the bone matrix, the 
bone lining cells covering the bone surface and the capillary blood supply 
(Kularet al., 2012) and under the control of various circulating factors includ-
ing calcium, phosphate and parathyroid hormone (PTH) (Henriksen et al., 
2009).  Bone remodeling starts with an initiation phase which includes the 
recruitment of osteoclast precursors, then their differentiation into mature os-
teoclasts as well as activation of bone resorption.  This phase is followed by 
a resorption phase, which starts with the reaction of osteoclasts in response 
to mechanical or endocrine signals via the engagement of preosteoclastic 
cells to the location of remodeling.  Cytokines secreted by osteoblasts, pro-
mote the propagation of these osteoclastic cells along with coordinating the 
differentiation to multinucleated mature osteoclasts, which further stimulate 
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bone resorption.  This phase is followed by the reversal phase whereby oste-
oclast cells remove matrix debries before producing signals to initiate transi-
tion from bone resorption to bone growth in BMUs (Delaisse 2014).  The final 
stage is bone formation by the osteoblsats known as the termination stage, 
after comparable quantity of resorbed bone is restored with new stronger 
bone, the remodelling cycle is concluded (Raggatt et al., (2010) (Fig. 1.4).  
Mature osteoclasts adhere to bone and remove it by acidification and proteo-
lytic digestion and release minerals, this process is known as resorption, then 
osteoclasts die by apoptosis after leaving the resorption site.  Osteoblast 
precursors then enter the excavated area and differentiate into osteoblasts, 
which begin secreting osteoid and are subsequently mineralized to new 
bone.  The lifespan of an osteoclast is two weeks, after which they are re-
placed by new pre-osteoclasts that originate in the bone marrow and travel 
via the circulation to the site of resorption.  Osteoblasts have a longer 
lifespan (approximately 3 months).  They form most rapidly initially, slowing 
progressively with some becoming embedded as osteocytes, some dying 
and the remainder becoming lining cells (Manolagas 2000).  Bone is able to 
avoid damage by minimizing stress (load/area) through modeling and re-
modeling bone structure, mainly during growth.  Signals from damaged areas 
within mineralized matrix as a result of impact or fatigue loading and dam-
aged osteocytic processes within their canaliculae are transported to the flat-
tened osteoblasts lining the bone surface adjacent to marrow in the case of 
cortical and trabecular bone, and adjacent to a haversian canal on the intra-
cortical surface.   
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Figure 1.4: The bone remodellingcycle. Bone remodeling cycle begins with attraction of 
osteoblast precursor which is derived from mesenchymal stem cells to the site of the resorp-
tion. Followed by reversal phase whereby osteoclast bone formation is inhibited and osteo-
clasts undergo apoptosis. The final stage is bone formation by the osteoblats and called ter-
mination stage Osteoblast can be buried as osteocyte or remain in the bone surfaceas bone 
lining cells or undergo apoptosis. (Hill 1998). 
 
 
Bone develops fatigue damage, the effecter cells are able to detect the dam-
age location to removes and replace it with new bone to restore material 
composition and micro-/macro-architecture (Parafitt 2002).  The resorptive 
phase of the remodelling cycle removes damaged bone, while extended re-
modeling suppression using anti-resorptive therapy may result in micro-
27 
 
damage accumulation, fractures, and reduced bone healing (Odvina 2005).  
An equal amount of bone will be removed and replaced during the remodel-
ing process in the healthy situation.  The newly deposited osteoid undergoes 
rapid primary mineralization as it is laid down, and then secondary minerali-
zation (enlargement of deposited calcium hydroxyapatite-like crystals) during 
the next 12 months (Martin et al., 2008). 
 
 
1.7 Hormone receptors on osteocytes 
Parathyroid hormone (PTH) has an intense effect on the skeleton, and its in-
creased level in the circulation can cause both catabolic and anabolic effects 
on bone depending on the temporal profile of its increase (Bellidoet al., 
2005).  Chronic excess of PTH, as in primary hyperparathyroidism or sec-
ondary to calcium deficiency, increases the rate of bone remodeling, and can 
result in bone loss.  In contrast, intermittent PTH elevation, as achieved by 
daily injections, cause bone gain, and it is the only current bone anabolic 
therapy.  High bone remodeling rates and bone loss with chronic PTH eleva-
tion are associated with excessive production of osteoclasts coupled to in-
creased osteoblasts, with imbalance between formation and resorption within 
each bone multicellular unit (BMU).  On the other hand, the main effect of in-
termittent PTH elevation is a rapid increase in osteoblasts and bone for-
mation, attributed to the ability of PTH to increase proliferation of osteoblast 
precursors, to reduce osteoblast apoptosis, to re-stimulate lining cells to be-
come matrix synthesizing osteoblasts, or a combination of these effects (Jilka 
2007, Kim et al., 2012).  PTH has an important role in the viability of osteo-
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cytes and the efficiency of cell-cell communication in the osteocytic network 
(Bivietal., 2011, Kimmel et al., 2011, Kimmel et al., 2010, Miyauchi et al., 
2000).  It has been determined that PTH inhibits the expression of the osteo-
cyte specific gene Sost, which is identified as a novel potent negative regula-
tor of bone formation.  Consistent with negative regulation of bone formation, 
overexpression of SOST in transgenic mice produced osteopenia due to re-
duced bone formation (Winkler et al., 2003).  Most importantly, SOST loss-of-
function mutations in humans are the cause of the autosomal recessive bone 
dysplasias Sclerosteosis and Van Buchem disease, which are characterized 
by massive bone overgrowth throughout life and increased bone strength and 
serum markers of bone formation (Demiralp et al., 2002).  It has been 
thought that PTH possibly stimulates bone formation via direct actions on os-
teocytes (Bellido et al., 2005; Keller and Kneissel 2005).  Consistent with this 
idea, expression of parathyroid hormone receptor 1 (PTHR1) has been 
demonstrated in osteocytes (Fermor and Skerry 1995).  It has been reported 
that activation of PTHR1 signalling exclusively in osteocytes in transgenic 
mice is sufficient to decrease sclerostin (the protein product of Sost gene) 
expression, increase Wnt signaling, and increase bone mass (Glass and 
Karsenty 2007).  PTHR1 activation in osteocytes also accelerates the rate of 
bone remodeling. Deletion of the Wnt co-receptor LRP5 attenuates the high 
bone mass phenotype induced by the transgene, but does not affect the in-
creased remodeling. Thus, PTH signaling in osteocytes stimulates the in-
crease of bone mass and increases the rate of bone remodeling by LRP5-
dependent and independent mechanisms, respectively.Therefore, the skele-
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tal effects of PTH and PTHrP may be due in part to the actions of PTHR1 ac-
tivation in osteocytes (O'Brienet al., 2008). 
 
 
1.7.1 Estrogen  
Estrogen, a well-known steroid hormone is essential to maintain bone health. 
In addition, mechanical loading, in which estrogen signaling may interact with 
the Wnt/β-catenin pathway, is essential for bone maintenance (Kondohv et 
al., 2014).  Estrogen’s osteo-protective effects are also demonstrated by reg-
ulating the life span of osteoclast through osteoclastic and osteoblastic ERα 
and also inhibiting osteoblast and osteocyte apoptosis (Martin-Millan et al., 
2010, Almeida et al., 2010).  The effects of sex hormones on bone tissue can 
be considered as direct effects on bone cells, and indirect effects on other 
tissues (Imai et al., 2010).  The indirect effects of estrogen on bone through 
other tissues have been well described, such as modulation of cytokine pro-
duction by immune cells and the increased induction of pituitary gland hor-
mones (Sun et al., 2006, Pacifici 2008).  However, the direct effect of estro-
gens on bone tissue is not fully understood.  ERα in osteocytes was found to 
play an important role in maintaining bone mass by regulating osteoblastic 
bone formation only in females and supports maintenance of trabecular bone 
mass not only under normal loading conditions but also under tail suspen-
sion-induced unloading, which can be considered as experimental recapitula-
tion of immobilization or space flight (Lee et al., 2003).  However, these re-
sults show that, the absence of this receptor protected against cortical bone 
loss and bone mass adaptation induced by mechanical loading was impaired 
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in ERα total KO mice (Lee et al., 2003).  Together, these results indicate that 
osteocyte mechanosensation may, at least in part, occur via osteocytic ERα.  
Osteocytic ERα might play a role in estrogen's osteoprotective action by con-
trolling the expression of Wnt antagonists, which regulate osteoblastic bone 
formation in trabecular bone (Kondoh et al., 2014). 
Almost all osteocytes in the rat tibia express ERα (Braidman et al., 2000). 
Osteocytes in the cortical bone of the midshaft express significantly higher 
levels per cell than those in the trabeculae of the metaphysis and epiphysis 
(Bordet al., 2001).  Ovariectomy (OVX) is associated with a decrease of ERα 
per osteocyte in the cortex, where levels are initially high, and has no effect 
in the secondary spongiosa where initial levels are low. Strain has only a 
small but positive correlation with the level of ERα per osteocyte (Ehrlich et 
al., 2002).  Strain as well as estrogen stimulates transient translocation of 
ERα to the nucleus.  Strain but not estrogen also induces isolate membrane 
localization of ERα.  Bone cells response to strain and estrogen involve ERα, 
but only estrogen regulates its cellular concentration. Bone loss associated 
with estrogen deficiency, is a consequences of decreased number and activi-
ty of ERα which is associated with lower estrogen concentration reducing the 
anabolic response of bone to strain (Zaman et al., 2006).  Generally, ERα 
orchestrates most actions of estrogen on bone cells (Barkhem et al., 1998, 
Hall and McDonnell1 999).  In vitro studies conducted have suggested that 
estrogen’s bone-sparing effects are mediated by both estrogen and androgen 
receptors (Kousteni et al., 2001).  The mechanism in which information is 
transduced from ligand-bound receptors had been thought to be via the bind-
ing of ligands to the ERs causing a conformational change leading to recep-
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tor dimerization and binding to specific DNA sequences known as estrogen 
response elements (EREs) (Smith and O’Malley 2004).  The formation of a 
complex along with co-activator proteins results in the activation of general 
transcriptional machinery and leads to increased expression of target genes 
via chromatin remodelling.  In addition, ERs also have the ability to recruit co-
repressors, which play a role in negatively regulating ER-dependent gene 
expression.  Furthermore, other mechanisms of activation besides the tradi-
tional mode of gene activation have been stipulated that are responsible for 
the ability of estrogen in the stimulation and repression of gene expression 
encoding critical osteoclastogenic factors such as IL-6, TNF-α, and M-CSF.  
For instance, the activated ERs have the ability to bind to transcription factors 
such as NF-κB and therefore, blocking binding to DNA, which demonstrates 
in which how estrogen represses IL-6 production (Steinand Yang 1995).  
Similarly, estrogen exerts its effects on many families of kinases. For exam-
ple, casein kinase 2 (CK2) activity has been known to be decreased by es-
trogen resulting in reduced phosphorylation of the nuclear protein Egr-1.  
Dephosphorylated Egr-1 has increased affinity for the transcriptional activator 
Sp-1, a factor critical for expression of the MCSF gene (Srivastava et al., 
1998).  During estrogen deficiency the formation of aEgr-1/Sp-1 complex oc-
curs, causing a decrease in the nuclear level of free Sp-1 and thus reducing 
MCSF transcription.  Moreover, Estrogen also has the ability of reducing JNK 
activity.  The decreased production of activator protein 1 (AP1) factors ex-
plains the repressive effects of estrogen on TNF gene expression (Srivasta-
vaet al., 1999) as well as why estrogen decreases the sensitivity of maturing 
OCs to the osteoclastogenic factor receptor activator of NF-κB (RANK) ligand 
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(RANKL) (Srivastava et al., 2001).  Although many estrogenic effects are 
mediated by nuclear ERs, some responses initiate in the plasma membrane.  
In fact, estrogen produces rapid effects in various cell types, including in 
bone cells. These nongenomic actions are due to signaling by a membrane 
receptor.  The ability of estrogen to induce OC apoptosis and inhibit OB 
apoptosis is linked to its ability to increase ERK1 and ERK2 phosphorylation 
and inhibit JNK activity (Kousteniet al., 2001, Kousteniet al., 2003). The 
phosphorylation of these cytoplasmic kinases and their transport to the nu-
cleus modulate the activity of transcription factors required for antiapoptotic 
actions of estrogen (Kousteniet al., 2003). 
 
 
1.8 Apoptosis 
Apoptosis is programmed cell death characterized by morphological chang-
es, which include cytoplasmic shrinkage, nuclear chromatin condensation, 
and DNA fragmentation into apoptotic bodies (Fig.1.5).  The content of dying 
cells is eliminated without inflammatory response within the body (Kerr 2002).  
In contrast, necrosis is a cell death characterized by a chromatin flocculation, 
loss of membrane integrity, and a general local inflammatory response (Kerr 
et al., 1972). 
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Figure 1.5: Schematic diagram illustrating the basic differences between apoptotic 
and necrotic cells. The onset of apoptosis is characterized by cellular shrinking, chromatin 
condensation and margination at the nuclear periphery with the formation of membrane-
bound apoptotic bodies that contain organelles, cytosol and nuclear fragments are phagocy-
tosed without triggering inflammatory processes. The Signs of early necrosis in an irreversi-
bly injured cell include clumping of chromatin and gross swelling of organelles. At a later 
stage, membranes rupture and the cell disintegrates (Gewies 2003). 
 
 
 
1.9 Bcl-2 family and mitochondrial role in apoptosis 
The Bcl-2 family (B cell leukemia/lymphoma 2-like proteins) is a main regula-
tor of apoptotic events regulated by mitochondria and is a member of a grow-
ing gene family consisting of two subfamilies that can inhibit (pro-survival) or 
promote (pro-apoptotic) apoptosis (Marsden et al., 2003).  The interaction 
between pro-apoptotic and pro-survival proteins plays an important role in 
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determining the final ending (death or survival).  Bax is a pro-apoptotic mem-
ber of the Bcl-2 family which acts as a death receptor and exists in both cyto-
plasm and mitochondria and during apoptosis a substantial fraction of the cy-
toplasmic Bax moves to the mitochondria to form dimmers (Tsujimoto 1998).  
Previous studies have shown that the Bcl-2 (pro-survival)-to-Bax (pro-
apoptotic) ratio in the cell determines initiation of cell apoptosis or alternative-
ly, re-enters the cell cycle (Delpoetaet al., 2003).  This was represented by 
the finding that over expression of Bcl-2 (therefore, a higher Bcl-2: Bax ratio) 
permitted for continued cellular proliferation through antagonism of apoptotic 
signals transported by the pro-apoptotic Bax, as seen in the continuous 
growth and division of malignant cells (Zhang and Insel  2001).  
 
 
1.10 Caspases (Cysteine Aspartate Protease) 
Caspases are a family of genes important for maintaining homeostasis 
through regulating cell death and inflammation (McIlwain.et al., 2013).  Apop-
totic caspases are divided into two classes: initiator and executioner caspa-
ses. Initiator caspases (caspase 2, caspase 8 and caspase 9) are the im-
portant caspases in signaling cascades and their activation is normally re-
quired for executioner caspase (caspase 3, caspase 6 and caspase 7) acti-
vation.  The content of initiator caspase substrates is limited and includes 
self-cleavage, Bcl-2 homology 3 (BH3)-interacting domain death agonist 
(BID) and executioner caspases.  Executioner caspases cleave hundreds of 
different substrates and are mostly responsible for the observable character-
istic changes seen during apoptosis. Initiator caspase activation first involves 
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dimerization of inactive caspase monomers. In the case of caspase 8, its 
monomers are recruited following death receptor ligation, and dimers for-
mation through their pro-domains to the adaptor molecule FAS-associated 
death domain protein (FADD). Dimerization and interdomain cleavage are 
required for the activation and stabilization of mature caspase 8 (Stephen et 
al., 2010). 
 
 
1.11 Death receptors 
Death receptors are part of a family of tumour necrosis factor receptor super-
family (Bhardwaj and Aggarwal 2003).  Eight members of the death receptor-
family have been recognized, Fas, TNFR1, or the TRAIL receptors DR4 and 
DR5 are implicated in diverse diseases. Death receptor of the Fas/tumor ne-
crosis factor receptor (TNF) family is transmembrane protein characterized 
by cytoplasmic death domain (DD) of 65-80 amino acids.  The death receptor 
family comprises TNFR1, death receptor (DR3), (APO-3/TR-MP/WSI/LARD), 
DR4 (TRAIL), DR5 (TRAIL-R2/TRICK2/killer) DR6 and CD95 (APO-1Fas) 
(Ashkenazi 1999).  All death receptors have the ability to induce apoptosis 
when ligated by their similar ligands.  Therefore, ligand binding of the Fas re-
ceptor triggers receptor trimerization and aggregation of the intracellular 
death domains.  These trigger interaction with C-terminal DD of the adaptor 
molecule FADD which recruits caspase-8 and creates Fas-FADD-Caspase-8 
complex (Fig. 1.6) (Boldin et al., 1996).  Although Caspase-8 is characterized 
as a major up-stream caspase effecter of death receptor signaling, some evi-
dence indicates that it is also recruited by other apoptotic signals and impli-
36 
 
cated in detachment- induced apoptosis.  However, the exact mechanism of 
its activation is unclear as it is inhibited not only by a dominant negative 
FADD, suggesting death receptor involvement, but also by Bcl-2, suggesting 
mitochondrial involvement and does not require downstream caspase -3 or -
9(Rytommaet al., 1999). 
 
  
 
 
 
Figure 1.6: The role of FADD in Fas and TRAIL signaling.Fas and TRAIL-R are activated 
by FADD, an essential adaptor protein that links death receptor for FasL or TRAIL to caspa-
se-8, thereby inducing DISC formation. These complexes have a capability to induce both 
apoptosis and necroptosis (Lee et al., 2012). 
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1.12 Osteocyte Apoptosis 
Osteocyte death occurs as a result of ageing, after the menopause, reduced 
bone loading and due to pathological conditions such as microcracks and the 
death of osteocytes is strongly associated with bone resorption (Noble and 
Reeve 2000; Cardoso et al., 2009; Emerton et al., 2010).  Osteocytes die 
through one of three ways, apoptosis, autophagic cell death and necrosis 
(Bursch2001), (Fig. 1.7).  It has been suggested that apoptotic bodies de-
rived from osteocytes, independent of pro-osteoclastogenic factors, are as-
sociated with efficient osteoclastogenic activity capable of bone local resorp-
tive activity (Kogiani et al., 2008).  Bone fragility is thought to be as a result of 
failure of apoptotic osteocytes to sense microdamage and subsequently they 
fail to signal to the bone surface for repair (Noble 2008; Noble 2000; Noble et 
al., 2003, Manolagas 2010; Manolagas 2000).  Osteocyte apoptosis also oc-
curs in association with the area surrounding a microcrack leading to remod-
elling and repair of the damaged area (Noble et al., 2003).  In contrast to 
overloading, which induces microdamage and microcracking, a physiological 
level of load on bone in vivo may inhibit apoptosis in the osteocyte network 
(Noble. et al., 2003).  On the other hand, lack of mechanical loading or dis-
use can lead to apoptosis of osteocytes by oxygen deprivation, especially if 
associated with immobilization (Aguirre et al., 2006; Basso and Heersche 
2006).  It appears that mechanical stimulation provides essential oxygen lev-
els to keep osteocytes viable (Gross et al., 2005).  Thus, it appears that 
apoptotic osteocytes disrupt the integrity of the osteocyte network, this dis-
ruption functions as a signaling mechanism for the bone to initiate repair and 
adaptation to mechanical strain resulting from mechanical stimulation.  Age-
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ing results in accelerating osteocyte death through a mechanism associated 
with oxidative stress, as evidenced by a reduction in antioxidant enzymes, 
and phosphorylation of oxidative stress markers, p53 and p66Shc in bone 
from ageing mice (Almeida et al., 2007).  One of the characteristics of osteo-
cyte apoptosis is glucocorticoids- induced bone disease in human and mice 
(Noble 2000).  The pro-apoptotic effect of the steroids, mediated via the glu-
cocorticoid receptor, is independent of gene transcription and results from the 
activation of the focal adhesion related kinase Pyk2/JNK signaling pathway 
(Poltkin et al., 2007).  This leads to cell detachment-induced apoptosis.  In 
addition, the action of glucocorticoid on osteoblasts might induce osteocyte 
apoptosis.  This includes the local suppression of the synthesis of survival 
factors such as insulin-like growth factor 1 (IGF-1), interleukin 6 (IL-6), matrix 
metaloproteinases (MMPs) (Canalis and Delany 2002) and the induction of 
the Wnt antagonist SFRP- 1 (Wang et al., 2002).  The effect of glucocorti-
coids has also been associated with increased oxidative stress (Almeida 
2011; Jia et al., 2011) and contributes to the increase in reactive oxygen 
species and osteocyte apoptosis during ageing.  Both estrogens and andro-
gens prevent osteocyte apoptosis (Kousteni et al., 2002).  Similar effect has 
been demonstrated with the selective estrogen receptor modulator (SERM) 
(Van et al., 2007).  The effect of the sex steroids can be exerted via activa-
tion of estrogen receptor is independent of gene transcription (Kousteni et al., 
2001). 
Apoptotic osteocytes show development of osteoclastogenesis in vitro (Kogi-
anni et al., 2008; Al-Dujaili et al., 2011; Cheung et al., 2012). Studies con-
ducted have shown that osteoclastogenesis can be induced by addition of 
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osteocyte apoptotic bodies (OABs) to the surface of bone-forming areas in 
murine calvariae in vivo and also the potential for OABs to promote osteo-
clastogenesis in vitro after their introduction to bone marrow–derived osteo-
clast precursors (OPs) in the absence of pro-osteoclastogenic factors RANKL 
and macrophage-colony stimulating factor (M-CSF) (Kogianni et al., 2008). 
 
Figure 1.7: Osteocytes die mainly through one of three pathways: apoptosis, autophagic 
cell death and necrosis During the terminal phase of apoptosis autophagic cell death, osteo-
cytes which are not engulfed by phagocytes undergo secondary necrosis. Immunostimulato-
ry molecules including high-mobility group box 1 (HMGB1), S100, heat shock protein (HSP), 
adenosine triphosphate (ATP) and uric acid are released from lacunae through canaliculi to 
the bone surface and vascular channels,where they assist macrophages activation, thus 
promoting the production of pro-inflammatory cytokines, including tumour necrosis factor-α 
(TNF-α), interleukin 6 (IL-6) and interleukin1 (IL-1), which induce osteoclastogenesis and 
bone resorption. Apoptotic osteocytes release osteoclastogenesis-promoting factors, includ-
ing soluble receptor activator of nuclear factor κ-B ligand (sRankl), IL-6 and soluble IL-6 re-
ceptor (sIL-6R) and induce TNF-α expression in osteoclast precursors in vitro (Komori 
2013). 
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1.12.1 The role of osteocytes in bone disease 
Osteocytes communication network can detect mechanical load and micro-
damage.  Drugs and bone active hormones control the bone strength and in-
tegrity of this network through the regulation of osteocyte cell death (Plotkin 
et al., 2005).  Osteocyte apoptosis has a critical role in determination of bone 
strength, as osteocyte apoptosis is the main feature of conditions of in-
creased bone fragility (Manolagas 2006).  Osteocyte cell death can occur in 
association with some pathologic conditions such as osteoporosis and oste-
oarthritis, leading to increased skeletal fragility (Weinstein et al., 2000).  Such 
fragility is considered to be due to loss of the ability to sense microdamage 
and/or signal repair.  Oxygen deprivation that occurs as a result of immobili-
zation has been shown to promote osteocyte apoptosis (Dodd et al., 1999).  
In addition, glucocorticoid treatment (Weinstein et al., 2000) and low levels of 
estrogen that result in bone loss is thought to be the product of  the imbal-
ance between bone formation and resorption, this is possibly caused by in-
creased osteoclast survival, as estrogen promotes osteoclast apoptosis 
(Tomkinson et al., 1997 and Emerton et al., 2010).  Tumour necrosis factor- 
α (TNF-α) and interleukin 1 (IL-1) have been reported to increase with estro-
gen deficiency and also induce osteocyte apoptosis (Bonewald et al., 2007).  
Studies on fluid shear stress in osteocytes, in which the mechanical bone 
loading was mimicked by applying pulsating fluid flow, the TNF-α induced os-
teocyte apoptosis was inhibited by mechanical loading.  However, this effect 
was just observed in osteocytes but not osteoblasts.  Since apoptotic osteo-
cytes attract osteoclasts, these results indicate that osteocyte apoptosis 
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plays a key role in osteoclastic bone resorption, which is in part modulated by 
TNF-α (Tan et al., 2006). 
 
 
1.13 Osteoclast apoptosis 
The number and activation of osteoclasts play a critical role in the determina-
tion of the balance between bone formation and resorption (Manolagas 
2000).  Osteoclast number is dependent upon relative rates of cell differentia-
tion and death.  Osteoclast differentiation in vitro is dependent on at least two 
extracellular factors, macrophage-colony stimulating factor (M-CSF) and re-
ceptor activator of nuclear factor-κB ligand (RANKL).  Other factors, such as 
IL-1, IL-6, TNF-α, and TGF-β, also affect osteoclast differentiation (Teitel-
baum and Ross 2003).  Osteoclast apoptosis has been reported to be in-
duced by some agents such as estrogen, tamoxifen and some bisphpspho-
nate molecules, however the mechanism is not fully clear (Boyce et al., 
2002).  Bisphosphonates induce apoptosis in osteoclast-like cells expressing 
the Fas gene, thus implicating Fas in osteoclast apoptosis (Wu et al., 2003). 
Estrogen has been reported to directly targets RANKL-induced osteoclast 
differentiation by repressing c-Jun activation and that this response was ER 
dependent (Shevde, et al., 2000) or through the production of transforming 
growth factor beta (TGF-β) produced by osteoblasts (Hughes et al., 1996). 
Estrogen regulates the life span of osteoclast through upregulation of Fas 
ligand (FasL) expression in osteoclasts of the trabecular bone of mice.  The 
expression of ERα was also required for the induction of apoptosis by ta-
moxifen and estrogen in cultured osteoclasts.  These results are a possible 
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explanation for the osteoprotective function of estrogen as well as SERMs 
(Nakamura et al., 2007). 
 
 
1.14 Osteoblast apoptosis 
Osteoblasts undergo an orderly developmental progression that finally ends 
in apoptosis.  It is still unclear what signal transduction pathway is used in 
programmed cell death in osteoblasts.  Glucocorticoid treatment and estro-
gen withdrawal promotes apoptosis in osteoblasts and osteocytes (Tom-
kinson et al., 1997and 1998, Weinstein et al., 1998).  Osteoblast apoptosis is 
in part responsible for osteoporosis in sex steroid deficiency, glucocorticoid 
treatment, and ageing, however overexpression of Bcl-2 in osteoblasts inhib-
its osteoblast differentiation, reduce osteocyte processes, and causes osteo-
cyte apoptosis (Moriishi et al., 2011).  The Fas/FasL death receptor pathway 
has been implicated in human and murine osteoblast apoptosis through in-
teraction with T cells (Kawakami et al. 1997) or exposure to pro-inflammatory 
cytokines such as TNF-α, IFN-γ (Ozeki et al. 2002).  Inorganic phosphate 
acts as local apoptogenes for osteoblasts, which is enhanced by increasing 
Ca2+ concentration (Adams et al., 2001).  Apoptosis of mature osteoblasts is 
influenced by cytokines such as IL-6 and TGF-β (Jilka et al., 1998), but sur-
vival and differentiation of osteoblast into osteocyte was dependent on matrix 
metalloproteinase activity, which is activated by p44/p42 MAPK pathway 
(Karsadal et al., 2002). 
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1.15 Oxidative stress and its role in promotion of osteoporosis 
The activity of reactive oxygen species, a by-product of aerobic respiration 
plays an important role in bone turnover particularly in bone resorption 
(Östmanet al., 2009).  The most common theory of ageing states that oxida-
tive stress is resulting from an increase in intracellular ROS which is the ma-
jor determinant of ageing (Giorgio et al., 2007, Lu and Finkel 2008), as well 
as the cause of several degenerative disorders associated with ageing 
(Balaban et al., 2005).  ROS formation occurs primarily in the mitochondria 
from the escape of electrons passing through the electron transport chain 
during aerobic metabolism, the process that is supported by nutrients such 
as glucose and is responsible for the formation of ATP (Giorgio et al., 2007, 
Newmeyer and Ferguson-Miller 2003).  ROS are also generated during fatty 
acid oxidation or in response to external stimuli, such as inflammatory cyto-
kines, growth factors, environmental toxins, chemotherapeutics, UV light, or 
ionizing radiation.  Free electrons are added to molecular oxygen to generate 
superoxide (O2-), hydrogen peroxide (H2O2), and the hydroxyl radical (OH-).  
Among these species, H2O2 has the highest oxidative activity and the highest 
stability.  As a result of its properties, H2O2 performs a critical role in signaling 
for the replicative capacity of regenerative cells, apoptosis, and changes in 
gene expression leading to ageing and ageing-related diseases (Giorgio et 
al., 2007).  The production of H2O2 is amplified considerably by the adapter 
protein p66shc, which is released from an inhibitor complex in the inner mito-
chondrial membrane in response to a variety of pro-apoptotic stimuli and acts 
as a redox enzyme catalyzing the reduction of O2 to H2O2 through electron 
transfer from cytochrome C (Giorgio et al., 2005; Camiciet al., 2007).  H2O2 in 
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turn causes opening of the permeability transition pore, swelling, and apopto-
sis.  Deletion of the p66shc gene enhances cellular resistance to apoptosis 
induced by H2O2 or UV light, and mice deficient in p66shc not only exhibit in-
creased resistance to oxidative stress but also have an increase in lifespan 
(Migliaccioet al., 1999).  Oxidative stress is characterized by increased level 
of reactive oxygen species (ROS) which is involved in bone homeostasis and 
affects bone remodelling by promoting bone resorption.  Many studies have 
suggested the role of oxidative stress in bone diseases such as osteoporosis, 
diabetes-induced bone diseases and vascular diseases.  
Oxidative stress is a physiological or pathophysiological condition which in-
creases with age and results in deregulation of redox balance in tissues, 
characterized by an excess formation of free radicals.  These free radicals 
are implicated in the apoptosis of osteoblasts, osteocytes and also in osteo-
blastogenesis, therefore in bone resorption as shown in vivo and in vitro stud-
ies (Ostmanet al., 2009), through the activation of a protein kinase C (PKC) 
β/P66shc/NF-kB signaling cascade. P66shc is an essential mediator of the 
stimulating effect of H2O2 on the apoptosis of osteoblastic cells as well as be-
ing able to activate NF-kB (Almaida et al., 2010).  ROS can either have bene-
ficial or harmful effects on tissues depending on concentration and have 
been known as a major contributor to the immune response (Bogdan 2001) 
and are involved in defence mechanism during inflammatory responses as 
well as cell signaling.  It has been shown that H2O2 in bone, oxidizes those 
proteins which are involved in cell differentiation and modulates their activity, 
either by inhibition or stimulation which includes signaling pathways involved 
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in bone cell differentiation, mitogen-activated protein kinases (MAPKs), 
Wnt/b-catenin and NF-kB (Lee et al., 2005). 
ROS have been reported to play an important role in ageing associated com-
plications (Krause 2007) and development of different types of degenerative 
diseases including cancer, cardiovascular disease, ischemia–reperfusion in-
jury, arthritis, diabetes and neurological disorders (Valko et al., 2007). 
ROS are also involved in defence mechanisms during inflammatory respons-
es and generating cell signals.  It has been suggested that lower concentra-
tion of ROS induce mitogenic response, whereas higher concentrations 
would induce cell death (Bergaminiet al., 2004).  ROS are produced abun-
dantly in mitochondria and its production is regulated by many complex en-
zymes such as cyclo-oxygenase, NADPH oxidase and cytochrome P450 
(Kadenbachet al., 2009).  It has been reported that ROS are involved in os-
teoclastogenesis regulation induced by RANKL (Lee et al., 2005) and in the 
apoptosis of osteoblasts/osteocytes, therefore influencing bone resorption 
(Almeida et al., 2007).  This has been shown in vitro and in in vivo animal 
studies (Garrett et al., 1990).  Wnt/β-catenin are widely used molecules in 
osteoblast function and bone formation.  The accumulation of β-catenin in the 
cytoplasm is promoted through Wnt signalling by preventing its degradation. 
β-catenin is translocated into the nucleus and is involved in the expression of 
osteoblastic markers hence, osteoblast differentiation (Manolagas and 
Almedia, 2007).  However, in conditions of oxidative stress, as induced by 
the lack of estrogen and ageing, Wnt-induced osteoblastic gene expression 
is inhibited through a mechanism which involves Forkhead box-O (FOXO) 
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transcription factor, and results in osteoblast and osteocyte apoptosis (Mano-
lagas and Almedia 2007). 
In vivo experiments support the role of ROS in age-related osteoporosis.  In 
ageing mice, male and female mice showed decreased bone formation rates, 
whereas ROS levels were up regulated, this might depend on antioxidant de-
fence failure and that the same changes in oxidative stress were reproduced 
by gonadectomy (Almeida et al., 2007).  In addition to ageing, ovariectomy 
induces oxidative stress in rat femurs with a decreased activity of antioxidant 
systems (Almeida et al., 2007; Muthusamiet al., 2005).  It has been demon-
strated that RANKL-induced osteoclastogenesis is regulated by ROS produc-
tion (Lee et al., 2005).   RANKL binds to its receptor, RANK at the surface of 
pre-osteoclasts.  This binding has been shown to induce differentiation of 
pre-osteoclast into mature osteoclast and induce bone resorption (Fig. 1.8). 
On the other hand OPG, the decoy receptor for RANKL produced by osteo-
blasts, prevents RANKL from binding to RANK on the surface of osteoclast, 
thus inhibiting osteoclast differentiation  and suppressing apoptosis induction 
(Theoleyre et al., 2004). 
Similarly over-expression of glutathione peroxidase 1 (Gpx1), one of the main 
antioxidant enzymes produced by osteoclasts, is responsible for the degrada-
tion of hydrogen peroxide as well as the inhibition of RANKL-induced osteo-
clastogenesis (Lee et al., 2005).  This suggests that H2O2 plays an important 
role in the formation of osteoclasts.  These changes in glutathione, influenced 
by increased ROS, contribute to decreased rate of remodelling and increased 
osteoblast/osteocyte apoptosis.  
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Studies in rodent bone marrow-derived osteoclasts have shown that 17β-
estradiol stimulates the expression of Gpx1; whilst estrogen deficiency re-
sults in the ROS-mediated expression of TNF-α and induce bone loss by 
lowering thiol antioxidants in osteoclasts and ultimately bone resorption 
(Lean et al., 2003).  Also CAT (another antioxidant enzyme) administration 
prevents the bone loss caused by ovariectomy and the effect of CAT on bone 
loss also has further significance.  CAT, unlike hydrogen peroxide, is unable 
Figure  1.8: Bone remodelling and oxidative stress. In the presence of the receptor 
activator of NF-kB ligand (RANKL), expressed by osteoblasts RANKL binding to the recep-
tor RANK at the surface of pre-osteoclasts stimulates cell fusion, activates resorption ca-
pabilities and enhances cell survival. OPG, a decoy receptor for RANKL, prevents osteo-
clast differentiation As a result of oxidative stress this bone coupling is unbalanced, and 
bone formation by osteoblasts is reduced, whereas osteoclast differentiation and activities 
and subsequent bone resorption are enhanced directly or indirectly through an increased 
RANKL production (Wauquier et al., 2009). 
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to diffuse across cell membranes.  Therefore, suppression of bone loss by 
CAT is due to degradation of H2O2 in the extracellular space.  This suggests 
that H2O2 causes bone loss through a paracrine or autocrine action (Lean et 
al., 2005). 
H2O2 is also known to induce inhibition of osteoblastic differentiation in prima-
ry mouse BMSCs (Liu et al., 2004), which is characterized by the reduction of 
ALP.  Similar results have been shown in term of suppression of osteoblastic 
differentiation marker when primary bone marrow stromal cells from rabbit 
BMSCs were treated with H2O2 (Bai et al., 2005).  This included, the nuclear 
phosphorylation of Runx2 (a transcription factor), ALP, colony- forming unit-
osteoprogenitor (CFU-O), and type I collagen.  Many studies have reported 
that ROS has a direct effect on the life span of osteocytes, and induce apop-
tosis in the same way as mentioned above and leading to bone loss (Bone-
wald 2011). 
 
 
1.16 Osteoporosis 
 
 Osteoporosis is a systemic skeletal disease characterized by decreased 
bone strength and an increased risk of fractures (NIH Consensus 2001).  It is 
a chronic disease of bone, characterized by reduced bone mass and micro-
architectural deterioration of bone tissue, leading to increased bone fragility 
and resulting in an increase fracture risk (Ray et al., 1997).  Osteoporosis is 
also associated with the normal ageing process and is a result of imbalance 
between the activity of osteoblasts and osteoclasts, ultimately leading to 
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bone loss (Dempster1995).  Primary osteoporosis mostly occurs in postmen-
opausal women due to estrogen deficiency that affects circulating levels of 
cytokines such as IL-1, TNF-α, granulocyte macrophage colony stimulating 
factor (GM-CSF) and IL-6.  The level of theses cytokines increases because 
of decreased estrogen levels, thus enhancing bone resorption by increasing 
differentiation and activation of osteoclasts (Horowitz 1993,  Manolagas 
1995).  This process is mediated by RANKL, produced from osteoblasts and 
other cell types, leading to increased bone resorption (Eghbali et al., 2003).  
Secondary osteroporosis occurs in men and women older than 75 years, but 
could also be induced in younger individuals by various diseases or by con-
tinual use of certain medications, such as corticosteroids.  Secondary osteo-
porosis is the result of other medical complications, changes in physical ac-
tivity or as a consequence of therapy for certain diseases (NIH Consensus 
2001).  Osteoporosis is defined as a bone mineral density (BMD) 2.5 stand-
ard deviations or more below the mean peak BMD for healthy adults, as 
measured by dual energy X-ray absorption (DXA) (World Health Organization 
1994).  Besides hip fractures, other debilitating fractures such as compres-
sion fractures of a vertebra are severe consequences of osteoporosis.  In 
addition, several other types of bone fractures such as Colles’fractures are 
seen at highly elevated rates in osteoporotic patients.  Osteoporosis is a mu-
tifactorial disease with potential contributions from genetic, endocrine func-
tional, exercise related and nutritional factors (Aaseth et al., 2012). 
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1.16.1 Osteoporosis and estrogen 
Bone fracture incidence increases clearly in women during the first decade of 
post menopause; this has been attributed to the rapid loss of bone mass and 
trabecular architecture that occurs with a decline in estrogen production as-
sociated with menopause (Raisz 2001). 
Estrogens exert a protective action in maintaining bone health by increasing 
osteoclast apoptosis (Kameda et al., 1997) and decreasing cytokines, which 
promote osteoclast activity (Pacificiet al., 1996).  It has been proposed that 
osteocytes may regulate bone remodeling activation via connection with 
bone lining cells (Bonewald 2007); therefore it is likely that osteocytes medi-
ate the anti-remodeling effects of estrogen.  Estrogen deficiency is associat-
ed with increased osteocyte apoptosis in humans (Tomkinson et al., 1997). 
Also estrogen is thought to have a great impact on skeletal mass and calcium 
metabolism, suppresses both directly, and indirectly bone resorption (Khosla 
etal., 2011) and its acute effect is blocking the new osteoclast formation.  In 
addition, estrogen modulates RANK signaling in ostoclastic cells through the 
suppression of  receptor activator of NF-κB ligand (RANKL) and macrophage 
colony-stimulating factor (M-CSF)-induced differentiation of myelomonocytic 
precursors into multinucleated osteoclasts (Srivastava et al.,1999; Shevdeet 
al., 2000) and induces osteoclast apoptosis (Nakamura et al., 2007, Martin-
Millanet al., 2010).  In term of bone formation, estrogen promotes osteoblast 
differentiation from mesenchymal stem cells (Okazaki et al., 2002; Dang et 
al., 2002), prolongs osteoblast life span (Kousteniet al., 2001) and increases 
the expression of osteoblast proteins such as (type 1 collagen, IGF and bone 
morphogenic protein-6) (Khosla et al., 2010) and inhibits osteoblast and os-
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teocyte apoptosis (Kousteniet al., 2001). 
Estrogen suppresses osteoclast activity by stimulating osteoclast cell apop-
tosis (Hughes et al., 1996) and by reducing osteoblast, T cell and B cell ex-
pression of RANK-L (Eghbali-Fatourechiet al., 2003).  In addition to having 
direct effects on the osteoblasts and osteoclasts, estrogen inhibits inflamma-
tory cytokine production from bone marrow stromal and mononuclear cells 
(Kitazawa et al., 1994; Jilkaet al., 1992).  This is an important bone protec-
tive-mechanism because inflammatory cytokines such as interleukin (IL-1, IL-
6) and TNF-α are known to be potent stimulators of osteoclastogenesis 
(Strand and Kavanaugh 2004).  Taken together, estrogen plays an anabolic 
role in the skeleton, and the decline in estrogen levels during menopause is-
correlated with loss of bone mass and increased risk of fracture (Marcus et 
al., 1994).  However, hormone replacement therapy (HRT) is able to reduce 
bone loss and fracture risk in postmenopausal women (Blank and Bockman, 
1999).  
 
 
1.17 Current treatments for osteoporosis 
1.17.1 Calcium & Vitamin D 
One of the first steps in the treatment of osteoporosis is considered to be 
Calcium and Vitamin D as they are essential for normal skeletal homeostasis. 
Reduced calcium absorption can result from an insufficient intake of Ca2+ and 
Vitamin D which lead to a rise in parathyroid hormone, an increased rate of 
bone remodelling and increased bone loss (Holick 2007).  It has been docu-
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mented that calcium and vitamin D levels have positive association with bone 
mineral density (BMD) (Bischoff-Ferrari 2004 and Dawson-Hughes 1997).  
Some trial results have shown that vitamin D supplementation had positive 
results and suggests that individuals would benefit by having 25 hydroxy vit-
amin D no lower than 70 nmol/l protecting against fracture by decreasing 
PTH and increasing bone mass (Dawson-Hughes and Bischoff-Ferrari 2007). 
Calcium supplements, alone or in combination with vitamin D are commonly 
used for the prevention of osteoporosis.  The recommended dose of calcium, 
usually in the form of calcium carbonate, is 1g daily with common side effects 
that include dyspepsia and constipation; however a meta-analysis report 
showed that calcium supplements without co-prescribed vitamin D have in-
creased risk of myocardial infarction (Bolland et al., 2010).  Vitamin D plays 
an important role in calcium absorption and bone health, this led to a con-
sensus that calcium should not be prescribed to patients with osteoporosis 
without Vitamin D.  
 
 
1.17.2 Bisphosphonates 
Bisphosphonates inhibit bone resorption and are now used in the treatment 
of osteoporosis (Russell 2011).  The molecular mechanism action of 
bisphosphonate is classified into two different classes, the nitrogen-
containing and non nitrogen-containing bisphosphonates, which have a struc-
ture similar to pyrophosphate and thus inhibit the activation of enzymes that 
use pyrophosphate (Dunford 2010).  The simple bisphosphonates such as 
(clodronate , etidronate and tildronate) can be metabolically incorporated into 
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non-hydrolysable analogues of adenosine triphosphate (ATP) that accumu-
late intracellularly in osteoclasts, resulting in induction of osteoclast apopto-
sis.  In contrast, the more potent, nitrogen-containing bisphosphonates (such 
as pamidronate, alendronate, risedronate, ibadronate and zoledronate) act 
as analogues of isoprenoid diphosphate lipids, thereby inhibiting farnesyl di-
phosphate synthase (FPPs) synthase, an enzyme  in the mevalonate path-
way necessary for prenylation of small GTPase that are critical for osteoclast 
cytoskeletal association and function, leading to osteoclast apoptosis induc-
ing bone resorption (Russell 2011, van beek et al., 1999).  Despite their posi-
tive effect, bisphosphonates have relatively common adverse side effects 
that limit their use such as upset stomach, oesophageal inflammation, flu-like 
symptoms, as well as a risk of renal toxicity and in some cases have also 
been associated with osteonecrosis of the jaw and mid-shaft and subtrochan-
teric femur fractures (Russell 2011, Rizzoli et al.,2008).Therefore, alternative 
treatments should be investigated. 
 
 
1.17.3 Hormone replacement therapy (HRT) 
HRT is a possible treatment option for women during menopause.  Estrogen 
is approved for the prevention, but not for treatment of postmenopausal oste-
oporosis (Vokes and Favus 2010).  It was demonstrated by studies conduct-
ed by Women’s Health Initiative (WHI), that increased risk of breast cancer, 
coronary heart disease, stroke and venous thromboembolism are all associ-
ated with estrogen treatment in combination with progesterone and this is 
despite the fact that estrogen treatment was found to reduce risk of osteopo-
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rotic fractures (Nelson et al. 2002).  Unopposed estrogen therapy has been 
shown to increase stroke and thromboembolism only.  HRT is not considered 
as first line therapy in postmenopausal osteoporosis management and this is 
due to the overall health risks of HRT exceeding the potential benefits. 
 
 
1.17.4 Selective estrogen receptor modulators (SERMs) 
Selective estrogen receptor modulators (SERMs) are a group of nonsteroidal 
compounds that are chemically different from estradiol and act as estrogen 
agonists in some tissues, such as bone, and as estrogen antagonists in other 
tissues, such as breast, through specific, high-affinity binding to the ER 
(Goldstein et al., 2000).  Raloxifene and tamoxifene are currently SERMs 
used for osteoporosis treatment; they have been proven to show beneficial 
effects on vertebral and nonvertebral fractures.  Raloxifene increases bone 
mineral density in postmenopausal women(Delma et al., 1997), reduces the 
risk of vertebral fracture in postmenopausal women with osteoporosis 
(Ettinger et al., 1999).  Tamoxifen which has been approved for prevention of 
breast cancer also may reduce fractures (Cooke et al., 2008) but appears to 
be less potent with a greater variability in the number of responders.  There-
fore, raloxifene is a preferred treatment for women who have more severe 
cases of osteoporosis than tamoxifene and, thus, may not be suitable for use 
in early postmenopausal women with severe vasomotor symptoms. Raloxi-
fene has been shown to increase thromboembolic risk, but not the risk of 
coronary heart disease (Barrett-Connor et al., 2006). 
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1.17.5 Parathyroid Hormone 
Recombinant Parathyroid Hormone (PTH) 1-34 (teriparatide) is the only ana-
bolic therapy currently used for osteoporosis (Hodsman et al., 2005).  Teri-
paratide binds to the PTH receptor type I on osteoblasts and stimulates oste-
oblastic bone formation more than bone resorption leading to an increase in 
bone mass (Boron and Boulpaep 2005).  It has been found that once daily 
injection of teriparatide reduced vertebral and non-vertebral fractures in 
women with osteoporosis (Neer et al. 2001).  Intermittent treatment with PTH 
over a limited period supports bone formation; in contrast, prolonged treat-
ment with PTH supports bone resorption by stimulating proteosomal degra-
dation of the critical transcription factor Runx2 in the osteoblast, shortening 
its anti-apoptotic effect, and by stimulating induction of RANKL that in turn 
stimulates osteoclastogenesis (Ishizuya et al., 1997; Bellido et al., 2003; 
Walker et al., 2011).  Teriparatide is not recommended for patients at risk of 
sarcoma due to theoretical concerns that teriparatide risks of osteosarcoma, 
which was based on rodent toxicity studies in which prolonged high-dose 
therapy was associated with osteosarcoma in rats.  There have been no re-
ported cases of osteosarcoma in humans receiving teriparatide (Favus and 
Vokes 2010).  Teriparatide is a potentially exciting treatment for osteoporosis; 
it endorses the regeneration of trabecular connectivity and cortical thickness, 
which translates into improved mechanical strength of bone (Bouxsein and 
Radloff 1997).  The bone mass which is gained during Teripatatide treatment 
may be lost in the months after completion of treatment, therefore follow on 
anti-resorptive treatments may be needed to maintain the new bone mass 
(Favus and Vokes 2010).  
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1.17.6 Calcitonin 
Calcitonin is a 32-amino acid linear polypeptide hormone that is secreted by 
thyroid C cells (Pagonis et al., 2014).  It acts to reduce blood calcium (Ca2+), 
opposing the effects of PTH (Boronand Boulpaep 2004).  Calcitonin interacts 
with G-protein-coupled receptors on osteoclast surfaces during the final 
stages of differentiation and causes osteoclasts to withdraw from active sites 
of bone resorption by flattening their ruffled border in the resorption pit 
(Adami 2008).  Calcitonin is an anti-resorptive of modest potency.  In clinical 
trials, calcitonin reduced vertebral but not hip fractures (MacLean et al. 
2008), and is generally not a first choice anti-resorptive. 
 
 
1.18 Phytoestrogens 
Phytoestrogens (PEs) are naturally occurring plant compounds that are struc-
turally and/or functionally similar to mammalian estrogens and their active 
metabolites (Whitten et al 1997).  They are non-steroidal plant derived com-
pounds which can exhibit estrogen effects in estrogen target tissues, includ-
ing bone (Viereck et al., 2002; Weaver & Cheong, 2005).  Most PEs are phe-
nolic compounds, among these compounds, isoflavones and coumestans are 
the most widely researched groups (Adlercreutz 2002).  Isoflavones are pre-
sent in berries, wine, grains and nuts, but are most abundant in soybeans 
and other legumes (Kurzer and Xu 1997).  Epidemiological studies indicated 
that populations consuming a large amount of soy bean have lower risk of 
chronic diseases such as osteoporosis (Coxam 2008).  In contrast to these 
beneficial health claims, the anti estrogenic properties of PEs have also 
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raised concerns since they might act as endocrine disruptors, indicating a po-
tential to cause adverse health effects (Wuttke et al., 2007; Andres et al., 
2011; Rietjens et al., 2013).  Altogether, the health benefits or risks of isofla-
vones and other PEs are still controversial, and the question of whether PEs 
are beneficial or harmful to human health remains unresolved. 17β-estradiol 
(E2) is the dominant form of estrogen in the body, although any compounds 
which can bind estrogen receptors (ER) inducing receptor dimerization and 
consequent binding to estrogen response elements, can be considered es-
trogens (Cornwell et al., 2004).  This includes the PEs, which are able to in-
duce similar responses in various cells including bone tissues and cell lines 
as estradiol and mimic estrogen regardless of their mechanism via estrogen 
receptor (Adlercreutz 1999).  They can act as estrogen agonists and antago-
nists by blocking or altering ERs, thus they are more similar to natural selec-
tive estrogen receptor modulators (SERMS) (Brzezinski & Debi 1999).  PEs 
have been found in almost all plants (Ososki and Kennelly 2003); they are 
sub-divided into many classes and the most used in human are isoflavones, 
lignans and coumestans (Adlercreutz 2002).  Soybeans contain a large 
amount of isoflavones, including genistein (4', 5',7-trihydroxyisoflavone), dai-
dzein (4', 7-dihydroxy isoflavone), glycitein (6-methoxydaidzein) and their 
glycosides (Murphy et al., 1982).  Experimental evidence suggests that soy 
isoflavones have many properties including estrogenic (Song et al., 1999), 
antioxidant (Carroll 1991), hypocholesterolemic (Anthony et al., 1998) and 
inhibition of cell proliferation and DNA synthesis (Pan et al., 2001, Santellet 
al., 2000).  PEs exert estrogen agonist and antagonist characteristics (Zhao 
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et al 2002); they have differential binding affinities for the estrogen receptor 
(ER) isoforms; with higher affinity for ERβ than for ERα (Kuiper et al., 1998). 
PEs have a phenolic group (Fig.1.9), which is essential for binding to ER, and 
have similar molecular weight to E2.   
 
 
 
 
 
Figure 1.9: Chemical  structures of 17β-estradiol and PEs. All have the  presence of 
phenolic ring containing a free-OH group thought to be responsible for the reaction with 
oxyradicals by H atom transfer due to the weakness of O-H bond of the hydrogen group. 
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The cellular effects of PEs are affected by different factors, including conctr-
tion, ER status, presence or absence of endogenous estrogens, and the tar-
get tissue (Setchell 1998).   PEs exert agonistic and antagonistic estrogenic 
effects and also induce differentiation as well as inhibit angiogenesis, cell 
proliferation, tyrosine kinase, and topoisomerase II (Oseni et al., 2008).  The 
presence of a phenolic ring and the distance between the two opposing phe-
nolic oxygen atoms in isoflavone structure is similar to E2.  This resemblance 
confers the binding of isoflavones to the ER, effectively displacing E2 (An et 
al., 2001), which may help to explain how PEs protect against breast cancer, 
because ERβ signalling inhibits mammary cell growth (Lazennec et al., 
2001).  The antioxidant activity of PEs is related to the presence of free hy-
droxyl groups in the aromatic ring and ability to bind between aromatic rings 
(Burda and Oleszek, 2001).  The presence of C3-OH grouping in PEs is 
thought to assist the reduction of oxidative stress or inhibit the oxidative 
stress-induced apoptosis of osteoblasts/osteocytes (Behl et al., 1997).  This 
protection was not restricted to bone cells, but also neurons were reported to 
be protected from oxidative stress by estrogen through the A ring of the ster-
oid which has the C3-OH group (Behl et al., 1997). 
Although PEs generally, have positive effects, consumption of high amount of 
PEs may lead to undesirable health effects.  Many studies have shown pre-
natal exposure to Genistein resulted in effects in the progeny e.g. fetal eryth-
ropoiesis and altered gene expression as well as altering DNA methylation of 
hematopoietic cells which result in long-lasting effects on the endocrine and 
immune system and altered stress response and post weaning growth 
(Vanhees et al., 2011).  Soy consumption in pregnant mice, in doses below 
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the range of human consumption standardized per weight, showed Genistein 
accumulation in the fetus.  The effect of genistein includes changes in blood 
composition observed in mice that were prenatally exposed to Genistein, 
which  was associated with increased granulopoiesis and erythropoiesis to-
gether with moderate macrocytosis; these changes may be attributed to es-
trogenic properties of genistein, due to its structural similarity to 17β-estradiol 
(Miodini et al., 1999).  This was supported by other studies which showed 
that genistein inhibited testosterone secretion in fetal Leydig cells (interstitial 
cells of Leydig, in the testicle) during early fetal development, suggesting that 
genistein concentrations relevant for human consumption, may affect the de-
velopment and function of the male reproductive system (Lehraki et al., 2011, 
Lee et al., 2004).  Therefore, future studies on PEs could help to identify the 
safest dose for these dietary levels and explain the mechanism of health 
risks and/or therapeutic action involved. 
 
 
1.19 Genistein (GEN) 
Phytoestrogens are classified in four main distinct classes: isoflavones, 
lignans, coumestans and stilbenes Isoflavones, originated from soy and soy 
derivatives are the most common PEs with Genistein and Daidzein being the 
most abundant and frequently studied (Dixon 2004).  Isoflavones, including 
GEN and DZ, are polyphenolic compounds commonly found in legumes. 
They have a broad variety of physiological and pharmacological functions 
and are known to act as antioxidants in vivo and in vitro; their activity in-
cludes anti-estrogenic (Muller et al., 2004; Ratna et al., 2002), anticancer 
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(Chen 2005; Miltyk 2003; Tsuchiya 2002), anti-inflammatory (Marotta et al., 
2006), cardio protective (Park et al., 2005) and enzyme-inhibitory effects 
(Woclawek-Potocka et al., 2005).  Isofavones have similar structure to estro-
gen molecules (Fig.1.9), which is thought to play an important role in the  
prevention of osteoporosis (Ward et al., 2007), and have also been reported 
to inhibit resorption activity and survival of osteoclasts in vitro and prevent 
trabecular bone loss in vivo following ovariectomy (OVX) in rodents (Rein-
wald and Weaver, 2006).  The hydroxyl group in the B-ring is important to 
enable the scavenging of reactive nitrogen or oxygen species (Sekheret al., 
2001).  Isoflavones such as GEN have also been known to donate hydrogen 
atoms from the phenolic group (Heim et al., 2002). 
 GEN aglycone is an isoflavone found in soybeans (Messina et al., 2004), 
structurally resembles E2 and may positively regulate bone cell metabolism 
without harmful estrogenic activity in the breast and uterus (Cassidy 2003).  
This safe profile results from the greater affinity of GEN for estrogen recep-
tor-β, which is more abundant in bone, than for estrogen receptor-α, which is 
abundant in reproductive tissue.  Observational studies suggest that post-
menopausal Asian women who consume diets high in isoflavones have a 
lower rate of fracture than other groups (Setchell et al., 2002).  However, the 
mechanism of action of genistein on bone is not yet fully understood.  In 
postmenopausal women daily treatment with genistein at concentration of 
54mg increased BMD in lumbar spine and femoral neck with no undesirable 
effects on breast and uterus (Morabito et al. 2002, Crisafulli et al., 2004, Ma-
rini et al., 2007).  Also GEN decreases the ratio of soluble receptor activator 
of nuclear factor-B ligand to osteoprotegerin, which may partly account for its 
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positive effects on BMD (Crisafullietal., 2004).  Furthermore, studies con-
ducted show that GEN at doses adjusted for rat body weight was more effec-
tive than alendronate or raloxifene or estradiol in treating primary osteoporo-
sis induced by ovariectomy (Bitto et al., 2008) and secondary osteoporosis 
(Bitto et al., 2009).  According to these studies, it has been suggested that 
GEN aglycone may be an option for osteoporosis prevention. 
 
 
1.20 Daidzein (DZ) 
DZ, a soybean isolavone, is metabolized to equol in the gastrointestinal tract 
by gut microflora (Fujioka et al., 2004).  Equol possesses a stronger affinity 
for estrogen receptors than DZ (Fujioka et al., 2004), and is derived from cer-
tain plants such as soybeans, legumes and peas.  DZ in soy products can be 
found in two chemical forms, aglycones (unconjugated form) and glucosides 
(which are bound to a sugar molecule).  The main dietary source of daidzein 
is the biologically active glucoside daidzin.  As with GEN, fermentation or di-
gestion of soy products results in the release of the sugar molecule from the 
glucoside DZ, which results in the formation of the other form, the aglycone 
DZ (Rowland et al., 2003).  This process normally occurs in the stomach 
through acid hydrolysis and in the intestine through the action of the bacterial 
enzymes (Rowland et al., 2003).  Daidzein has a direct stimulatory effect on 
bone formation in cultured osteoblastic cells in vitro, which may be mediated 
by increased production of bone morphogenic protein (BMP-2), a potent in-
ducer of osteogenic differentiation and a target for isoflavones (Jia et al., 
2003).  DZ has been shown to increase bone formation in an animal model of 
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bone defect healing (Wong and Rabie 2009).  This was demonstrated by 
measuring bone forming ability in vivo for the repair of bone defects by using 
a carrier to enable its use in the clinical setting and the amount of new bone 
formed in collagen matrix carrier with DZ grafted into bony defects and com-
pared with that of the collagen carrier alone.  Using DZ in collagen matrix 
significantly enhanced new bone formation locally when grafted into skull de-
fects.  It may be the long-sought-after agent for bone induction and bone de-
fect repair (Wong and Rabie 2009). 
 
 
1.21 Resveratrol (Resv) 
Many studies have shown that resveratrol (3,4-,5-trihydroxystilbene), a poly-
phenolic constituent in grapes and red wine, has various benefits, such as 
protecting against neurodegeneration, cardiovascular disease, cancer, diabe-
tes, as well as obesity-related disorders (Baur and Sinclair, 2006).  This wide 
range of positive biological effects might be explained by resveratrol’s antiox-
idant properties which include increases in catalase and superoxide dis-
mutase (SOD) activity (Rubiolo et al., 2008).  In addition, the antioxidant ca-
pability of resveratrol might be mediated by activation of the transcription fac-
tor nuclear factor erythroid 2-related factor 2 (Nrf2) which controls the orches-
trated expression of phase II enzymes and genes involved in oxidative de-
fence such as glutathione (GSH) S transferase (GST), heme oxygenase-1 
(HO-1), NAD(P)H quinone oxido-reductase1 (Rubiolo et al., 2008).  The anti-
oxidant effect of resveratrol has been suggested to be due to the presence of 
hydroxyl phenolic groups in its chemical structure (Leonard et al., 2003).  
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Resveratrol has been known as an excellent scavenger of superoxide, hy-
droxyls and other radicals (Leonard et al., 2003). Furthermore, it protects 
DNA from oxidative stress-induced damage and therefore cell apoptosis 
(Wang et al., 2007; Gehmet al., 1997).  Resveratrol has been reported toha-
ve the capacity to bind to estrogen receptors and can turn on estrogen re-
sponsive genes.  It is, therefore, postulated that resveratrol can act as a phy-
toestrogen in the absence of estrogen in postmenopausal women as well as 
elderly men.  The protective effect of resveratrol has also been investigated 
in bone loss induced by disuse, which in turn has been linked with increased 
intracellular ROS (Boissy et al., 2005).  In vitro studies have shown that 
resveratrol inhibits osteoclast formation and promotes osteoblast differentia-
tion (Boissy et al., 2005).  On the other hand, several studies have reported 
that it has a low bioavailability and weak ability to scavenge ROS (Leonard et 
al., 2003).  In vitro and in vivo study studies show that resveratrol is absorbed 
and metabolized.   Around 75% of this polyphenol are secreted via faeces 
and urine (Walle et al., 2004).  The oral bioavailability of reseveratrol has 
been thought to be almost zero due to rapid and extensive metabolism and 
the consequent formation of various metabolites as resveratrol glucuronides 
and resveratrol sulfates.(Wenzel and Somoza 2005).  However other studies 
suggested that,  dietary Resveratrol can have beneficial effects in mice (Baur 
et al., 2006; Lagouge et al., 2006), it is thought that when Resveratrol enters 
circulation, retention of some pharmacological activity of these metabolites 
occurs, thereby releasing the pharmacologically active parent compound.  
The potential biological activity of resveratrol should be considered in future 
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to assess the significance of resveratrol in humans, and understanding of its 
role in estrogenic actions. 
 
 
1.22 Fucosterol 
Fucosterol (24-ethylidene cholesterol) is a sterol that can be isolated from 
algae, seaweed and diatoms.  Fucosterol exhibits a range of biological activi-
ty with therapeutic potential that include antioxidant and anti-osteoporotic ef-
fects (Abdul et al., 2016).  Fucosterol is isolated from brown algae and has a 
similar structure to human estrogen (Fig. 1.9) (Gaulin et al., 2010) and can be 
found abundantly in some species of brown algae such as Hizikiafusiforme.  
Recent studies have shown that Fucosterol promotes cell proliferation in hu-
man osteoblast like cells MG63 and elevated ALP and inhibits osteoclast dif-
ferentiation, RANK expression in TRAP assay, thus it has been suggested 
that Fucosterol has the dual potential to activate osteoblastic bone formation 
and suppress osteoclastic differentiation. This dual effects represents a 
benefit for treatment of postmenopausal osteoporosis, as an alternative to 
using a purely anti-resorptive approach, in order to inhibit bone remodeling 
(Lee et al., 2014).  Fucosterol, through its biological activities, may play an 
important role in preventing osteoporosis and might be useful as a supple-
ment for postmenopausal women.  Further clinical studies will be vital to 
identify the specific role of Fucosterol in the mechanism of bone metabolism 
and assess its estrogen-like actions in postmenopausal women. 
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1.23 6-Gingerol 
Ginger has been used historically as a traditional medicine in India. Several 
studies have shown evidence that compounds found in ginger contribute to 
relief of symptoms from chronic inflammatory diseases (Srivas, 1984; Kiuchi 
et al., 1992; Tjendraputra et al., 2001).  Ginger consists of different phyto-
chemicals such as 6-Gingererol, 8-Gingerol and 6-Shogaol.  Among these 
compounds, 6-Gingerol (Fig.1.9) exhibits a wide range of biochemical and 
pharmacological properties and has been reported that it possesses antioxi-
dant and anti-inflammatory properties as well as anti-mutagenic potential 
(Shukla et al., 2007).  6-Gingerol has been shown to induce apoptosis in 
cancer cells through depolarization of mitochondrial membrane potential, 
cleavage of caspase 3 and results in DNA fragmentation (Chakraborty et al., 
2012).  Earlier studies showed the anti-cancer potential of 6-Gingerol in the 
treatment of colorectal cancer cells through mitochondrial damage and cell 
survival pathway (Lee et al., 2008).  6-Gingerol also stimulates osteoblast dif-
ferentiation in normal physiological andinflammatory settings and improves 
TNF-α-suppressed osteoblast differentiation.  Thus, it is suggested that 6-
Gingerol may have beneficial effects on bone as a therapeutic agent for treat-
ing bone disorders such as osteoporosis (Fan et al., 2015). 
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Hypothesis 
PEs have antioxidant activity that prevent oxidative stress induce bone c ell 
death. 
Aim of study 
The primary goal of this project is to study the potential protective effect of 
phytoestrogen against osteocyte apoptosis induced by H2O2.  Specifically, 
the objectives and their associated aims of this project are as follow: 
 Firstly, to study the effect of PEs (Genistein, Daidzein and Resveratrol, 
Fucosterol and 6-gingerol) in the protection of osteocyte like cells 
MLO-Y4 from apoptosis induced by H2O2. 
 Secondly to study the protective effect of PES on different bone cells 
such as osteoblast like cells MC3T3-E1 cells and whether these PEs 
inhibit osteoclastogenesis by testing their effect on differentiation of 
RAW264.7 cells into osteoclast cells. 
 Thirdly, we sought to determine whether the effct of these PEs is di-
rect or indirect. 
 To evaluate the effect of the chemical structure of PEs (Genistein and 
Daidzein) in protecting MLO-Y4 cells against oxidative stress through 
modification of OH group. 
 To evaluate the effect of PEs on cytokines release in MLO-Y4 cells in 
response to oxidative stress induced by H2O2. 
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CHAPTER TWO: MATERIALS AND METHODS 
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2.1 Materials: 
Al the chemicals were purchased from Sigma UK and all tissue culture rea-
gents from Gibco/ Invitrogen UK unless otherwise stated. Tissue culture 
flasks and well plates were purchased from Coring USA.  Annexin V and 
Propidium iodide from Invitrogen life technology USA. 17β-estradiol, 
Genistein, Daidazein, Resveratrol, Fucosterol and 6-Gingerol from (Sigma 
Aldrich).  Estrogen receptor inhibitor (ICI 182780) from Tocris Bioscience 
(R&D system).  IL-6 and TNF-α ELISA kit from (Biolegend).  RANKL ELISA 
kit from (Boster Biological Technology).  Catalase activity assay kit from (Cell 
Biolabs, INC.). 
 
 
2.2 Methods: 
2.2.1 Cell culture: 
The cell lines used in the present study were murine long- bone derived os-
teocyte like MLO-Y4 cell lines, a gift from Prof. Lind Bonewald, MC3T3-E1 
osteoblast cells and RAW264.7 cells.  MLO-Y4 cells were grown in 75 cm2 
tissue culture flasks, which were pre-coated with 0.15mg/ml type 1 collagen 
solution prepared in 0.1M acetic acid. The cells were cultured under standard 
sterile conditions in pre-coated T-75 flask comprising growth medium: Mini-
mal Essential Medium alpha (αMEM) supplemented with 10% foetal bovine 
serum 1% penicillin/streptomycin (P/S) (Gibco)and 1% (1ml) Glutamax (Gib-
co). Cells were grown in continuous monolayer and maintained in an incuba-
tor at 370C in a humidified atmosphere of 5% CO2. Sub culturing was per-
formed twice a week upon reaching 90% confluence. The monolayer of cells 
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were detached by adding 1 ml of 2.5 % trypsin for 3 minutes followed by add-
ing 5ml of fresh growth medium to stop trypsin reaction, cell suspension at 
dilution of 1:10 was added to a new flask which was pre coated with type 1 
collagen to help maintain cells. 
 
 
2.2.2 MC3T3-E1 cell culture 
MC3T3-E1 cells were grown in Minimal Essential Medium alpha (αMEM) 
supplemented with 10% foetal bovine serum (FBS, Sigma) 1% penicillin/ 
streptomycin (P/S) (Gibco) and 1% L-Glutamine (Gibco) in 75 cm2 tissue cul-
ture flask. Cells were maintained in 75 cm2 tissue culture flasks as described 
in 2.2.1. 
 
 
2.2.3 Cell culture for RAW264.7 
Murine macrophage RAW264.7 cells are adherent cells and were cultured in 
DMEM medium supplemented with 10% foetal calf serum, 1%l glutamine, 1% 
penicillin/streptomycin. Cells were maintained as described by replacing me-
dium with fresh medium every 2-3 days.  
 
 
2.2.4 Osteoclast differentiation 
RAW 264.7 cells were seeded in 12-well plates (3 × 104 cells/well) in appro-
priate medium.  In test samples, the growth medium DMEM was replaced by 
differentiation medium, comprising (100 ng/mL RANKL and 50 ng/ml M-
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CSF).  The differentiation medium was changed every 2 days.  After 5 days, 
the medium was removed, and the cell monolayer was gently washed twice 
using PBS, fixed and stored at 40C for microscopic imageing. 
 
 
2.2.5 Assesment of Tartrate-Resistant Acid Phosphatase  activity 
Osteoclast formation was evaluated by staining for the specific osteoclastic 
marker TRAP.  Cells were fixed prior to immuno-histochemistry in 4% para- 
formaldehyde for 10 min and washed with distilled water.  The cells were in-
cubated at 370C in a humid and light-protected incubator for 1 h in the reac-
tion mixture of a leukocyte acid phosphatase assay kit (Sigma-Aldrich), as 
directed by the manufacturer.  The cells were washed three times with dis-
tilled water, and TRAP-positive multinucleated cells containing three or more 
nuclei were counted under a light microscope. The number of TRAP-positive 
cells was counted and the results expressed as the number of cells per 5 
fields of view.  All experiments were performed in triplicate.  
 
 
2.2.6 Fixation 
Following experimental procedure, cells were fixed with 4% paraformalde-
hyde (PFA) for 10 minutes at room temperature.  The cells were then washed 
with 1x PBS and stained with DAPI.  
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2.2.7 DAPI staining 
Cells were stained with 4’, 6- diamino-phenylindole (DAPI) 4mg/ml for 15 
minutes in the dark at room temperature.  Cells were then washed twice with 
1X PBS and visualized under microscope. 
 
 
2.2.8 Induction of apoptotic bodies using H2O2 
MLO-Y4 cells were plated on 6 well plates coated with collagen at a density 
of 5x104 cells/ml.  H2O2  was used at different concentrations (0.3, 0.4, 
0.5mM) for 2 hours, (n=2 wells per treatment). These concentrations were 
used based on studies conducted in previous literatures (Mann et al., 2007).  
Cells without H2O2  treatment were used as a control.  Cells were incubated 
at 370c for 2 hours after treatment with H2O2.  Media was removed, centri-
fuged and cells washed with PBS, then stained with 10 µl of (1mg/ml) of  An-
nexin V, followed by 5 µl of (1mg/ml) propidium iodide (PI) for 15 minutes and 
then visualized under fluorescence microscope (Carl Zeiss inverted micro-
scope) at 494nm/518nm for Annexin V and 535nm/617nm for PI. 
 
 
2.2.9 Characterization of apoptotic bodies by Annexin V FITC binding 
and PI staining. 
Osteocyte apoptotic bodies (OAB) were collected from cells, medium was 
removed and cells washed in PBS, centrifuged for 5 minutes at 6000rpm and 
supernatant was removed.  Cell density was determined and diluted in An-
nexin binding buffer to prepare sufficient volume to have 10000 OAB/ 100µl 
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Percentage of apoptotic cells = X100 
Average number of apoptotic cells from 3 fields 
Average number of cells from 3 fields 
per assay.  Annexin binding buffer was prepared as follows (10mM HEPES, 
140mM NaCl, 2.5mM CaCl2).  A quantity of 10 µl of (1mg/ml) FITC conjugat-
ed Annexin V was added to each 100µl of OAB suspension followed by 5 µl 
of (1mg/ml) propidium iodide (PI) and incubated at room temperature for 15 
minutes, 50µl was then spotted on a slide and visualized under fluorescence 
microscope to distinguish between viable (FITC negative, PI negative), early 
apoptosis (FITC positive, PI negative) and late apoptotic (FITC positive, PI 
positive) or necrotic cells (FITC negative, PI positive). Apoptotic cells were 
expressed as the percentage of ratio of Annexin V positive and PI negative 
from 3 fields over the total number of cells estimated from those fields. The 
total cell numbers were counted from using bright field microscopy. 
 
 
 
 
 
2.2.10 Treatment of MLO-Y4 cells with 17β-Estradiol or phytoestrogens 
(Genistein, Diadzein and Resveratrol): 
Cells were seeded at a density of 3x104 cells/well 24 hours prior to the exper-
iment (n= 3 wells per treatment).  Untreated cells were used as a negative 
control and cells treated with H2O2 only were used as a positive control. Cells 
were pre-treated with a dose range of (10nm, 100nM and1µM) for each of 
E2, Geistein, Diadzein and Resveratrol for 1 hour prior to incubation with 
0.4mM H2O2 for two hours to induce apoptosis. Cells were fixed and stained 
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with DAPI as described previously and visualized under fluorescent micro-
scope.  
 
 
2.2.11 Treatment of MLO-Y4 cells with Estrogen Receptor Inhibitor prior 
to treatment with 17β-Estradiol or phytoestrogen (Genistein, Diadzein 
and Resveratrol): 
Cells were treated with 10nM ICI 182780(RI) for 1 hour prior to treatment with 
10nM 17β-Estradiol or phytoestrogens.  Untreated cells were used as a neg-
ative control and cells treated with H2O2 only were used as a positive control.  
Apoptosis was induced by treatment with 0.4mM H2O2 for 2 hours.  After in-
cubation, cells were fixed and stained with DAPI.  Images were taken with an 
Inverted Carl Zeiss microscope, 3 images from 3 different fields of view per 
well (n=9 in total per treatment).  
 
 
2.2.12 Detection of Caspase 3 and 7 activities 
Caspase activity is a key event in apoptosis.  Untreated cells were used as a 
negative control. Apoptotic cells were detected by staining the cells with Im-
age live red caspase detection kit (FLICA)from (Sigma) for 1 hour.  Cells 
were washed with culture media, stained with Hoechst stain for 2-10 minutes 
then washed with wash buffer and visualized under fluorescence microscope 
at 595nm for FLICA. 
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2.2.13 Detection of intracellular reactive oxygen species 
Detection of reactive oxygen species was determined with 2, 7’-
dichlorodihydrofluorescein-diacetate (H2DCF-DA) which is a non-fluorescent 
substrate used as an indicator for reactive oxygen species (ROS).  Upon 
cleavage of the acetate groups by intracellular esterases and oxidation, the 
non-fluorescent H2DCF-DA is converted to the highly fluorescent 2', 7’-
dichlorofluorescein.  
H2DCF-DA was added to the cell culture media at a concentration of 10 µM 
for 45 minutes followed by incubation with either E2 or other PEs (Genistein, 
Daidzein and Resveratrol) at a concentration of 10nM. Untreated cells were 
used as control. The cells were incubated with these reagents for 1 hour prior 
to incubation with 0.4mM H2O2 for 2 hours.  All the reagents remained in the 
culture media during treatment with H2O2, which were then removed and 
washed twice with PBS. The rate of oxidation was monitored by a fluores-
cence microscopy. ROS positive cells were detected at 490nm FITC excita-
tion and images were captured at 20 x with the inverted microscope.  
 
 
2.2.14 Enzyme-linked immunosorbent assay (ELISA) for cytokines 
(RANKL, IL-6 and TNF-α) 
ELISA kit for RANKL was obtained from Booster Biological Technology, and 
ELISA kit for IL-6 and TNF-α were obtained from Biolegend.  Cytokine pro-
duction was measured in supernatants obtained from experimental culture 
following pre-treatment of MLO-Y4 cells in 24 well plates at a density of 
3x104 cells/ml.  Cells were treated with E2 and PEs (Genistein, Didzein and 
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Resveratrol) at a concentration of 10nM each for 1 hour prior to treatment 
with H2O2 for 2 hours.  Supernatants from samples were collected and stored 
at -80oC for later analysis.  ELISA experiments were carried out according to 
the manufacturer’s instructions, 96 wells palates were coated with 100µl/well 
of capture antibody in coating buffer and incubated over night at 4oC.  The 
wells that had been coated previously were aspirated and washed 5 times 
with wash buffer and followed by blocking them with 200 µl/well of 1xAssay 
diluent.  The plate was incubated at room temperature for 1 hour followed by 
washing as previously.  Standard curve was obtained by adding 100 µl/well 
of diluted standard to specific wells. Performing 2 fold serial dilution of the top 
standard to generate a standard curve to calculate the concentration of 
RANKL, IL-6 and TNF-α released in the cells supernatant, then 100 µl/well of 
samples supernatants were added to the appropriate wells.  The Plate was 
covered and incubated at room temperature for 2 hours followed by a total of 
5 washes. Then the detection antibody (100 µl/well) diluted in 1x assay dilu-
ent was added and incubated in room temperature for 1 hour.  Following 
washing, 100 µl/well of Avidin–HRP was added to the all wells and the plate 
was sealed and incubated at room temperature for 30 minutes.  Aspirating 
and washing was carried out for 5 times.  Substrate solution was then added 
to each well at 100 µl/well, and incubated at room temperature for another 15 
minutes.  After that 50 µl/well of stop solution (1M H3PO4) was added to each 
well.  Finally, the plate was read by micro plate reader at 450nm and 570nm.  
  
77 
 
2.2.15 Modification of Genistein and Daidzein 
Due to high cost and limited funding, experimentation with Resveratrol, Fu-
costerol and 6-Gingerol was not possible.  However, Genistein and Daidzein 
were readily available to be modified.  DZ approximately (0.54 g, 2mmol) was 
dissolved in acetone (50 ml) in two necked round bottom flask.  Potassium 
carbonate (2g) was added to this solution and the mixture was stirred under 
argon via magnetic stirrer then refluxed for 10 minutes.  Iodomethane (0.124 
ml, 2mmol) was added to 20ml of acetone, then added dropwise to the mix-
ture over 30 minutes and the mixture was refluxed for 2h.  The solvent was 
evaporated under reduced pressure and the residue was dissolved in di-
chloromethane and washed twice with pure water.  The solvent was dried 
over magnesium sulphate then evaporated under reduced pressure.  The 
crude Genistein and Daidzein were purified with flash chromatography by Pu-
riFlash instrument (Interchem) after determining the eluent solvent system by 
TLC (Thin Liquid Chromatography), a technique used to separate the com-
ponents of a mixture using silica gel cartridge (High Performance Spherical 
Silica 15 μ). The crude product was fractionated with dichloromethane and 
methanol (9:1) and the fractions were collected and the solvents evaporated 
under vacuum. Each fraction were purified again with semi-preparative HPLC 
over isomer’s separation column (COSMOSIL PYE, Pyrenylethyl group 
bonded, 4.6x15 mm), eluted with (0.5% formic acid, methanol and acetoni-
trile, and water, 80:15:4.5).  The fractions were collected and solvents were 
evaporated in vacuum, ready for structural analysis.  Genistein (0.5g, 
1.9mmol) was dissolved in acetone (50ml) in two necks round bottom flask 
and the procedure for purification was repeated as above.  
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2.2.16 Catalase Activity Assay 
Catalase activity assay is a direct measurement of catalase activity from cell 
lysate.  MLO-Y4 cells were seeded at a density of 1x106 cells / well for 24 
hours then treated with E2 or PEs for 1 hour prior to treatment with H2O2 for 
2 hours.  Media was removed and cells washed with cold PBS.  Cells were 
harvested with a rubber scraper, and homogenized on ice in 1 ml cold PBS, 
1mM EDTA, centrifuged at 10,000 x g for 15 minutes at 4°C.  Supernatant 
was removed and stored on ice then in -80 0C freezer until further use.  The 
procedure was carried out by adding 20 μL of diluted catalase standard or 
test samples to a 96-well microtiter plate, then 50 μL of the Hydrogen Perox-
ide working solution (12mM) was added to each well and incubated for 1 mi-
nute.  The reaction was stopped by adding 50 μl of the Catalase Quencher 
into each well and mixed thoroughly by using pipette, and then 5 µl of each 
reaction was transferred to a fresh well, 250 µl of chromogenic working solu-
tion to each well and plate was incubated 40-60 minutes with vigorous mix-
ing. Optical densityat 520nm was measured on an Omega Microplate Reader 
(Thermo scientific). 
 
 
Statistical analysis 
Statistical differences between groups were evaluated by using ANOVA test 
followed by Tukey post-hoc test.  The Statistical significance was indicated 
on graphs by *p≤ 0.05 and **p≤0.001 when compared to H2O2 treatment and 
# for significance when compared to control. Analyses were performed with 
the software programm “Graphpad Prism 5”. 
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CHAPTER THREE: INVESTIGATION OF THE EFFECT OF 
PHYTOESTROGENS IN THE PREVENSION OF OXIDANT IN-
DUCED APOPTOSIS IN MLO-Y4 CELLS 
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3.1 Introduction 
Osteoporosis is a chronic bone disease, characterized by a decrease in bone 
density, ultimately osteoporosis leads to loss in bone strength and increased-
susceptibility to fracture (Kular et al., 2012).  Estrogen exerts a protective ac 
tion in maintaining bone health by increasing osteoclast apoptosis (Mano-
lagas et al., 2013) and decreasing cytokines which promote osteoclast activi-
ty (Pacifici 1998).  Estrogen deficiency promotes bone loss at every age 
(Seeman et al., 2002) and causes an imbalance between the lifespan of os-
teoclasts and osteoblasts, this leads to a decrease in bone formation 
(Hughes et al., 1996).  On the contrary, hormone replacement therapy (HRT) 
is able to reduce bone loss and related fractures in postmenopausal women 
(Prelevic et al., 2005).  In 2002, the Women’s Health Initiatives (WHI) was the 
first large clinical trial to show a significant overall reduction in osteoporotic 
fractures in women receiving HRT compared with placebo, but this study re-
ported an increased risk of breast and endometrium cancer and of heart dis-
ease in the HRT group (Manson et al., 2003).  Therefore, potential supple-
mentary treatments that do not have these negative effects should be con-
sidered.  Women are at a greater risk of bone loss and eventually osteoporo-
sis due to estrogen withdrawal after the menopause.  It has been reported 
that osteocytes respond to estrogen, therefore, estrogen deficiency has been 
linked to osteocyte death in both human and rat bone (Tomkinson et al., 
1997 and 1998).  The main aim for an effective osteoporosis treatment is to 
reduce fracture risk and increase bone mineral density.  The reason for age 
related osteocyte loss is unclear but osteocyte apoptosis is caused by differ-
ent conditions including glucocorticoid treatment (Kogiani et al., 2004), micro 
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damage (Noble et al., 2003), estrogen loss (Tomkinsin et al., 1997) and oxi-
dant stress (Kikuyama et al., 2002).  The free radical theory of ageing is 
based on the evidence suggesting that ROS production and the response to 
oxidative stress contribute to a number of age related phenomena (Finkel 
and Holbrook 2000). 
Phytoestrogens are non-steroidal plant derived compounds that exhibit the 
effect of estrogen in estrogen target tissues, including bone (Viereck et al. 
2002; Weaver & Cheong, 2005).  Isoflavones are the main flavones in soy-
beans (Wang et al., 1994) and have gained great attention in protection 
against several diseases such as cardiovascular disease, cancer, osteoporo-
sis, and postmenopausal syndrome (Adlercreutz et al., 1999), and have been 
reported to reduce risk of endometerial cancer in women when compared 
with women on low levels of isoflavone consumption (Horn-Rosset al., 2003).  
Isoflavones have structural similarity to estrogen-like molecules, and it has 
been proposed that they play an important role in the prevention of osteopo-
rosis (Ward et al., 2007) through the presence of hydroxyl group in the B-ring 
to enable the scavenging of reactive nitrogen or oxygen species (Sekher et 
al., 2001), which might act be directly through lowering oxidative stress (Has-
san and Abdel-Wahhab, 2012).  Therefore, the potential anti-oxidant effects 
of phytoestrogens in the prevention of oxidative stress induced apoptosis in 
the osteocyte like cell line MLO-Y4 was investigated.  
Phytoestrogens such as isoflavones are plant-derived substances that struc 
 
turally resemble estrogen and display hormonal activity ( Dan et al., 2005).  A  
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range of phytomolecules such as Fucosterol and 6-Gingerol were used to in-
vestigate their protective effect on MLO-Y4 cells from apoptosis induced by 
H2O2.  Fucosterol was first isolated in 1934 from brown algae, where it is 
abundant and its structural backbone is similar to human estrogen (Gaulin et 
al., 2010).  Previous studies have shown that Fucosterol has anti-
inflammatory and anti-cancer effects, and protects skin from ultraviolet-
induced damage (Khanavi et al., 2012).  However, this study investigated the 
ability of Fucosterol to counter osteocyte apoptosis induced by H2O2.  6-
Gingerol is another phytochemical compound which contains a phenolic 
group and has a number of diverse effects such as anticancer, antioxidant, 
and anti-inflammatory. It is of interest to investigate the effect of this com-
pound on bone cells. Previous studies have determined the effect of 6-
gingerol on proliferation and differentiation of osteoblasts by measuring alka-
line phosphatase (ALP) activity, collagen type I synthesis, and bone minerali-
zation in 6-gingerol-treated human osteoblast-like MG-63 cells (Fan et al., 
2015).  Previous studies showed that 6-gingerol had no cytotoxic effects on 
MG-63 cells.  Furthermore, 6-gingerol was shown to possess anti-
inflammatory activity in MG-63 cells stimulated with TNF- (Fan et al., 2015). 
6-Gingerol and estrogen share a similarity in structure, as both compounds 
possess hydroxyl groups.  Therefore, it would be beneficial to explore the ef-
fect of this compound on MLO-Y4 cells and whether it can protect these cells 
from oxidative stress induced by H2O2.  
 
 
83 
 
3.2 Characterisation of osteocyte apoptotic bodies 
In order to establish the cell assay and to determine dose and time of expo-
sure of MLO-Y4 to H2O2 that induced apoptosis (but did not reduce cell num-
ber).  MLO-Y4 cells were exposed to H2O2 in a dose dependent manner over 
a 2 hour incubation period.  The percentage of apoptotic cells stained with 
Annexin V (early stage of apoptosis) was increased at a concentration of 
0.4mM of H2O2 at 2 hours (% apoptosis 0.4mM H2O2 40% ± 1.7 vs.  Control 
5.4% ± 1.6; p=0.0001) and the number of apoptotic cells stained positive for 
Annexin V and PI) was 10% ± 2.2 (Fig.3.1 and Fig.3.2), meanwhile the per-
centage of cells at early stage apoptosis at concentration of 0.5mM of H2O2 
were stained positive for Annexin V decreased (37%± 2.1), and the number 
of apoptotic cells that were stained positive for Annexin V and  (PI) (late 
stage of apoptosis were increased 22.6% ± 2.08).  The optimial concentration 
of H2O2 used to induce apoptosis was 0.4mM, which is in line with previous 
studies (Mann et al., 2007).  Therefore, this concentration was used to induce 
apoptosis in subsequent experiments.  DAPI staining was also used to de-
termine MLO-Y4 apoptosis as evidenced by morphological changes such as 
chromatin condensation, shrinkage of nuclei and the fragmentation of nuclear 
material into small blebs (Elmore 2007) Fig.3.3.   
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Figure 3.1: Induction of apoptotis in MLO-Y4 cells on treatment with0.4mM H2O2.  Repre-
sentative Phase contrast, Annexin V and Annexin V PI images for MLOY4 treated with 
0.4mM H2O2 for 1 hour; 2 hours; 3 hours and 4 hours.  FITC staining (green) repre-
sents Annexin V positive cells (early stage of apoptosis), PI staining (red) represents 
necrotic cells and orange colour represents Annexin V and PI positive cells (late stage 
of apoptosis) are indicated with white arrows. Scale bar = 50µm. 
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Figure 3.2: Induction of apoptosis in MLO-Y4 cells on treatment with different concen-
trations of  H2O2 for 2 hours. A 2 h incubation of MLO-Y4 cells with varying concentration 
of H2O2 between 0.3 and 0.5mM was used to induce oxidative stress cell death. The per-
centage of apoptotic cell death increased significantly compared to control at a concentration 
of 0.4mM. Data were expressed as mean ± SD of triplicate wells (three fields per well count-
ed) **p<0.001 versus control and *p<0.05.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: MLO-Y4  cells apoptosis. Cells were treated with  0.4 mM H2O2  
for 2 hrs and stained with DAPI. Apoptotic cells exhibiting membrane blebbing 
indicated with white arrow. 
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3.3 The anti-apoptotic effect of E2 on H2O2 induced apoptosis in MLOY4 
This assay was conducted in oreder  to provide a relative level of protection 
in the comparison between E2 and PEs.  MLO-Y4 was cultured and treated 
as described in section 2.2.8.  The percentage of apoptosis induced by 
0.4mM H2O2 (32% ± 4.06) was significantly reduced on pre-treatment with E2 
for 1 hour at a concentration of 10nM (16% ± 0.86, p=0.002), 100nM (20% ± 
3.9, p=0.011) and 1µM (18% ±1.61, p=0.02).  Treatment with E2 alone at 
concentration of 1µM induced MLOY4 apoptosis when compared to control 
(Control 15.5% ± 3.5) vs 1µM E2 (18.94% ±2.9, p=0.0001) (Fig 3.4). 
 
 
 
Figure 3.4: Effect of 17β-estradiol (E2) on H2O2 induced apoptosis in MLOY4. Pre-
treatment of MLO-Y4 with (E2) at a concentration of 10nM, 100nM and 1µM all significantly 
(p<0.001) reduced the percentage of apoptosis induced by treatment with [0.4mM] H2O2 for 2 
hours. Data were expressed as mean ± SD of triplicate wells (nine fields of view per well 
were counted).*p˂0.05 versus H2O2, # versus control. 
 
 
87 
 
3.4 The anti-apoptotic effect of Genistein, Daidazein and Resveratrol on 
osteocyte apoptosis induced by H2O2. 
 
MLO-Y4 at a density of 3 × 104 cells/well were plated in 24 well plates for 24 
hours, and then treated with Genistein for 1 hour at concentrations of 10nM, 
100nM and 1µM prior to treatment with 0.4mM H2O2 for 2 hours. The per-
centage of apoptotic cells induced by H2O2 (48% ± 3.8) was significantly re-
duced after pre-treatment with Genstein at a concentration of 10nM (25% 
±1.7, p=0.0013), 100nM (27% ± 2.5, p=0.0017) and 1µM (31% ± 2.3, 
p=0.012) Fig. 3.5. 
 
 
 
Figure 3.5: Effect of Genstein on on H2O2 induced apoptosis in MLOY4 cell line. Pre-
treatment of MLO-Y4 cells with Genistein at concentrations of 1µM, 100nM and 10nM re-
duced the percentage of MLOY4 apoptosis induced by treatment with 0.4mM H2O2. Data 
were expressed as mean ± SD of three wells (three fields per well were counted), n=9, 
*p˂0.05 versus H2O2, # versus control 
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Similarly, Daidazein was able to reduce H2O2 induced apoptosis.  The per-
centage of apoptotic cells induced by H2O2 (26.9% ± 2.1) was significantly 
reduced after pre-treatment with Daidzein at a concentration of 10nM (15.6% 
± 1.5, p=0.001), (17% ± 2.06, p=0.0165) at a concentration of 100nM, (15% ± 
2.2, p=0.021) at a concentration of 1M (Fig. 3.6), (p<0.05).  
Pre-reatment of MLO-Y4 cells with Resveratrol at a concentration of 10nM 
significantly reduced the percentage of apoptosis induced by H2O2 (48% ± 
3.8) at a concentration of 10nM (16.5% ± 2.4, p=0.001), (20% ± 2.1, p=0.016) 
at 100nM and (22% ± 0.5, p=0.017) at 1µM (Fig. 3.7). 
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Figure 3.6: Effect of Daidzein on H2O2 induced apoptosis in MLOY4 cell line. Pre-
treatment of MLO-Y4 cells with Daidazein at concentrations of 10nM, 100nM and 1µM re-
duced the percentage of apoptotic bodies induced by treatment with 0.4mM H2O2. Data rep-
resent  mean ± SD of three wells (three fields per well were counted), n=9, *p˂0.05 ver 
sus H2O2, # versus control 
 
 
 
 
Figure 3.7: Effect of Resveratrol on H2O2 induced apoptosis in MLOY4 cell line. Pre-
treatment of MLO-Y4 cells with Resveratrol at concentrations of 10nM, 100nM and 1µM re-
duced the percentage of apoptotic osteocytes induced by treatment with H2O2 at concentra-
tion of 0.4mM. Pre-incubation of Resveratrol at a concentration of 10nM reduced the per-
centage of apoptosis in MLO-y4 cells significantly, but the reduction was not significant at 
other concentrations. Data is expressed as mean ± SD of three wells (three fields per well 
were counted), n=9, *p<0.05,  **p<0.001 versus H2O2, # versus control. 
90 
 
3.5. Effect of Fucosterol on oxidative stress induced by Hydrogen Per-
oxide in MLO-Y4 cells 
 
The effect of Fucosterol on protecting MLO-Y4 cells from apoptosis induced 
by H2O2was investigated.  MLO-Y4 were plated in 24 well plates for 24 
hours, and then treated with Fucosterol for 1 hour at a range of concentra-
tions (10nM-1µM) before treatment with 0.4mM H2O2 for 2 hours.  The per-
centage of apoptosis induced by 0.4mM H2O2 (11.5% ± 2.2) was significantly 
reduced on pre-treatment with Fucosterol for 1 hour at concentrations of 
10nM (6.2% ± 1.39, p=0.02), 100nM (6.3% ± 2.92; p=0.011) and 1µM (8.97% 
± 2.63; p=0.02) Fig.3.8. 
 
 
 
Figure 3.8: Effect of Fucosterol treatment on H2O2 induced apoptosis in MLOY4 cell 
line. Pre-treatment of MLO-Y4 with Fucosterol at concentrations of 10nM, 100nM and 1µM 
all significantly reduced the percentage of apoptosis induced with H2O2 at concentration of 
0.4mM for 2 hours. Data were expressed as ± SD of three wells (three fields per well were 
counted), *p<0.05 versus H2O2, # versus control 
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3.6 Effect of 6-Gingerol on protecting MLO-Y4 cells from apoptosis 
The protecting effect of 6-Gingerol on osteocytes from H2O2 induced apopto-
sis was investigated.  MLO-Y4 were plated in 24 well plates for 24 hours, pri-
or to treatment with 6-Gingerol for 1 hour at a concentration of 10µM, prior to 
treatment with 0.4mM H2O2 for 2 hours.  The percentage of apoptosis in-
duced by 0.4mM H2O2 (12.10% ± 1.58) was significantly reduced on pre-
treatment with 6-Gingerol for 1 hour (6.2± 2.7, p=0.015) Figure 3.9. 
 
 
 
Figure 3.9: Effect of 6-Gingerol treatment on H2O2 induced apoptosis in MLOY4 
cells. Pre-treatment of MLO-Y4 cells with 10µM of 6-gingerol reduced the percentage of 
apoptosis induced with H2O2 at a concentration of 0.4mM for 2 hours. Data were ex-
pressed as ± SD of three wells (three fields per well were counted), n=9, *p˂0.05 versus 
H2O2, #versus control. 
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3.7 Detection of intracellular ROS 
ROS is the key factor with regards to ageing and is involved in several de-
generative disorders and could be the cause of osteocyte death on E2 with-
drawal (Bonwald 2011).  The majority of cellular ROS are generated by the 
mitochondrial electron transport chain during normal metabolism.  In order to 
determine whether phytoestrogen could reduce ROS generation induced by 
H2O2 in MLO-Y4 cells, cells were exposed to E2 or Genistein, Daidazein and 
Resveratrol at a concentration of 10nM for 1 hour prior to incubation with 
H2O2 at a concentration of 0.4mM for 2 hours.  These concentrations were 
used based on the previous experiments.  The ability of H2O2 to generate 
ROS was investigated using 2’, 7’-dichlorofluorescein (H2DCF-DA) Fig.3.10.  
The proportion of ROS positive cells was increased after 2 hours of treatment 
with H2O2 when compared to control (ROS Positive cells 2.8% ±1.1 vs. H2O2 
56.5% ± 1.79, p=0.001).  Treatment with E2, which was used as a positive 
control to compare with PEs reduced the percentage of ROS positive cells 
(10.37% ± 2.12, p=0.0001) Fig.3.11.  Also treatment with Genistein, Daidze-
in, and Resveratrol reduced the level of positive ROS cells at concentration 
of 10nM each  which was similar to that seen in treatment with E2 at a con-
centration of 10nM.  The percentage of ROS positive cells in pre-treatment 
with Genistein was (10.7% ± 1.5, p=0.0001) Fig. 3.12, Daidzein (11.87% ± 
1.526%, p=0.0001) Fig.3.13 and Resveratrol (10.27% ± 1.535, p=0.0001) 
Fig.3.14. 
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Figure 3.10 Representative images of ROS activity in MLO-Y4 cells. Phase contrast and H2DCF-
DA. (A) Represents control. (B) Treatment with H2O2 at a concentration of 0.4mM. (C) Treatment with 
E2 at a concentration of 10nM (D) Treatment with E2 at a concentration 10nM prior to treatment with 
H2O2. (E) Treatment with Genistein at concentration of 10nM. (F) Treatment with Genistein at a concen-
tration of 10nM prior to treatment with H2O2. (G) Treatment with Daidazein at a concentration of10nM. 
(H) Treatment with Daidzein at a concentration of 10nM prior to treatment with H2O2. (I) Treatment with 
Resveratrol at concentration of10nM. (J) Treatment with Resveratrol at a concentration of 10nM prior to 
H2O2 treatment.  White arrows indicate ROS positive cells. Scale bar 50µm. 
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Figure 3.12: Percentage of ROS positive cells in MLO-Y4 cells pre-treated with 
Genistein at a concentration of 10nM prior to treatment with 0.4mM H2O2. Pre-
treatment of MLO-Y4 cells with 10nM of Genistein significantly reduced the percentage of 
ROS positive cells on H2O2  treatment. Data were expressed as means ± SD of triple 
wells (3 fields per well were counted)  **   p< 0.0001versus H2O2, # versus control. 
 
Figure 3.11: Percentage of ROS positive cells in MLO-Y4 cells pre-treated with E2 at 
a concentration of 10nM (E2) prior to treatment with H2O2  at a concentration of 
0.4mM. E2 Pre-treatment significantly reduced the percentage of ROS positive cells on 
H2O2  treatment. Data were expressed as means ± SD of triple wells (3 fields per well 
were counted)  ٭ p<0.0001 versus H2O2, # versus control. 
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Figure 3.13: Percentage of ROS positive cells in MLO-Y4 cells treated with Daidzein 
at a concentration of 10nM prior to treatment with 0.4mM H2O2. Pre-treatment with 
10nM of Daidzein significantly reduced the percentage of ROS positive cells on H2O2 
treatment. Data were expressed as means ± SD of triple wells (3 fields per well were 
counted)  ٭ p< 0.0001 versus H2O2, # versus control. 
 
Figure 3.14: Percentage of ROS positive cells in MLO-Y4 cells pre-treated with 
Resveratrol at a concentration of 10nM prior to treatment withH2O2. Pre-treatment 
with 10nM of Resveratrol significantly reduced the percentage of ROS positive cells on 
treatment with H2O2. Data were expressed as means ± SD of triple wells (3 fields per well 
were counted) **p< 0.0001versus H2O2, # versus control. 
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3.7.1 Effect of Fucosterol on intracellular ROS generation 
To determine the effect of Fucosterol on ROS generation induced by H2O2 in 
MLO-Y4 cells, cells were treated with fucosterol at a concentration of 10nM 
for 1 hour prior to incubation with H2O2 for 2 hours.  The ability of ROS gen-
eration by H2O2 was investigated using 2’, 7’-dichlorofluorescein (H2DCF-
DA).  The level of ROS positive cells was detected by counting ROS positive 
cells which had increased after 2 hours of treatment with H2O2 compared to 
control ( H2O2 25.85% ± 4.5 vs. Control 5.52% ± 1.5, p=0.000).  Treatment 
with Fucosterol at a concentration of 10nM significantly reduced the level of 
ROS positive cells to (12.16% ± 2.89, p=0.0001) Fig. 3.15. 
 
 
 
Figure 3.15: Percentage of ROS positive cells in MLO-Y4 cells treated with Fucos-
terol at a concentration of 10nM prior to treatment with H2O2. Pre-treatment with 
10nM Fucosterol significantly reduced the percentage of ROS positive cells on treatment 
with H2O2. Data were expressed as means ± SD of triple wells (3 fields per well were 
counted) **p< 0.0001 versus H2O2, # versus control. 
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3.7.2 Effect of 6-Gingerol on intracellular ROS generation 
The ability of ROS generation in MLO-Y4 cells was investigated by H2O2 us-
ing 2’, 7’-dichlorofluorescein (H2DCF-DA). The level of ROS positive cells 
was detected by counting ROS positive cells which had increased after 2 
hours of treatment with H2O2 (56.93% ± 2.7).  Treatment with 10µM of 6-
gingerol significantly reduced the percentage of ROS generation (8.10 ± 4, 
P=0.0001) Fig. 3.16. 
 
 
 
 
 
 
 
 
 
Figure 3.16: Percentage of ROS positive cells in MLO-Y4 cells treated with 6-Gingerol at 
a concentration of 10 µM prior to treatment with H2O2. Pre-treatment with 6-Gingerol at a 
concentration of 10µM significantly reduced the percentage of ROS positive cells on treatment 
with H2O2.  Data were expressed as means ± SD of triple wells (3 fields per well were counted) 
**p< 0.0001 versus H2O2, # versus control. 
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3.8 Investigation of role of E2 and Genistein, Daidzein and Resveratrol 
on caspase3, 7 activation 
A distinctive feature of the early stages of apoptosis is the activation of 
caspase enzymes, these enzymes participate in a series of reactions that are 
triggered in response to pro-apoptotic signals and result in the cleavage of 
protein substrates and in the subsequent disassembly of the cell.  The effect 
of E2 and PEs on caspase activation induced by H2O2 in MLO-Y4 cells was 
investigated.  Cells were pre-treated with either E2, Genistein, Daidzein or 
Resveratrol followed by treatment with H2O2 as described in material and 
method section 2.2.12.  Caspase activation was detected using Image-iT ™ 
live red Caspase-3 and -7-detection kit, (Figure 3.17 and 3.18).  Incubation of 
MLOY4 with H2O2 at a concentration of 0.4mM increased caspase activity.  
The percentage of cells staining positive for Caspase -3 and -7 were de-
creased in MLOY4 following pre-treatment with E2 (6.81% ± 0.7 vs. H2O2 
treatment 12.81% ± 3.7; p=0.002) Fig.3.19. 
In a similar way treatment with Genistein, Daidzein and Resveratrol signifi-
cantly inhibited caspase activity.   The percentage of cells stained positive for 
caspase 3, 7 in cells pre-treated with Genistein was (6.97% ± 1.41, p=0.0363) 
Fig.3.20, cells pre-treated with Daidzein (8.8% ± 1.1, p=0.038) Fig.3.21 and 
in cells treated with resveratrol is (6.82% ± 1.11, p=0.02) Fig.3.22. 
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Figure 3.17: Detection of caspase activity in MLO-Y4 cells induced by H2O2. Cells 
were pre-treated with 10nM E2 for 1 hour followed by treatment with H2O2 at a concentra-
tion of 0.4mM for 2 hours. Cells were labelled with FLICA reagent and viewed under fluo-
rescence. White arrows indicate cells staining positive for Caspase 3 and 7. 
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Figure 3.19: Detection of caspase 3 and 7 activity in MLO-Y4 cells pre- treated with E2 
prior to H2O2 treatment at a concentration of 0.4mM. Pre-treatment of cells with E2 de-
creased Caspase activity on challenge with H2O2. Data were expressed as means ± SD of triple 
wells (three fields per well counted) *p<0.05 versus H2O2, # versus control. 
 
 
 
Figure 3.20: Detection of caspase 3 and 7 activity in MLO-Y4 cells pre-treated with 
Genistein prior to H2O2 treatment at a concentration of 0.4mM. Pre-treatment of MLO-Y4 
cells with 10nM of Genistein significantly reduced caspase activity on challenge with H2O2.  
Data were expressed as means ± SD of triple wells (three fields per well counted) *p<0.05 
versus H2O2, # versus control. 
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Figure 3.22: Detection of caspase 3 and 7 activity in MLO-Y4 cells pre-treated with 
Resvertrol prior to H2O2 treatment at a concentration of 0.4mM.  Pre-treatment of MLO-
Y4 cells with Resveratrol at a concentration of 10nM significantly reduced caspase activity on 
challenge with H2O2. Data were expressed as means ± SD of triple wells (three fields per well 
counted) *p<0.05  versus H2O2, # versus control. 
 
 
Figure 3.21: Detection of caspase 3 and 7 activity in MLO-Y4 cells pre- treated with 
Daidzein prior to H2O2 treatment at a concentration of 0.4mM. Pre-treatment of MLO-Y4 
cells with Daidzein at a concentration of 10nM significantly reduced caspase activity on chal-
lenge with H2O2. Data were expressed as means ± SD of triple wells (three fields per well 
counted) *p<0.05 versus H2O2, # versus control. 
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3.9 Effect of 6-Gingerol on caspase activity 
The effect of 6-Gingerol on caspase activity was detected using Image-iT ™ 
live red Caspase-3 and 7 detection kit after treatment with 10µM of 6-
Gingerol before treatment with 0.4mM H2O2 for 2 hours.  H2O2 tratment in-
creased the caspase activity in MLO-Y4 cells.  The percentage of cells 
stained positive for caspase 3, 7 were decreased in MLOY4 cells following 
pre-treatment with 6-Gingerol (6.61% ± 0.90, vs H2O2 treatment 16.69% ± 
1.58,  p =0.002) Fig 3.23. 
 
 
 
 
Figure 3.23 : Detection of caspase 3 and 7 activity in MLO-Y4 cells pre-treated with 6-
Gingerol prior to H2O2 treatment at a concentration of 0.4mM.  Pre-treatment of MLO-Y4 
cells with 6-Gingerol at a concentration of 10µM significantly reduced caspase activity. Data 
were expressed as means ± SD of triple wells (three fields per well counted) *p<0.05 versus 
H2O2, # versus control. 
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3.10 Discussion 
In this study, H2O2 has been shown to induce MLO-Y4 apoptosis as con-
firmed by Annexin V staining.  H2O2 induced osteocyte apoptosis in a dose 
dependent manner, which is consistent with other studies (Mann et al., 
2007).  Many conditions such as ischemia, reperfusion and myocardial infarc-
tion can indirectly lead to oxidative stress, which could influence osteocytes 
resulting in an increase in intracellular ROS that is the major determinant of 
ageing (Manolagas 2010).  Increased levels of ROS generation has been in-
volved in tissue homeostasis in bone tissue and affects bone remodelling by 
promoting bone resorption (Wauquier et al., 2009).  Studies have suggested 
the role of oxidative stress in bone diseases such as osteoporosis, diabetes-
induced bone diseases and vascular diseases (Hamada et al., 2014).  Oxida-
tive stress results in the disregulation of redox balance in the tissue.  In this 
study, H2O2 was used as a model of ROS to induce apoptosis in MLO-Y4 os-
teocyte like cell line.  The concentration of H2O2 used was based on other 
literature (Mann et al., 2007).   
Estrogen deficiency in postmenopausal women increases the incidence of 
osteogenesis-associated fracture and estrogen HRT has been suggested as 
the first-line treatment for osteoporosis, but prolonged usage of HRT is one of 
the risk factors for incidence of breast, endometrial and high level of ovarian 
cancer as well as cardiovascular diseases (Beral 2003). 
In this study, the effect of a range of phytomolecules, Genistein, Daidzein, 
Resveratrol, Fucosterol and 6-Gingerol on H2O2 induced apoptosis in MLO-
Y4 cells were examined.  Apoptosis was induced in MLOY4 by exposure to 
H2O2, as evidenced by a range of methods such as Annexin V staining, mor-
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phology characterisation such as membrane blebbing evidenced by DAPI 
staining (Fig.3.3) and caspase activation (Fig.3.16).  It has been  observed 
that MLO-Y4 cells pre-incubated with 17β-estradiol prior to H2O2 treatment 
reduced the number of apoptotic nuclei.  This protective action was dose de-
pendent namely 1µM, 100nM and 10nM.  A maximal effect was detected at a 
concentration of 17β-estradiol 1µM however, at this concentration, apoptosis 
was also increased when compared to control (Fig.3.4); this result was con-
sistent with other work published by (Mann et al., 2007) and provides a com-
parator for the potential protecting effects of phytoestrogen molecules.  Cell 
treatment with 17β-estradiol at a concentration of 10nM has shown to be 
non-toxic to MLO-Y4 cells, on the other hand, blocked the apoptotic effect 
induced by H2O2, as previously described (Mann et al., 2007).  Geistein, Dai-
dazein and Resveratrol were also shown to block MLOY4 apoptosis induced 
by H2O2.  This protection is thought to be due to the structural similarity of 
these phytomolecules to estrogen which is related to the presence of hydrox-
yl group at the C3 position of the A ring of the hormone (Behl et al., 1997).  
Genistein and Daidzein have been found to have a stimulatory effect on pro-
tein synthesis and on alkaline phosphatase release by osteoblastic MC3T3-
E1 cells in vitro (Sugimoto et al., 2000, Yamaguchi et al., 2000).  More re-
cently, Genistein has been found to stimulate the production of osteopro-
tegerin by human osteoblasts, providing a further mechanism for the bone-
sparing effects of soy isoflavones (Viereck et al., 2002).  Genistein and Dai-
dzein both inhibit osteoclast activity by a number of possible mechanisms, 
including induction of apoptosis, activation of protein tyrosine phosphatase, 
inhibition of cytokines, changes in intracellular Ca2+, and membrane depolari-
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zation (Ming et al., 2013, Williams et al., 1998).  The presence of estrogen 
receptors in osteoblasts, osteoclasts and osteocytes (Arts et al., 1997, Onoe 
et al., 1997) and the wide-ranging biological properties of these non-steroidal 
dietary estrogens (Akiyama et al., 1987, Kim et al., 1998) provide good foun-
dation for thinking that dietary phytoestrogens could play a role in bone re-
modelling. 
Resveratrol has been thought to be involved in promotion of osteopontin and 
osteocalcin expression, the main osteoblastic markers in human bone mar-
row mesenchymal stem cells and regulates the expression of 1, 25-dihydroxy 
vitamin D3 and calcium uptake to help in bone formation.  Additionally, in 
vitro studies suggested that Resveratrol prevents osteoclast formation 
through inhibiting receptor activator of nuclear factor-κB (NF-κB) ligand–
induced formation of tartrate-resistant acid phosphatase (TRAP)–positive 
multinucleated cells, TRAP activity in the medium, up-regulation of cathepsin 
K gene expression, and bone resorption (Boissy et al., 2005).  These inhibi-
tions are associated with a down-regulation of RANK expression at both 
mRNA and cell surface protein levels, and a decrease of NFATc1 stimulation 
and NF-κB nuclear translocation, whereas the gene expression of c-fms, 
CD14, and CD11a is up-regulated. Finally, Resveratrol promotes dose-
dependently the expression of osteoblast markers like osteocalcin and oste-
opontin in human bone marrow mesenchymal stem cells (Boissy et al., 
2005).  Moreover, it has been proven that Resveratrol prevents bone resorp-
tion and enhances osteoblast differentiation and has been proven to act as 
phytoestrogen (Gehm et al., 1997).  The anti-oxidative activity of Resveratrol 
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is claimed to be due to the presence of hydroxyl phenolic group in its chemi-
cal structure (Leonard et al., 2003). 
In this study, PEs have also been shown to influence caspase activation in 
apoptotic MLO-Y4 cells induced by H2O2, as assessed by selective caspase-
3, 7.  Activation of caspase enzyme is the distinctive feature for early stage 
apoptosis and involves an intrinsic proteolytic cascade within which caspase 
family of enzymes is critical (Nicholson and Thornberry 1997).  The detection 
of caspase is based on the fluorescent inhibitor of caspase (FLICA), which is 
a cell inhibitor, cell permeant and non-cytotoxic.  
 
One of the fascinating roles of ROS at a cellular level is controlling normal 
cell signalling, regulation of growth and apoptosis and at system level control-
ling blood pressure and immune function (Brieger et al., 2012).  Conversely, 
ROS participate in normal ageing and age related diseases such as cancer, 
atherosclerosis and neurodegeneration (Finkel 2000).  Many studies suggest 
that osteoporosis is one of the consequences of oxidative stress which is as-
sociated with reduced bone mineral density (BMD) (Basu et al 2001).  ROS 
generation causes bone resorption by active osteoclasts (Garrett et al 1990), 
and their activity is dependent upon several intracellular signals that are sen-
sitive to ROS (Lean et al 2003).  Regarding antioxidant potency of phytoes-
trogens, this study shows that these plant derivatives are capable of reducing 
the level of ROS. 
In this study, a range of phytomolecules were also used such as Fucosterol 
and 6-Gingerol, which have been known to have antioxidant effects on differ-
ent cell types, therefore, these effects on MLO-Y4 were assessed. 
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Fucosterol has been known to possess anti-inflammatory, anti-cancer proper-
ties as well as being effective in the protection of skin from ultraviolet induced 
damage through inhibition of ROS generation (Yoo et al., 2012, kimet al., 
2013).  However, to date, the effects of Fucosterol on bone degeneration 
have not been thoroughly investigated.   In this study, the ability of Fucosterol 
in counter act oxidative stress induced by H2O2 treatment of MLO-Y4 was in-
vestigated.  The results obtained showed that treatment with Fucosterol re-
duced the percentage of apoptosis in MLO-Y4 cells when compared to H2O2 
treatment and intracellular ROS generation was also reduced.  Previous 
studies have suggested the role of Fucosterol in bone formation by increas-
ing osteogenesis through cell proliferation and ALP expression in comparison 
to those of estradiol in an osteoblastic cell line (MG63) which has a potential 
to activate osteoblast (Lee et al., 2014).  
Ginger (Zingiber officinale roscoe, Zingiberaceae) is a medicinal plant that 
has been widely used in Chinese medicine, and is a commonly used  spice in 
many parts of the world (Ali et al., 2008), which contains  6-Gingerol, 8-
gingerol and 6-shogaol all of which are phytochemical compounds.  Among 
all these fractions, 6-Gingerol displays a wide array of biochemical and 
pharmacologic activities. 6-Gingerol, the major pharmacologically active 
component of Ginger, was reported to exhibit antioxidant and anti-
inflammatory properties (Shukla et al., 2007).  Previous studies have not ac-
tively tested the anti-apoptotic effect of 6-Gingerol and mostly focused on the 
apoptosis-promoting properties in certain cancer cells.  However, an active 
component of dried Ginger, Shogaol, attenuated apoptotic cell death in a spi-
nal cord injury model by inhibiting poly(ADP-ribose) polymerase activity and 
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reducing astrogliosis (change in astrocyte phenotype in response to all CNS 
injuries and diseases)  (Kyung et al., 2006). 
An earlier study reported that 6-Gingerol had genotoxic effects on liver carci-
noma and it could destabilize the lysosomal membrane with higher ROS in-
duction (Elmore 2007), leading to apoptosis of HepG2 cells (Yang et al., 
2010).  Other studies have reported that 6-Gingerol had no toxic effect on 
normal cells (Singh et al., 2009).  However, the mechanism of action of 6-
Gingerol remains unclear, and therefore needs further study.  In this study, 
the main objective was to explore its role in prevention of oxidant-induced 
apoptosis in MLO-Y4 cells.  It was also interesting to see whether 6-Gingerol 
pre-treatment was able to protect MLO-Y4 cells against oxidative stress in-
duced by H2O2 and decrease the percentage of apoptosis compared to treat-
ed cells with H2O2. 
The anti-oxidative effect of 6-Gingerol was detected by H2DCFDA and as 
predicted, 6-Gingerol as an antioxidant was shown to protect MLO-Y4 cells. 
Moreover, it induced inhibition of caspase 3 activation which is the most im-
portant type of caspase which actively takes part in proteolytic cleavage of 
PARP (poly-ADP ribose polymerase) protein.  Increased expression of PARP 
is indication of a greater extent of DNA degradation.  Caspase 3 and PARP 
are therefore considered as significant markers of cells undergoing apoptosis 
(Biswas et al., 2011).  To further determine the involvement of caspase 3 in 
6-Gingerol treated cells, caspase 3 activation was assessed and activation 
subjected with red (FLICA) reagent was also assessed.  The results sug-
gested that the inhibition of caspase 3 activation in MLO-Y4 cells might ac-
count for the mechanism of 6-Gingerol protection from apoptosis.  This sug-
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gest that 6-Gingerol protect cells from apoptosis by mediating reactive oxy-
gen species and inhibition of caspase activation, as would be the case for 
other PEs, as these all had the same effect on caspase activation. 
Fucosterol and 6-Gingerol which share structural similarities to E2 also have 
similar effects to that of Genistein, Daidzein and Resveratrol on protecting 
cells from oxidative stress and inhibition of ROS generation.  These results 
provide further evidence that PEs have a potential in the prevention of oxi-
dants induced in MLO-Y4 cells.  Therefore, it is worth exploring the potential 
protecting effects of Genistein, Daidzein and Resveratrol in osteoblasts in-
duced by H2O2 and the potential to influence osteoclast differentiation. 
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CHAPTER FOUR: THE EFFECT OF PHYTOESTROGEN ON 
HYDROGEN PEROXIDE INDUCED APOPTOSIS IN MC3T3-E1 
AND RAW 264.7 CELLS DIFFERENTIATION 
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4.1 Introduction 
Soy is a component of several foods which are thought to maintain bone 
health (Katsuyama et al. 2009).  Several studies noted decreases in resorp-
tion markers following PEs supplementation (Weaver et al., 2009) and in-vitro 
studies show a direct suppressive effect of PEs on cytokine-induced osteo-
clast differentiation (Karieb and Fox, 2011).  In addition to suppressing re-
sorption, PEs have also been shown to increase bone formation markers 
such as serum ALP and osteocalcin levels in post-menopausal women (Mo-
rabito et al. 2002, Roudsari et al., 2005).  Genistein has also been shown to 
increase mineral apposition and bone formation rates in ovariectomised rats 
(Dai et al. 2008) and PEs stimulate osteoblast differentiation and mineralisa-
tion in-vitro (Kanno et al. 2004; Wu et al. 2009).  Estrogen loss has been 
Bone remodelling is a constant process in the skeleton to ensure correct 
mineral homeostasis and to maintain the structural integrity and thereby bone 
strength (Martin and Seeman, 2008, Henriksen, et al. 2009).  This process is 
maintained by osteoblasts, bone forming cells and osteoclasts, bone resorb-
ing cells. 
Ageing and loss of sex steroids have adverse effects on skeletal homeosta-
sis. Changes in bone strength which is associated with a decrease in bone 
remodelling as evidenced by decreased osteoblast and osteoclast numbers 
and decreased bone formation rate; as well as increased osteoblast and os-
teocyte apoptosis (Almeida, et al. 2007).  Low E2 levels in post-menopausal 
women results in an increase in bone remodeling and increased bone resorp-
tion (Manolagas et al. 2002).  Thus, bone loss increases fracture risk in tra-
becular areas such as the femoral neck and distal radius and ulna.  
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shown to increase the levels of reactive oxygen species (ROS) and conse-
quently, increased bone porosity as a result of an imbalance in the bone re-
modeling process.  Therefore, it is important to look at the effect of PEs on 
other bone cells such as osteoblasts and osteoclasts. Also if PE’s have the 
potential to augment therapeutic interventions it will be important to under-
stand the effects on other bone cells.  Murine cells MC3T3-E1 and RAW 
264.7 cell lines were used as models for osteoblasts and osteoclasts respec-
tively.   
 
 
4.2 Saving effect of PEs on MC3T3-E1 cells 
The effect of E2 and PEs (Genistein, Daidzein and Resveratrol) on H2O2 in-
duced apoptosis were evaluated in MC3T3-E1 cells.  Cells were cultured as 
described in section 2.2.1 and treated with E2 or PEs (Genistein, Daidzein 
and Resveratrol) at a concentration of 10nM.  Apoptotic cells were detected 
via morphological changes as mentioned in section 2.2.7.  The percentage of 
apoptosis induced by 0.4mM H2O2 (18.05% ± 1.33, p=0.0002 vs control (6.04% 
± 1.4, p=0.0002) was significantly reduced on pre-treatment with E2 for 1 
hour at a concentration of 10nM (9.49% ± 1.23 p=0.009).  Furthermore, pre-
treatment with PEs at a concentration of 10nM reduced the percentage of 
MC3T3-E1 apoptosis.  Genistein (9.58% ± 0.97 p=0.006), Daidzein (10.7% ± 
2.16, p=0.0056) and Resveratrol (10.9% ± 1 p=0.0022) Figure 4.1. 
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Figure 4.1: Effect of E2 and Ps on MC3T3-E1 cell apoptosis induced by H2O2. Pre-
treatment of MC3T3-E1 cells with E2 and different PEs (Genestein, Daidzein. and Resveratrol) 
at a concentration of 10nM decreased the percentage of MC3T3-E1 cells apoptosis induced by 
H2O2.  Data were expressed as ± SD of three wells (three fields per well were counted), n=9, 
*p˂0.05 versus H2O2, # versus control. 
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4.3 Measurement of intracellular ROS 
 
The oxidative stress induced by H2O2 treatment in MC3T3-E1 cells was eval-
uated by measuring ROS generation.  Oxidative stress may initiate a mito-
chondrial permeability transition event, which is an early mediator of cell 
apoptosis. When cells were treated with 0.4mM H2O2, the level of cells posi-
tive for ROS was significantly increased when compared with control (Control 
3% ±1.7 vs H2O2  20.73% ± 2.28, p=0.0004), while treatment with E2 reduced 
the level of ROS generation (4.7% ± 0.89, p=0.0003) Fig.4.2, also PEs 
(Genistein, Daidzein and Resveratrol) at 10nM in the presence of H2O2  re-
duced ROS positive cells, Genistein (6.3% ±1.6, p=0.0009), Daidzein (7%  
±1.5, p=0.001) and Resveratrol (6.6% ±1.4, p=0.0008).(Fig.4.3, 4.4 and 4.5)  
respectively. 
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Figure 4.3:  ROS activity in MC3T3 cells treated with Genistein prior to treatment 
with H2O2. Pre-treatment with Genistein significantly reduced the percentage of ROS posi-
tive cells on treatment with H2O2.Data were expressed as means ± SD of triple wells (3 
fields per well were counted) **p<0.0001 versus H2O2, # versus control. 
 
Figure 4.2: ROS activity in MC3T3 cells treated with 17- estradiol (E2) prior to treat-
ment with H2O2. Pre-treatment with E2 significantly reduced the percentage of ROS posi-
tive cells on treatment with H2O2. Data were expressed as means ± SD of triple wells (3 
fields per well were counted) **p<0.0001 versus H2O2, # versus control. 
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Figure 4.4:  Ros activity in MC3T3 cells treated with Daidzein prior to treatment with 
H2O2. Pre-treatment with Daidzein significantly reduced the percentage of ROS positive cells 
on treatment with H2O2.  Data were expressed as means ± SD of triple wells (3 fields per well 
were counted) **p<0.0001 versus H2O2, # versus control. 
 
 
Figure 4.5: ROS activity in MC3T3 cells treated with Resveratrol prior to treatment 
with H2O2. Pre-treatment with Resveratrol significantly reduced the percentage of ROS 
positive cells on treatment with H2O2.  Data were expressed as means ± SD of triple wells 
(3 fields per well were counted) **p<0.0001 versus H2O2, # versus control. 
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4.4 Effects of PEs on differentiation of RAW 264.7 cells and Tartrate-
resistant Acid Phosphatase 
Bone homeostasis is preserved by the balance between bone formation and 
resorption (Boyle et al., 2003).  Osteoclasts are bone-resorbing multinucleat-
ed cells, formed by the fusion of their mononuclear precursor’s monocytes 
and macrophages.  Osteoclast differentiation of precursors can be stimulated 
by (RANKL) produced by osteoblasts.  Binding of RANKL to its receptor in-
duces small non-toxic amounts of ROS, various growth factors, as well as 
cytokines including TNF-α.  A low-level increase of ROS may be required as 
a secondary messenger in RANKL-induced signalling pathways for osteo-
clast differentiation.  In this study, the effect of PEs on osteoclast differentia-
tion from murine macrophage RAW264.7 cells induced by RANKL and MCSF 
was investigated.  The murine macrophage/osteoclast precursor cell line 
RAW264.7 is largely used pre-osteoclast model that differentiates into osteo-
clasts when stimulated with M-CSF and RANKL (Wei et al., 2001). 
The effect of PEs on osteoclast differentiation was investigated and RAW 
264.7 cells were exposed to the receptor activator of nuclear factor Kappa-B 
ligand (RANKL) and MCSF, as mentioned in section 2.2.4.  Treatment with 
RANKL and MCSF induced osteoclast formation in these cells, identified via 
light microscopy as large TRAP + cells.  The number of TRAP + cells were 
(480 ± 20, p=0.0001), while treatment with E2 reduced the number of TRAP 
+ cells to (244 ± 8.7, p=0.0001), Genistein (215 ± 27.8, p=0.0002), Daidzein 
(248 ± 9.6, p=0.0001)  and Resveratrol (252 ± 16.25, p=0.0001) compared to 
control (Figure 4.6 B). 
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Figure 4.6: Effect of E2 and PEs on RANKL-induced osteoclast differentiation. 
Treatment with E2 or PEs (Genistein, Daidzein and Resveratrol) significantly reduced 
RANKL induced osteoclast differentiation.[A] (i–vi) Representative images (20×) of oste-
oclasts differentiated in the presence of E2, Genistein, Daidzein and Resveratrol after 
treatment of RAW 264.7 with macrophage colony stimulating factor (M-CSF) and receptor 
activator of NF-κB ligand (RANKL). Cells were subsequently stained with TRAP to identify 
osteoclasts; (i) represents control without any treatment, (ii) treatment with RANKl and M-
CSF, (iii) treatment with E2, (iv) treatment with Genistein (v) treatment with Daidzein and 
(vi) treatment with Resveratrol. Osteoclasts were identified as large, TRAP+, (white ar-
rows in panels i-vi) and quantified as osteoclasts/field of view of culture dish, n = 5. [B] 
Data are expressed as the numbers of osteoclasts which were counted after taking ran-
domly fields in different areas of each well. At least 5 fields were used for each tested 
reagent and the values are expressed as mean ± SD. p < 0.05 compared with RANKL 
treatment (TC: treated control). 
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4.5 Discussion 
Osteoblast and osteoclast activity is tightly coupled during each remodelling 
cycle, such that bone resorption is linked to a subsequent formative phase. 
This coupling is lost in post-menopausal women which therefore contributes 
to the bone loss during both the initial and later stages of the disorder.  This 
study examined the effect of PEs on osteoblast apoptosis induced by H2O2.  
Genistein, Daidzein and Resverartrol have the ability to inhibit apoptosis in-
duced by oxidative stress in osteoblast cells MC3T3-E1 evidenced with DAPI 
staining and assessment of ROS generation.  H2O2 at concentration of 
0.4mM was used to induce oxidative cell injury in osteoblastic MC3T3-E1 as 
previously described (Zhang et al. 2013).  Yet, pre-treatment with E2 and 
PEs (Genistein, Daidzein and Resveratrol) revealed that H2O2 toxicity was 
decreased.  Oxidative stress affects cell viability and differentiation, this was 
observed in previous studies which have shown that H2O2 results in cell inju-
ry and inhibits osteogenic differentiation in osteoblastic MC3T3-E1 cells (Liu 
et al., 2004) and also resulted in decreased calcium mineralization, ALP ac-
tivity and lowered the production of osteogenic genes.  Studies have indicat-
ed that H2O2 was correlated with a decrease in calcium mineralization and 
ALP activity, and a lowered production of osteogenic genes, including 
BGLAP, COL1A1 and SPP (Huang et al., 2015).  Isofavones including 
Genistein and Daidzein are contained in soybean with high concentration; 
they are hydrolysed by β-glucosidase in the gastrointestinal system.  
Genistein has been found to inhibit tyrosine kinase enzyme activity and 
cause apoptosis in leukemic cells (Liu et al., 1994).  Isoflavones are thought 
to be an important tool for preventing bone loss that is due to ageing.  The 
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dietary intake of Genistein was shown to prevent bone loss in ovariectomized 
rats, an animal model of postmenopausal osteoporosis (Blair et al., 1996).  
Additionally, Genistein stimulates osteoblastic bone formation and minerali-
zation in vitro (Pan et al., 2005), and can stimulate protein synthesis in oste-
oblastic cells (Sugimoto and Yamaguchi 2000, Yamaguchi and Sugimoto 
2000).  In this study, investigation of MC3T3-E1, treated with PEs showed 
that Genistein, Daidzein and Resveratrol, like E2, significantly reduced the 
percentage of H2O2 induced apoptosis in these cells.  It has been found 
through the molecular examination of Genistein that it has an anabolic effect 
on MC3T3-E1 (Sugimoto and Yamaguchi 2000). 
Furthermore, previous studies have shown that Genistein inhibited osteoclas-
togenesis, in part through inhibition of protein kinase activation and suppres-
sion of protein tyrosine phosphatase activity as well as by inducing apoptosis 
of mature osteoclasts through a Ca2+ signalling mechanism (Gao and Yama-
guchi 2000).  Osteoblasts and osteocytes are derived from mesenchymal 
stem cells, which also differentiate into fibroblasts, chondrocytes, myoblasts 
and adipocytes.  Osteoclasts interact with osteoblasts at various stages of 
differentiation (Matsuo and Irie, 2008).  Several studies recognized the es-
sential osteoclastogenic ligand RANKL (also called TRANCE), a transmem-
brane glycoprotein belonging to the tumor necrosis factor (TNF-α1) super-
family and plays a key role in osteoclast development and in resorbing activi-
ty (Theill et al., 2002).  Increased osteoclast activity has been reported in 
many osteopenic disorders, including postmenopausal osteoporosis (Jones 
and Penninger 2002; Wang et al., 2002).  TRANCE interacts with two recep-
tors: a secreted decoy receptor osteoprotegerin, OPG (Simon et al., 1997), 
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and a transmembrane receptor, RANK (Anderson et al., 1997).  TRANCE 
and RANK interaction is essential for osteoclastogenesis because RANK is 
activated by TRANCE, and then associates with TNF receptor-associated 
family members to trigger downstream signaling events (Hsu et al., 1999).  
In the present study, the inhibitory effects of E2 and PEs (Genistein, Daidzein 
and Resveratrol) on osteoclast differentiation were investigated to establish 
their anti-osteoporotic activity through suppressing excessive bone resorp-
tion.  Osteoclast differentiation from murine macrophage RAW 264.7 cells 
was induced by RANKL and M-CSF, which is essential for the terminal differ-
entiation of monocytes/macrophages into osteoclasts (Ming and Xian 2013).  
TRAP-positive multinucleated osteoclasts were visualized by light micropho-
tography (Figure 3.24 A).  RANKL and MCSF treatment induced osteoclast 
formation from RAW 264.7 cells.  Treatment with E2 and PEs reduced the 
number of multinucleated TRAP positive cells (Figure 3.24 B) which is similar 
to previous studies using Genistein (Lee et al., 2014).  The RANKL-induced 
differentiation of RAW 264.7 could be through controlling ROS levels (Lee et 
al., 2014).  The inhibitory effects of natural flavonoids, such as Resveratrol 
(He et al., 2010), Curcumin (Kim et al., 2012) and Fisetin (Sakai et al., 2013) 
as potent antioxidants on osteoclast differentiation from osteoclastic precur-
sors through controlling ROS generation have also been reported.  The sup-
pressive effect on osteoclastogenesis via attenuating ROS production in 
RANKL-treated RAW 264.7 cells was also observed in other flavonoids such 
as luteolin, which showed a potent cellular antioxidant activity in rat C6 astro-
glioma cells (Lee et al., 2009).  It has been found that Genistein, Daidzein 
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and Resveratrol, like E2, inhibit the differentiation of osteoclasts from cultures 
of RAW 264.7 cells.  
Genistein has been shown previously to increase osteoprotegerin/ receptor 
activator of nuclear factor kB ligand (RANKL) ratio and reduce osteoclast dif-
ferentiation from hematopoietic stem cells which results in less bone resorp-
tion in vivo (Li et al.,2005).  Therefore, soy-based products containing 
Genistein may be used for the development of potential therapeutic agents 
preventing bone diseases, such as osteoporosis. 
In vitro studies have indicated that Resveratrol prevents bone resorption, en-
hances osteoblast differentiation, and has been shown to act as a phytoes-
trogen (Gehm et al., 1997).  The anti-oxidative activity of Resveratrol is 
claimed to be due to the presence of hydroxyl phenolic group in its chemical 
structure (Leonard et al., 2003).  
Studies conducted have shown that Resveratrol, in addition to its stimulatory 
effect on osteoblasts, can inhibit RANKL-induced osteoclastogenesis and 
thus induce apoptosis of differentiated osteoclasts (He et al., 2010).  A study 
conducted on an ovariectomized rat model of postmenopausal osteoporosis 
reported that Resveratrol supplementation attenuated estrogen deficiency 
induced bone loss and trabecular structural deterioration (Tou 2015).  Fur-
thermore, the dual effects, anti-resorptive and anabolic, on bone remodeling 
together with its tolerance in rat and human studies (Williams et al., 2009; 
Almeida et al., 2009) indicate that resveratrol is a potential candidate for anti-
osteoporosis therapy.  Despite the health benefits of Resveratrol, it’s molecu-
lar targets have not been fully determined.  A broad range of intracellular pro-
teins, including sirtuins, kinases, lipo- and cyclooxygenases, as well as ster-
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oid receptors, have been shown to be involved in Resveratrol signaling (Piro-
la and Fröjdö 2008).  Among these targets, Sirt1, a NAD+ dependent protein 
deacetylase, is thought to be the major mediator for stress resistance and 
considered as anti-ageing effects (Howitz et al., 2003).  However, it has been 
found that Sirt1 is not involved in inhibition of osteoclastogenesis by Resvera-
trol and its effect could not be attenuated by ICI-182780, a high affinity estro-
gen receptor antagonist.  This shows that the effect of Resveratrol is ER in-
dependent and also its inhibitory effect on osteoclastogenesis is mediated via 
ROS inhibition (He et al., 2010). 
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CHAPTER FIVE: INVESTIGATION OF POTENTIAL SAVING 
MECHANISM OF PHYTOESTROGEN 
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5.1 Introduction 
PEs have multiple mechanisms of action including estrogen agonist and an-
tagonist activity. They are markedly similar in chemical structure to the 
mammalian estrogen, estradiol, and bind to ERα and ERβ with a high affinity 
to ERβ (Younes and Honma 2011; Rietjens et al., 2013; Paterni et al., 2014).  
These receptors after binding with their ligand are able to move from cyto-
plasm to the nucleus, bind and affect the transcription-control regions of DNA 
and therefore, the expression of specific genes. Furthermore, steroids are 
able to bind to receptors of cell surfaces, promote formation of cytoplasmic 
cyclic nucleotides and related protein kinases, which in turn via transcription 
factors control the expression of target genes (Sirotkin, 2014; Yanagihara et 
al., 2014).  Therefore, PEs can potentially affect all the processes regulated 
by estrogens including induction sex hormone binding globulin and inhibition 
aromatase (Wang 2002).  ERs are present in different tissues such as central 
nervous system, reproductive tract, placenta, mammary gland, bones, gas-
trointestinal tract and lung.  This suggests that PEs may exert tissue specific 
hormonal effects (Cassidy 2003; Younes and Honma 2011; Böttner et al., 
2013).  Additionally, ERα is considered as a promoter of cell proliferation, 
whilst ERβ is responsible for promoting cellular apoptosis (Rietjens et al., 
2013).  PEs besides their ability to bind to ERs, have other biological effects 
which are not mediated through these receptors such as activation of seroto-
ninergic receptors (Hajirahimkhan et al., 2013), IGF-1 receptors (Bourque et 
al., 2012), binding of free radicals (Wang 2002; Cassidy 2003; Vina et al., 
2011) and other intracellular regulators of cell cycle and apoptosis.  These 
abilities are probably responsible for anti-oxidant, anti-proliferative, anti-
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mutagenic and anti-angiogenic effects of PEs and their ability to promote 
human health (Kurzer and Xu 1997; Wang 2002; Cassidy 2003; Vina et al., 
2011; Hajirahimkhan et al., 2013; Ming et al., 2013). 
The estrogenic effect of Genistein and Daidzein is dependent on two main 
properties.  The first being the presence of a phenolic ring A that mimics E2’s 
receptor binding A ring; and the second, a similar distance between the 7- 
and 4'-hydroxyl groups in isoflavones and the C3 and C17 hydroxyl groups of 
estradiol (Dixon 2004).  The presence of a phenolic ring enables PEs to bind 
to ERs and provides the major basis of their estrogenic action (Wuttke et al., 
2003).  In addition to their estrogenic effect, PEs also function as antioxidants 
and many such as Genistein can modify tyrosine kinase activity (Anderson 
and Garner 1998).   
 
 
5.2  Investigation of Estrogen Receptor Inhibitor effect on anti-apoptotic 
effect of estrogen and phytoestrogen 
Estrogen receptor inhibitor, ICI 182 780, is a specific ER inhibitor which is an 
estradiol derivative containing alkyamide extension in the 7 position.  The 
non-receptor mechanism of protection was investigated for E2 and PEs 
whether they exert anti-apoptotic effect.  MLO-Y4 cells were pre-treated with 
(10nM) of the receptor antagonist ICI 182 780 prior to treatment with E2 and 
PEs at a concentrations of 10nM did not block the anti- apoptotic effect of E2 
(15.77% ± 1.98 vs. H2O2 treatment 27.78% ± 4, p=0.0096) (Fig. 5.1).  In a 
similar way the anti-apoptotic effects of Genistein, Daidazein and Resveratrol 
were not blocked by pre-treatment with ICI 182 780 (Gen.17% ± 1, p=0.0106, 
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Fig.5.2), (Dai.13.79% ± 1.94, p=0.005, Fig. 5.3) and (Resv. 20.2% ± 3, p= 
0.05, Fig. 5.4).  Treatment with ICI 182 780 alone also significantly reduced 
H2O2 induced apoptosis, indicating that ICI 182780 has anti-apoptotic activity.  
In order to further elucidate the potential contribution of estrogen receptor 
mediated in this response, HEK293 human embryonic kidney epithelial cell 
line which is ER-α and ER-β negative were used (Zhao et al., 2007).  Treat-
ment of H2O2 induced apoptosis in HEK293 cells at a concentration of 0.4mM 
for 2 hours indicated the percentage of apoptosis was (18.49% ± 2.4 vs. con-
trol 10.7% ±1.3, p=0.002).  Pre-incubation of HEK293 cells with PEs signifi-
cantly reduced the percentage of apoptosis Genistein (12.11% ± 1.7, 
p=0.0021), Daidzein (12.74% ± 1.5, p=0.0011) and Resveratrol (10.63% ± 
1.4, p=0.001).  The saving effect of these PEs on HEK293 cells were similar 
to that of E2 (11.22% ± 1.2, p=0.001) Fig. 5.5, indicating an estrogen recep-
tor-independent effect of these compounds.  The effect of E2 on HEK cells 
was reported previously by (Mann et al., 2007). 
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Figure 5.1: Effect of estrogen receptor inhibitor (ICI 182780) on protecting effect of E2. 
Pre-treatment of MLO-Y4 cells with 10nM of estrogen receptor inhibitor ICI 182 780 prior to 
treatment with 10nM of E2 and 0.4mM of H2O2 did not block the protecting effect of E2. Data 
are expressed as mean ± SD of three wells (three fields per well were counted), *p˂0.05 ver-
sus H2O2, # versus control.  
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Figure 5.2: Effect of estrogen receptor inhibitor (ICI 182780) on saving effect of 
Genstein. Pre-treatment of MLO-Y4 cells with 10nM of estrogen receptor inhibitor ICI 
182 780 prior to treatment with 10nM of Genistein and 0.4mM of H2O2 did not block the 
protecting effect of Genistein. Data are expressed as mean ± SD of three wells (three 
fields per well were counted), *p˂0.05 versus H2O2, # versus control. 
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Figure 5.3: Effect of estrogen receptor inhibitor (ICI 182780) on saving effect of Daidzein. 
Pre-treatment of MLO-Y4 cells with 10nM of estrogen receptor inhibitor ICI 182 780 prior to 
treatment with 10nM of Daidazein and 0.4mM of H2O2  did not block the protecting effect of 
Daidzein. Data are expressed as mean ± SD of three wells (three fields per well were counted), 
* p˂0.05 versus H2O2, # versus control. 
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Figure 5.4: Effect of estrogen receptor inhibitor (ICI 182780) on saving effect of 
Resveratrol. Pre-treatment of MLO-Y4 cells with 10nM of estrogen receptor inhibitor ICI 182 
780 prior to treatment with 10nM of Resveratrol and 0.4mM of H2O2 did not block the protect-
ing effect of Resveratrol. Data are expressed as mean ± SD of three wells (three fields per 
well were counted), * p˂0.05 versus H2O2and # p< 0.05 versus. Control 
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Figure 5.5: Effect of 17-estradiol (E2) and PEs on HEK 293 cells apoptosis. Pre-
treatment of ER negative HEK293 cells with E2 0r PEs (Genstein., Daidzein, and 
Resveratrol) all significantly reduced H2O2 induced apoptosis. Data are expressed as 
mean ± SD of three wells (three fields per well were counted), n=9, *p˂0.05 vs H2O2, # vs 
control. 
 
 
5.3 Effect of Genistein, Daidzein and Resveratrol on catalase (CAT) en-
zyme activity 
Among the antioxidant enzymes, Catalase is a ubiquitous antioxidant en-
zyme that is present in most aerobic cells. Catalase (CAT) is involved in the 
detoxification of H2O2, which is a toxic product of both normal metabolism 
and pathogenic ROS production.  CAT catalyses the conversion of two mole-
cules of H2O2 to molecular oxygen and two molecules of water.  The experi-
ment was carried out as previously described in section 2.2.1 by culturing 
MLO-Y4 cells and treating them with PEs prior to treatment with H2O2 
(Fig.5.6).  Catalase assay was carried out to determine the effects of E2, 
Genistein, Daidzein and Resveratrol on enzyme activity, described in section 
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2.2.16.  Catalase activity was examined in the supernatants and the Catalase 
assay was performed using a kit which exploits the peroxidatic function of 
CAT for the determination of enzyme activity.  Treatment of MLO-Y4 cells 
with E2 or PEs alone did not increase catalase activity significantly, while 
treatment with H2O2 increased the activity of CAT enzyme in the media com-
pared with control (44.4Unit/ml ± 6.2 vs H2O2 treatment 212.1Unit/ml ± 3, 
p=0.001).  Treatment of cells with 10nM of E2 or PEs prior to treatment with 
H2O2 decreased the activity of CAT in the supernatant when compared to 
treatment with H2O2 alone, E2 (124.4Unit/ml ± 1.9, p=0.004), Genistein 
(95.9Unit/ml ± 1.4, p=0.0025), Daidzein (87.8Unit/ml ± 2.5, p= 0.0022), 
Resveratrol (138Unit/ml ± 1.7, p=0.012). 
 
 
Figure 5.6: Catalase activity in MLO-Y4 cells after PES exposure. Cells were exposed 
to 10nM of E2 and PEs (gen., dai. And resv.) for 1 hour prior to H2O2 for 2 hours. The assay 
was carried out using catalase activity assay kit. The assay utilizes visible light (520 nm), 
which reduces sample interference. The kit is designed for use in microplate readers. The 
reaction was carried out for one minute, at which time the catalase was quenched with so-
dium azide. The result is expressed as the amount of catalase enzyme produced in unit /ml. 
Data is expressed as means of ±SD, n=3 different experiments; *P<0.05 vs. H2O2, # vs. 
control. 
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5.4 Modification and the structural rational strategy 
In order to provide an insight into the role of the hydroxyl groups (OH) in the 
activity of Genistein and Daidezein, modification of the OH groups was car-
ried out.  The molecular weight of Genistein is 270.24g/mole and that of 
Daidezein is 254.24gm/mole.  Both compounds could be subjected to modi-
fications by masking one, two and/or three (in case of Genistein) of their OH 
groups with an alkyl group, which is non-cleavable within the cellular com-
partment such e.g. CH3 to give methoxy groups.  Several possibilities of 
mono-methoxy, di-methoxy groups or tri-methoxy could occur for Genistein, 
on either positions (5 & 7), (5 & 4’), or (7 & 4’), while postions (5, 7, and 4’) 
for all the three OH groups.  Daidzein could be modified on either hydroxyl 
position 7, 4’ or both.  The molecular weight of Genistein and Daidzein 
would change if modified, this was shown in (Table 5.1) and confirmed by 
Mass spectrometry analysis which indicated that the synthetic modification 
occurred on both OH groups of Daidzein and a mixture of two and three OH 
groups of Genistein, which was based on the changes in the molecular 
weight of these compounds.  Upon isolation and purification pure di-methoxy 
Daidzein was obtained.  While the mixture of di-methoxyand tri-methoxy 
were purified and separated by chromatography on normal phase silica gel.  
The location of the two modified OH groups in di-methoxy Genistein was 
identified as being on positions 5, and 7, as confirmed by mass spectrosco-
py fragmentation analysis MS/MS. The total ion mass of the di-methoxy 
Genistein m/z was 298 D (Figure 5.7).  The ion masses (166 and 137 Dal-
ton) of two fragments for Genistein gave evidence for the modified hydroxyl 
groups being on the same aromatic ring at position 5 and 7 (Figure 5.8).  Di-
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methoxy Daidzein ionic mass, m/z was 282 Dalton, confirmed by addition of 
sodium ion 305 and cluster of two ions of the compound with sodium to give 
mass of 587 Dalton (Figure 5.10).  Table 5.1 shows the molecular weight of 
modified and unmodified compounds of Daidzein and Genistein. The modi-
fied Daidzein and Genistein alongside the unmodified counterparts were in-
vestigated in vitro to assess their protective effects on oxidative stress in-
duced by H2O2 in MLO-Y4 cells. 
 
 
Table 5.1: Molecular weight of Modified and unmodified Genistein and Daidzein. The 
molecular weight increased by 15 Dalton for each hydroxyl group removed and replaced 
with methyl group and H
+ 
from methanol which was used as a solvent which protonate the 
compound. 
 
Compounds Molecular weight g/mole 
Daidzein 254.24 
Modified Daidzein  A 282.09=  
(CH3x2)=30+H+- 2H from re-
moving 2H of two OH groups 
Genistein 270.24 
Modified Genistein A  298.08= 
(CH3 x 2)=30+H+- 2H from 
removing 2H of OH groups 
Modified Genistein B  312.10= 
(CH3 x 3)=45+H+- 3H from 
removing 3H of OH groups 
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Figure 5.7: Mass spectra of di-methoxy Genistein: ESI-MS, m/z: [M+H]
+
, 299D.The 
spectra above shows the fragmentation of the molecules which represented by numerous 
peak observed. The structure of di-methoxy substituted: 3(4-hydroxyphenyl)-5,7-dimethoxy-
4H-chromen4 –one. 
 
 
 
Figure 5.8: Mass spectra of MS/MS fragmentation of di-methoxy Genistein, MS/MS: 
284 [M
+
-CH3], 267 [M
+
-CH5O], 256 [isotope M
+
-CH3O2], 243 [isotope M
+
-C2H6O2, 184 [M
+
-
C9H12O4], 166 [M
+
-C9H10O3], 137 [M
+
-C8H9O2]. The spectra above shows the fragmentation 
of the molecules which represented by numerous peak observed. The structure of di-
methoxy substituted: 7-hydroxy-5methoxy-3-(4-methoxyphenyl)-4H-chromen-4-one.   
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Figure 5.9: Mass spectra of tri-methoxy Genistein ESI-MS, m/z: [M]
+
312, 351 [M
+
+K], 
663 [2M
+
+K] The spectra above shows the fragmentation of the molecules which represent-
ed by numerous peak observed. The structure of tri-methoxy substituted: 5,7-dimethoxy-3-
(4-methoxyphenyl)-4H-chromen-one.  
 
 
Figure 5.10: Massspectrometry analysis of di-methoxy Daizein: ESI-MS, m/z: 282[M
+
+H] 
305 [M
+
+Na], 587 [2M
+
+Na. The spectra above shows the fragmentation of the molecules which 
represented by numerous peak observed.  The structure of di-methoxy substituted: 7-mehoxy-3-
(4-methoxyphenyl)-4-chromen-4-one. 
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5.5 Fluorometric assay of MLO-Y4 cells treated with modified Genistein 
and Daidzein via H2DCF-DA 
This method is based on a fluorometric assay using H2DCFHDA dye which is 
used as an intracellular probe for direct measurement of the cell redox state 
(Tammariello et al., 2000; Ottonello et al., 2001).  DCFH-DA is a compound 
that is diffused into cells where it can be hydrolysed by intracellular esterases 
to cell membrane impermeable and non-fluorescent 2, 7-dichlorofluorescein 
(H2DCF) which does not permeate membranes.  H2DCF is then oxidized by 
the intracellular H2O2 to a highly fluorescent compound DCF, which is mem-
brane permeable and can leak out of cells over time.  Accumulation of DCF 
in cells or extracellular supernatant may be measured by a production of the 
fluorescence at 530 nm when the sample is excited at 485 nm.  MLO-Y4 cells 
were treated with 10nM of unmodified Genistein, Genistein A, Genistein B 
and also, unmodified Daidzein and Daidzein A.  The result in (Figure. 6.3) 
shows that treatment with modified Genistein did not protect the cells from 
oxidative stress induced by H2O2 and the fluorescent intensity was not signif-
icant when compared with H2O2 treatment (26300.66 ± 31.68, p=0.302) for 
Genistein A and (28328.34 ± 82.03, p=0.325) for Genistein B vs. H2O2 
(34791.33 ± 81.32).  While treatment with unmodified Genistein reduced the 
fluorescent intensity compared to cells treated with H2O2 (12265.32 ± 68.32, 
p=0.03) (Fig.5.11).  Similar results were observed with cells treated with un-
modified and modified Daidzein.  The fluorescence intensity was not signifi-
cant in comparison to H2O2 treatment (21206.67 ± 25.01 vs. H2O2 34791.33 ± 
81.32, p=0.106), while treatment with unmodified Daidzin reduced the fluo-
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rescence intensity in comparison to cells treated with H2O2 (12360.67 ± 23, 
p=0.01) (Fig.5.12). 
 
 
 
Figure 5.12:  Fluorescence intensity in MLO-Y4 cells using H2DCF-DA. Cells were pre-
treated with H2DCF-DA at concentration of 10µM for 45 minutes prior to treatment with 
modified unmodified Daidzein at concentration of 10nM for 1 hour, then treated with 0.4mM 
H2O2 for 2 hours and then the fluorescence intensity was measured.  Data are expressed as 
mean ± SD of 3 wells, p<0.05 versus H2O2, # versus control. 
Figure 5.11: Fluorescence intensity in MLO-Y4 cells using H2DCF-DA.. Cells were pre-
treated with H2DCF-DA at concentration of 10µM for 45 minutes prior to treatment with modi-
fied and unmodified Genistein at concentration of 10nM for 1 hour, then treated with 0.4mM 
H2O2 for 2 hours and then the fluorescence intensity was measured.  Data are expressed as 
mean ± SD of 3 wells, p<0.05 versus H2O2, # versus control. 
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5.6 The anti-apoptotic effect of modified Genistein and Daidazein on os-
teocyte apoptosis induced by H2O2. 
Based on the previous data in (Figure 5.11 and 5.12), Genistein A , B and 
Daidzein A were used further to test their protective effect on MLO-Y4 cells 
from apoptosis induced by H2O2 subjected with DAPI staining by taking the 
percentage of apoptotic cells.  It was found that none of the tested modified 
Genistein and Daidzein exhibited rescuing effect against apoptosis induced 
by H2O2.  MLO-Y4 cells were plated in 24 well plates for 24 hours, and then 
treated with Genistein and two different groups of modified Genistein (A and 
B) for 1 hour at concentration 10nM prior to treatment with 0.4mM H2O2 for 2 
hours.  The percentage of osteocyte apoptosis induced by H2O2 (H2O218.5% 
± 1.33 vs. control 7.40 ± 0.9, p=0.01) was significantly reduced after pre-
treatment with unmodified Genistein at concentration of 10nM (11.8% ± 1.09, 
p=0.002), but it was not significant after treatment with modified Genistein A 
(17.24 ± 1.7, p=0.36) and Genistein B (17.11% ± 2.1 p=0.38) Fig. 5.13.  The 
percentage of osteocyte apoptosis was reduced after treatment with unmodi-
fied Daidzein (8.1% ±1 vs. H2O2 19.7% ± 1.26, p=0.0002) with no significant 
changes in the percentage of apoptosis in cells pre-treated with modified 
Daidzein (16.5% ± 1.05, p=0.106) (Fig 5.14). 
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Figure 5.13:  Effect of modified Genistein on osteocyte apoptosis induced by H2O2.  
MLO-Y4 cells were pre-treated with Genistein and modified Genistein at concentration of 
10nM prior to treatment with 0.4mM of H
2
O
2
.  Pre-incubation of modified Genistein A and 
B at a concentration 10nM did not reduce the percentage of apoptosis in MLO-Y4 cells 
significantly, but the reduction was significant after treatment with unmodified Genistein 
p<0.05.  Data are expressed as mean ± SD of three wells (three fields per well were 
counted), n=9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14:  Effect of modified Daidzein on osteocyte apoptosis induced by H2O2.  
MLO-Y4 cells were treated with 10nM of unmodified and modified Daidzein A prior to 
treatment with 0.4mM H2O2. Cells were fixed and stained with DAPI and visualized under 
microscope.  Pre-incubation of modified Daidzien A at a concentration 10nM did not re-
duce the percentage of apoptosis in MLO-Y4 cells significantly, but the reduction was sig-
nificant after treatment with unmodified Daidzein p<0.05. Data are expressed as mean ± 
SD of three wells (three fields per well were counted), n=9. 
 
143 
 
5.7 Discussion 
The mechanism of action of PEs on MLO-Y4 cells was investigated as to 
whether it was direct or indirect through ER.  E2 was used as a control for its 
saving effect as it has been demonstrated previously that E2 had a direct ef-
fect on saving MLO-Y4 cells from apoptosis induced by H2O2 (Mann et al., 
2007).  The protective effect of PEs was investigated, whether it was mediat-
ed in a similar way to E2 directly or via ER. 
Genistein has been identified to have a similar structure to E2, binds to ERs 
(Kurzer 2002) and it has been found to stimulate ER responsive gene 
through its interaction with ERs (Birt etal., 2001; Kostelac et al., 2003; Zierau 
et al., 2006), with higher affinity to ERβ (Pike et al., 1999).  Some studies 
suggested that Genistein should be classified as a selective estrogen recep-
tor modulator (SERMs), due to its similar interaction manner with raloxifene 
(Pike et al., 1999) and similar effect on the skeletal system in ovariectimized 
mice (Śliwiński et al., 2009). 
Estrogen receptor inhibitor ICI 182780 is the most commonly known as pure 
anti-estrogen.  It is derived from estradiol but contains alkylamide extension 
in the 7 alpha position, the effect of this anti-estrogen was to reduce the level 
of ER and also affect the receptor shuttling between nucleus and cytoplasm 
(Dauvoise et al.,1993).  Pre-treatment of MLO-Y4 cells with ICI 182 780 did 
not block the protective effect of PEs and E2.  However the incubation of 
cells with estrogen antagonist ICI 182 780 alone also prevented the cells 
from undergoing apoptosis induced by H2O2.  Thus it is possible that ICI 180 
780 is capable of antioxidant activity which can explain its ability to save os-
teocytes against oxidant attack in the absence of estradiol and this also indi-
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cates that ER might not be involved in the pathway response.  This study is 
consistent with previous studies which show, PEs in addition to their estro-
genic activity have been reported to exert various non ER-related actions in-
cluding inhibition of tyrosine kinase activity, inhibition of protein kinase C, in-
hibition of DNA topoisomerases I and II, inhibition of angiogenesis, antioxi-
dant effects and modification of prostaglandin synthase activity (Kurzer and 
Xu, 1997, Arora et al., 1998, Markovits et al., 1995). 
The inhibition of tyrosine kinase by Genistein may explain the mechanism by 
which it disturbs cancer cell growth (Ibarreta et al., 2001).  PEs can also af-
fect steroid bioavailability by interacting with key enzymes involved in the 
steroid synthesis such as 5α reductase, 17β-OH-steroid-dehydrogenase and 
aromatase (Makela et al., 1995, Kao et al., 1998, Rice et al., 2006, Lacey et 
al., 2005).  In addition, PEs stimulate the production of sex hormone binding 
globulin (Pino et al., 2000), suggesting their role in altering steroid hormone 
bioavailability. 
Also in this study, the activity of antioxidant enzyme catalase in MLO-Y4 cells 
exposed to H2O2 with or without PEs was determined.  In the present study, 
treatment with H2O2 alone at concentration of 0.4mM induced cell apoptosis.  
PEs partially protected these cells from apoptosis and accumulation of ROS. 
Regulation of antioxidant enzyme in cells is an important process that bal-
ances the generation and the abolition of reactive oxygen species. Among 
the antioxidant enzymes, catalase is an important antioxidant enzyme, which 
eliminates hydrogen peroxide directly.  According to the results in this study, 
catalase activity was higher in the hydrogen peroxide group compared to the 
control group.  This seems to be consistent with previous studies which have 
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tested  the neuroprotective and antioxidant effect of Resveratrol against H2O2 
in embryonic neural stem cells, showing that H2O2 treatment increased CAT 
activity when compared with control (Konyalioglu et al., 2013).  However, 
treatment with PEs decreased the catalase activity, indicating a reduction in 
reactive oxygen species production.  Resveratrol was known as a potent di-
rect radical scavenger and has also been demonstrated to interact with redox 
systems in vivo by increasing the expression of antioxidant enzymes such as 
CAT, SOD or GSH-Px directly (Pignitter et al., 2016).  The prevention of oxi-
dative stress induced apoptosis is thought to be through its direct activity and 
is related to the presence of C3-OH group (Heim et al., 2002).  The protective 
effects of these OH groups on PEs was investigated by modifying their struc-
ture, and removing these groups to test their effect on oxidative stress in-
duced by H2O2.   
The presence of free hydroxyl groups on the aromatic ring of Daidzein and 
Genistein was assumed to play significant roles in the antioxidant activity of 
PEs, owed to their ability in scavenging ROS.  Modification of the hydroxyl 
groups at positions 5 and 7 for Genisten, or all the hydroxyl groups, endorsed 
the significant structural relationship activity of those functional groups within 
the biological system.  The fluorescence intensity of H2DCFDA probe corre-
lated negatively with the strength of the ROS quenching by the hydroxyl 
groups.  The cellular fluorescence production of H2DCFDA gave clear evi-
dence for the reduced capacity of the modified hydroxyl groups in ROS scav-
enging in MLO-Y4 cell line, as compared to unmodified counterparts.  Stud-
ies conducted by (Wang 2005) tested the anti-osteoporotic activity of 
Genistein whether they can be enhanced by their modification and substitut-
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ed of their C-7 or C-4’ hydroxyl with a number of chemical groups.  In this 
study, Genistein and Daidzein were modified by masking their hydroxyl group 
and testing them for their effect on saving osteocytes from apoptosis induced 
by H2O2.  Two groups of modified Genistein A, B and modified Daidzein A 
were tested for their effect on saving MLO-Y4 cell from ROS generation after 
treating MLO-Y4 with H2DCFDA and then treated with 10nM Genistein and 
Daidzein prior to treatment with H2O2.  The assay is rapid and sensitive tech-
nique for detecting ROS generation due to oxidative stress induced by H2O2.  
Results show that treatment with modified Genistein A, B and Daidzein A did 
not increase oxidative stress in cells when compared with control.  On the 
other hand they did not protect cells from oxidative stress induced by H2O2. 
The antioxidant activity of PEs is thought to be related to the presence of free 
hydroxyl groups in the aromatic ring and ability to bind between aromatic 
rings (Burda and Oleszek, 2001).  The hydroxyl group in the B-ring is im-
portant to enable the scavenging of reactive nitrogen or oxygen species 
(Pannala et al., 2001).  The mechanism by which PEs are able to scavenge 
free radicals is dependent on the ability of these compounds to donate a hy-
drogen atom or transfer an electron from C-3-OH in the B-ring to hydroxyl to 
peroxy and peroxynitrite radicals.  This stabilizes the reactive species and 
gives rise to a relatively stable PE radical (Heim et al., 2002).  Studies sug-
gest that the antioxidant capacity of flavonoids strongly correlates with the 
number of hydroxyl groups in the B-ring, whereas hydroxyl groups in the A-
ring may have little correlation with antioxidant activity (Heim et al., 2002). 
Interestingly, isoflavones such as Genistein have also been known to donate 
hydrogen atoms from the phenolic group (Heim et al., 2002).  Therefore, PEs 
147 
 
scavenging ability of free radicals is attributed to the subtitutional reactivity of 
hydroxyl which participate in the following reaction F-OH + R= F-O· + RH 
(Heim et al., 2002).  (F= phytoestrogens).  Additionally, Genistein may also 
prevent oxidative stress by increasing the production of antioxidant enzymes 
such as glutathione peroxidase which maintains the reduction-oxidation reac-
tion (redox) state by reducing oxygen peroxide, thus protecting against oxida-
tive DNA damage (Suzuki et al., 2002; Raschke et al., 2006). 
The chemical structure of isoflavones when compared with estradiol shows 
that the structure of isoflavones consists of two benzene rings, which are 
linked by a heterocyclic pyrane ring.  Also, one hydroxyl group (-OH) is found 
attached to each benzene ring.  Genistein and Daidzein differ by one hydrox-
yl group on the A ring of the isoflavone structure. The structures of isofla-
vones have simliar characteristics to the structure of 17‚-estradiol.  Both 17-
estradiol and isoflavones have an aromatic ring with a hydroxyl group and a 
similar distance between two hydroxyl groups (Setchell and Cassidy 1999)).  
It is not surprising then, that isoflavones can bind to the estrogen receptor 
because of their structural similarity to estradiol.  
Isoflavones and estradiol as well as other environmental estrogen like mole-
cules bind to estrogen receptors (ERs).  The isoflavones have higher binding 
affinities for the ERs in mammalian cells than most other estrogen like mole-
cules but lower than that of estradiol.  Isoflavones cross the cell membrane 
when they reach the target tissue by passive diffusion; then bind to ERs in 
the cytosol and form an isoflavone-ER complex; this complex then translo-
cates into the nucleus for activation of the estrogen response element (ERE), 
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which is involved in the regulation of DNA-directed mRNA synthesis and the 
production of new proteins (Kuiper et al., 1998). 
Several PEs, which have structural similarities with mammalian E2 are capa-
ble of binding to ERs.  They have been shown to have estrogen-like activity 
as they relieve postmenopausal complaints, increase bone formation and re-
press adipose tissue similar to E2 and they seem to have less or no side ef-
fects and have a lower cancer risk - although such risks cannot be complete-
ly excluded.  Therefore, the food intake of plant hormone-containing fruits 
and legumes (like red grapes and soybeans) or the administrations of the ac-
tive pharmaceutical ingredients have been considered as substitutes for the 
missing endogenous E2 production (Schlling et al.,2014). 
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CHAPTER SIX: THE EFFECT OF PHYTOESTROGENS ON CY-
TOKINE PRODUCTION IN MLO-Y4 IN RESPONSE TO HY-
DROGEN PEROXIDE 
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6.1 INTRODUCTION 
Pro-inflammatory cytokines are known as the most powerful stimulants of 
bone resorption.  They mediate the differentiation and proliferation of early 
osteoclast precursors to mature osteoclasts, which determine bone resorp-
tion capacity (Jilka et al., 1992).  RANKL is a type II transmembrane TNF 
family protein which is expressed in different types of cell including bone mar-
row stromal cells, osteocytes, chondrocytes, and lymphocytes (Ikeda et al., 
2001).  RANKL binds to the receptor activator of nuclear factor kB (RANK) or 
OPG.  RANK expressed on osteoclast progenitor cells binds to RANKL to in-
duce osteocalastogenesis (Lacy et al., 2012).  Previous studies have shown 
that osteoclastogenesis requires cell-to-cell contact, while new studies sug-
gest that condition media from apoptotic osteocytes which contains large 
amount of RANKL is sufficient for this process (Kogiani et al., 2008).  This 
suggests the important role of RANKL in osteoclastogenesis (O'Brien, 2013).  
While basal levels of RANKL is essential for physiological osteoclast renewal, 
additional cytokines either produced or regulated by T cells are responsible 
for the up regulation of osteoclast formation observed during estrogen defi-
ciency (Weitzmann and Pacifici 2005).  One such factor is TNF, a cytokine 
that enhances osteoclasts formation directly (Kim et al., 2005) and by up 
regulating the bone marrow stromal cells production of RANKL and the re-
sponsiveness of osteoclasts precursors to this factor (Cenci et al., 2000).  It 
has been suggested that ROS may play a role in postmenopausal bone loss 
by generating a more oxidized bone micro-environment (Basu et al., 2001). 
Interleukin-6(IL-6) is a pleiotropic cytokine produced by immune cells and 
other organs (Papanicolaou 2000).  It has been proposed that overexpres-
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sion of IL-6 enhances bone remodeling and bone loss due to increasing bone 
resorption (De Benedetti et al., 2006; Rufo et al., 2011).  However, in vivo 
studies showed that mice lacking IL-6 experience low bone mass, decreased 
osteoblast number and slow fracture healing (Yang et al., 2007).  
TNF-α is a pro-inflammatory cytokine which induces apoptosis in osteoblast 
and fibroblast cells (Alikhani et al., 2004).  Recent studies show that E2 dis-
rupts the balance between bone formation and resorption after menopause, 
this imbalance is thought to be at least in part due to elevated level of TNF-α 
(Weitzmann and Pacifici 2007).  E2 deficiency post menopause can cause 
elevated levels of TNF-α in human peripheral blood mononuclear cells 
(PBMC) (D’Amelio et al., 2005), while HRT treatment suppressed in vivo pro-
duction of TNF-α (Bernard-poenaru et al., 2001).  In addition TNF-α is in-
volved in chronic inflammatory diseases such as rheumatoid arthritis (Boyce 
et al., 2005) and also promotes osteoclast differentiation (Fox et al., 2008). 
The early intracellular signalling effect of TNF-α and RANKL are similar, each 
bind to a distinct receptors linked to different groups of tumor necrosis factor 
receptor (TRAF) signalling factors.  RANKL activates TRAF2, 3 and 6 while 
TNF-α predominantly activates TRAF 2 and 3.  Additionally RANKL activates 
more signal transduction factors than TNF-α, which are required to assist os-
teoclast formation (Fox et al., 2008).  As ROS activate the transcription factor 
(NF-ĸB) and regulate the gene expression of inflammatory cytokines (Seo et 
al., 2002).  Thus, the effect of PEs was investigated, whether they can inhibit 
TNF-α production in osteocytes in response to oxidative stress induced by 
H2O2.  MLO-Y4 were treated with E2, Genistein, Daidzein and Resveratrol 
prior to treatment with H2O2 to measure the amount of TNF-α release in cells. 
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6.2  Measurement of RANKL release 
The release of RANKL outside the cells was measured in MLO-Y4 cells 
seeded in 24-well plates at density of 3x104 cells per well for 24 hours and 
treated with E2 and different PEs as previously described in section 2.2.14. 
RANKL assay was performed with ELISA kit (Booster) according to the man-
ufacturer’s instructions.  The values were expressed as a total expression of 
RANKL concentration in pg/ml expressed relative to control.  These experi-
ments were performed to evaluate the relationship between antioxidants, 
apoptosis, and production of factors involved in bone remodelling such as 
RANKL.  RANKL level in supernatant from cells cultured with H2O2 was in-
creased after treatment to 70pg/ml ± 5 vs. control 9.6pg/ml ± 1.5, p=0.0001 
at 2 hours, 80.3pg/ml ± 2.51 vs. control 10.5pg/ml ± 0.40, p=0.0001 after 4 
hours and 102.5pg/ml ± 1.52l vs. control 8.3pg/ml ± 0.5, p=0.0001 after 24 
hours.  On the contrary, RANKL production in cells treated with E2 prior to 
H2O2 treatment was decreased to 30pg/ml ± 4.5, p=0.0005 at 2 hours, 
44.33pg/ml ± 2.08, p=0.0001 at 4 hours and 55.6pg/ml ± 0.86, p= 0.0001 at 
24 hours (Fig.6.1).  Similarly, the level of RANKL production also decreased 
in MLO-Y4 cells treated with Genistein 41.50pg/ml ± 3.12 at 2 hours, 
52.60pg/ml ± 5.03 at 4 hours and 62.32pg/ml ± 1.42 at 24 hours (Fig.6.2). 
Daidzein treatment reduced RANKL production to 42.76pg/ml ± 0.87 at 2 
hours, 48.33pg/ml ± 3.51 at 4 hours and 65.41pg/ml ± 1.42 at 24 hours 
(Fig.6.3) and in treatment with Resveratrol was 41.46pg/ml ± 2.21 at 2 hours, 
45.61pg/ml ± 3.51 at 4 hours and 67.04pg/ml ± 1.52 at 24 hours (Fig. 6.4). 
 
153 
 
 
 
Figure 6.1: Effect of E2 on the levels of RANKL production in MLO-Y4 cells for dif-
ferent time. Cells were treated with E2 for one hour prior to treatment with H
2
O
2
 for (2, 4 
and 24 hours). Media were collected and the concentration of RANKL was measured by 
ELISA. The levels of RANKL in cells treated with H
2
O
2
 was high at all hours, but lower in 
cells treated with E2 and * p< 0.05 versus H2O2, # versus control, n=3. 
Figure 6.2: Effect of Genstein on the levels of RANKL production in MLO-Y4 cells 
for different time. Cells were treated with Genstein for one hour prior to treatment with 
H
2
O
2
 for (2, 4 and 24 hours). Media were collected and the concentration of RANKL was 
measured by ELISA. The levels of RANKL in cells treated with H
2
O
2
 was high at all 
hours, but lower in cells treated with Gen and * p < 0.05 versus H2O2, # versus control, 
n=3. 
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Figure 6.4: Effect of Resveratrol on the levels of RANKL production in MLO-Y4 cells 
for different time. Cells were treated with Resveratrol for one hour prior to treatment with 
H
2
O
2
 for (2, 4 and 24 hours).  Media were collected and the concentration of RANKL was 
measured by ELISA. The levels of RANKL in cells treated with H
2
O
2
 was high at all 
hours, but lower in cells treated with Resv. and * p < 0.05 versus H2O2, # versus control, 
n=3. 
Figure 6.3: Effect of Daidzein on the levels of RANKL production in MLO-Y4 cells 
for different time. Cells were treated with Daidzein for one hour prior to treatment with 
H
2
O
2
 for (2, 4 and 24 hours). Media were collected and the concentration of RANKL was 
measured by ELISA. The levels of RANKL in cells treated with H
2
O
2
 was high at all 
hours, but lower in cells treated with Daidzein and * p < 0.05 versus H2O2, # versus con-
trol, n=3. 
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6.3 Measurement of TNF-α release 
MLO-Y4 cells were seeded in 24-well plates at density of 3x104 cells per well 
for 24 hours and treated with E2 , Genistein, Daidzein and Resveratrol  as 
previously described in section 2.2.14.  TNF- assay was performed with 
ELISA kit from (Biolegend) according to the manufacturer’s instructions.  The 
values were expressed as a total expression of TNF- concentration in pg/ml 
expressed relative to control.  The amount of TNF- was measured in MLO-
Y4 cells after treatment with E2 and PEs prior to treatment with H2O2 for 2, 4 
and 24 hours.  H2O2 increased the level of TNF-protein in the culture medi-
um of MLO-Y4 cells.  TNF- level in the supernatant from cells cultured with 
H2O2 was 136.60 pg/ml ± 2.06 vs. control (50.69pg/ml ± 2.1, p=0.0001) at 2 
hours, (140.60pg/ml ± 3.21 vs. control 54.17pg/ml ± 1.5, p=0.0001) at 4 
 
 
2 hours 4 hours 24 hours 
Control 
 
9.6pg/ml ± 1.5 10.5pg/ml ± 0.40 8.3pg/ml ± 0.5 
H2O2 
 
70pg/ml ± 5 80.3pg/ml ± 2.51                 102.5pg/ml ± 1.52 
E2 
 
30pg/ml ± 4.5 44.33pg/ml ± 2.08               55.6pg/ml ± 0.86     
Genistein 
 
41.5pg/ml ± 3.12 52.60pg/ml ± 5.03 62.32pg/ml ± 1.42 
Daidzein 
 
42.76pg/ml ± 0.87 48.33pg/ml ± 3.51 67.04pg/ml ± 1.42 
Resveratrol 
 
41.46pg/ml ± 2.21 45.61pg/ml ± 3.51 65.33pg/ml ± 1.52 
Table 6.1: Concentration of RANKL released in MLO-Y4 cells in response to H2O2 in 
presence and absence of E2 and PEs (Genistein, daidzein and Resveratrol). 
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hours and (187.55 pg/ml ± 2.43 vs. control 60.36pg/ml ± 1.7, p=0.001) at 24 
hours.  While treatment with E2 decreased the level of TNF-release in 
MLO-Y4 cells to (94.62pg/ml ± 1.05, p=0.0001) at 2 hours, (74.16pg/ml ± 
3.12, p=0.0001) at 4 hours and 108.61pg/ml ± 2.10, p=0.0005) at 24 hours 
(Fig.6.5).  Also treatment with Genistein prior to H2O2 treatment reduced 
TNF- level in MLO-Y4 cells (58.67pg/ml ± 0.91, p=0.0001) at 2 hours, 
(89.62pg/ml ± 2.33) at 4 hours and (98.61pg/ml ± 1.99, p=0.0001) at 24 
hours (Fig.6.6), while TNF- levels after  Daidzein treatment was 79.65 pg/ml 
± 0.91, p=0.0001 at 2 hours, 79.65pg/ml ± 3.2, p=0.0001) at 4 hours and 
(105.62pg/ml ± 2, p=0.0001) at 24 hours (Fig.6.7).  Resveratrol treatment al-
so reduced TNF- levels to (81.15pg/ml ± 2.07, p=0.0001) at 2 hours, 
(93.79pg/ml ± 3.07, p=0.0001) at 4 hours and (127.61pg/ml ± 4.81, p=0.0001) 
at 24 hours (Fig.6.8).  
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Figure 6.5: Effect of E2 on the levels of TNF-α production in MLO-Y4 cells for 
different time. Cells were treated with E2 for one hour prior to treatment with H
2
O
2
 
for (2, 4 and 24 hours).  Media were collected and the concentration of TNF-α was 
measured by ELISA.  The levels of TNF-α in cells treated with H
2
O
2
 was high at all 
hours, but lower in cells treated with E2 and * p< 0.05 versus H2O2, # versus con-
trol, n=3 
Figure 6.6: Effect of Genistein on the levels of TNF-α production in MLO-Y4 
cells for different time. Cells were treated with Genistein for one hour prior to 
treatment with H
2
O
2
 for (2, 4 and 24 hours). Media were collected and the concen-
tration of TNF-α was measured by ELISA.  The levels of TNF-α in cells treated with 
H
2
O
2
 was high at all hours, but lower in cells treated with E2 and * p < 0.05 versus 
H2O2, # versus control, n=3. 
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Figure 6.7: Effect of Daidzein on the levels of TNF-α production in MLO-Y4 cells for 
different time. Cells were treated with Daidzein for one hour prior to treatment with 
H
2
O
2
for (2, 4 and 24 hours). Media were collected and the concentration of TNF-α was 
measured byELISA. The levels of TNF-α in cells treated with H
2
O
2
 was high at all hours, 
but lower in cells treated with E2 and * p < 0.05 versus H2O2, # versus control, n=3. 
Figure 6.8: Effect of Resveratrol on the levels of TNF-α production in MLO-Y4 cells 
for ddifferent time. Cells were treated with Resveratrol for one hour prior to treatment 
with H
2
O
2
 for (2, 4 aand 24 hours). Media were collected and the concentration of TNF-α 
was measured by ELISA.  The lelevels of TNF-α in cells treated with H
2
O
2
 was high at all 
hours, but lower in cells treated with E2 and * p < 0.05 versus H2O2, # versus control, 
n=3. 
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 2 hours 4 hours 24 hours 
 
Control 
 
50.69pg/ml ± 2.06              54.17pg/ml ± 1.5               60.36pg /ml ± 1.7 
H2O2 
 
136.60pg/ml ± 2.06           140.60pg/ml ± 3.21             187.55pg/ml ± 2.43 
E2 
 
94.62pg/ml ± 1.05             74.16pg/ml ± 3.12              108.61pg/ml ± 2.10 
Genistein 
 
58.67pg/ml ± 0.91             89.62pg/ml ± 2.33              98.61pg/ml ± 1.99 
Daidzein 
 
79.65pg/ml ± 0.91            79.65pg/ml ± 3.2                105.62pg/ml ± 2 
Resveratrol 
 
81.15pg/ml ± 2.07             93.79pg/ml ± 3.07               127.61pg/ml ± 4.81 
 
 
6.4 Effect of PEs on IL-6 released in MLO-Y4 cells 
IL-6 release was measured in MLO-Y4 cells seeded in 24-well plates at den-
sity of 3x104 cells per well for 24 hours and treated with E2 and different PEs 
as previously mentioned in method chapter.  IL-6 assay was performed with 
ELISA kit from (Bio-legend) according to the manufacturer’s instructions.  
The values were expressed as the amount of IL-6 in pg/ml.  H2O2 increased 
the level of IL-6 protein in the culture medium of MLO-Y4 cells.  IL-6 level in 
cells cultured with H2O2 was (225.48pg/ml ± 4.7 vs. Control 110.38pg/ml ± 
13.7, p=0.0001) at 2 hours, (243.4pg/ml ± 2.5 vs. control 107.5pg/ml ± 6.3, 
p=0.0001) at 4 hours and (315.5pg/ml ± 5.3 vs. control 65.33pg/ml ± 1.5, p= 
0.0.0001) at 24 hours. While treatment with E2 decreased the level of IL-6 
release in MLO-Y4 (145.4pg/ml ± 6.7, p=0.0001) at 2 hours, (147.5pg/ml ± 
3.5, p=0.0001) at 4 hours and (184.50pg/ml ± 5.1, p=0.0001) at 24 hours 
(Fig.6.9).  Treatment with Genistein prior to H2O2 reduced IL-6 level in cells 
to (152.50pg/ml ± 3.88, p=0.0001) at 2 hours, (158.16pg/ml ± 3.36, p=0.0001) 
Table 6.2: Concentration of TNF-α released in MLO-Y4 cells in response to H2O2 in 
presence and absence of E2 and PEs (Genistein, daidzein and Resveratrol). 
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at 4 hours and (187pg/ml ± 8.08, p=0.0001) at 24 hours (Fig.6.10), also Dai-
dzein treatment reduced IL-6 concentration to (155.150pg/ml ± 3.88, 
p=0.0001) at 2 hours, (166.62pg/ml ± 3.36, p=0.0001) at 4 hours and 
(195.50pg/ml ± 5.19, p=0.0001) at 24 hours (Fig6.11) and Resveratrol de-
creased the level of IL-6 to (150.16pg/ml ± 5.88, p=0.0001) at 2 hours, 
(149.65pg/ml ± 2.05, p=0.0001) at 4 hours and (182.95pg/ml ± 3.05, 
p=0.0001) at 24 hours (Fig.6.12). 
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Figure 6.9: Effect of E2 on the levels of IL-6 production in MLO-Y4 cells for different 
time. Cells were treated with E2 for one hour prior to treatment with H
2
O
2
 for (2, 4 and 24 
hours).  Media were collected and the concentration of IL-6 was measured by ELISA.  
The levels of IL-6 in cells treated with H
2
O
2
 was high at all hours, but lower in cells treat-
ed with E2 and * p< 0.05 versus H2O2, # versus control, n=3. 
 
Figure 6.10: Effect of Genestein on the levels of IL-6 production in MLO-Y4 cells for 
different time. Cells were treated with Genistein for one hour prior to treatment with H
2
O
2
 
for (2, 4 and 24 hours). Media were collected and the concentration of IL-6 was measured 
by ELISA. The levels of IL-6 in cells treated with H
2
O
2
 was high at all hours, but lower in 
cells treated with E2 and * p < 0.05 versus H2O2, # versus control, n=3. 
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Figure 6.11: Effect of Daidzein on the levels of IL-6 production in MLO-Y4 cells for 
different time. Cells were treated with Daidzein for one hour prior to treatment with H
2
O
2
 
for (2, 4 and 24 hours). Media were collected and the concentration of IL-6 was measured 
by ELISA. The levels of IL-6 in cells treated with H
2
O
2
 was high at all hours, but lower in 
cells treated with E2 and * p < 0.05 versus H2O2, # versus control, n=3. 
Figure 6.12: Effect of Resveratrol on the levels of IL-6 production in MLO-Y4 cells 
for different time. Cells were treated with Resveratrolfor one hour prior to treatment with 
H
2
O
2
 for (2, 4 and 24 hours). Media were collected and the concentration of IL-6 was 
measured by ELISA. The levels of IL-6 in cells treated with H
2
O
2
 was high at all hours, 
but lower in cells treated with E2 and * p < 0.05 versus H2O2, # versus control, n=3. 
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2 hours 4 hours 24 hours 
Control 
 
110.38pg/ml ± 13.7     107.5pg/ml ± 6.3                    107.5pg/ml ± 6.3 
H2O2 
 
225.48pg/ml ± 4.7             243.4pg/ml ± 2.5                    315.5pg/ml ± 5.3 
E2 
 
145.4pg/ml ± 6.7               147.5pg/ml ± 3.5                     184.50pg/ml ± 5.1 
Genistein 
 
152.50pg/ml ± 3.88          158.16/ml ± 3.07            187pg/ml ± 8.08 
Daidzein 
 
155.150pg/ml ± 3.88         166.62pg/ml ± 3.36            195.50pg/ml ± 5.19 
 
Resveratrol 150.16pg/ml ± 5.88 149.65pg/ml ± 2.05              182.95pg/ml ± 3.05 
 
 
6.5 Discussion 
The role of oxidative stress on the release of cytokines in osteocytes was ex-
plored. Previous studies have documented increased oxidative stress partici-
pates in osteoporosis, induced by estrogen deficiency and ageing (Baek et 
al., 2010; Maggio et al., 2003).  The process of bone remodeling requires 
close communication and balance between osteoblasts and osteoclasts. Os-
teoblasts play an important role not only in bone formation but also work in 
conjunction with osteoclasts in the release of various bone resorbing cyto-
kines such as IL-6 and RANKL.  Receptor activator of nuclear factor (NFkB) 
ligand more commonly known as RANKL is a cytokine of tumor necrosis fac-
tor (TNF) family of proteins, which has been known to be vital in the trans-
duction of osteoclastogenesis (Lacey et al., 1998).  RANKL is highly ex-
pressed on osteoblasts, marrow stromal cells and T cells, and binds to the 
Table 6.3: Concentration of IL-6 released in MLO-Y4 cells in response to H2O2 in 
presence and absence of E2 and PEs (Genistein, daidzein and Resveratrol). 
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RANK receptor on osteoclast progenitor cells (Boyle et al., 2003).  Recent 
studies suggest that osteocytes including MLO-Y4 cells produce RANKL at a 
level 40 times higher in vitro than osteoblasts (Xiong et al., 2011, Nakashima 
et al., 2011, Zhao et al., 2002).  Osteoclastic differentiation and activation is 
known to be associated with the binding of RANKL and RANK resulting in the 
activation of nuclear factor-kB and c-jun N terminal protein kinase.  While, 
increased levels of ROS was found to stimulate RANKL mRNA and subse-
quent production of RANKL in human osteoblast-like MG63 cell line, primary 
bone marrow stromal cells (BMSCs) of mouse and calvarial osteoblasts.  
This suggests that accumulation of ROS in bone related diseases plays an 
important role through the stimulation of osteoclast differentiation and the ini-
tiating bone resorption (Bai et al., 2005).  Therefore, the development of 
therapies for the treatment of osteoporosis seems to be likely through the in-
hibition of RANKL (Gallagher and Sai, 2010).  
Soybean, which contains the active component of Genistein, a part of the 
Isoflavonoides, has been known to possess anti-inflammatory properties. 
Studies have documented the anti-inflammatory properties of Genistein, in 
which a reduction of inflammation in collagen induced RA in (CIA) rat model 
was observed.  For instance, it has been suggested that subcutaneous injec-
tion of Genistein exerts evident anti-inflammatory properties on CIA rats 
(Verdrengh et al., 2003).  Another study also reported the possibility for the 
use of Genistein in the treatment of RA-induced inflammation (Wang et al., 
2008).  PEs have been found to enhance or suppress immune response de-
pending on their concentrations.  The mechanism in which phytoestrogens 
elicit such a response is not well known, therefore further studies are re-
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quired to understand the underlying mechanisms involved.  Studies have 
demonstrated the ability of Genistein in reducing the production of IL-6, an 
inflammatory mediator in MH7A cells activated with TNF- α in vitro (Li et al., 
2014).  The anti-inflammatory properties of Genistein are known to be medi-
ated by the interruption of the ROS/Akt/NF-κB signaling pathway in MH7A 
cells which results in decreased production of TNF-α (Li et al., 2014). 
In this study, MLO-Y4 cells were pre-treated with PEs and then exposed to 
H2O2, then the effect of PEs on the production of IL-6, RANKL and TNF- α for 
2, 4 and 24 hours were investigated in which a significant decrease in level of 
cytokines were observed.  Studies have shown that ROS plays an important 
role in inducing inflammatory signals through Akt and NF-κB activation (Mor-
gan and Liu 2011, Asehnoune et al., 2004).  Furthermore, Genistein has 
been shown to reduce ROS by reducing the expression of ROS producing 
enzymes (Park et al., 2010).  A recent study has showed that Resveratrol 
treatment decreased in a dose- and time-dependent manner pro-
inflammatory cytokines, such as TNF- a and IL-6, induced in human peri-
oodontal ligament cells by gram negative bacteria (Rizzo et al., 2012). 
It has been assumed that the ROS-mediated activation of the PI3K/Akt path-
way is vital in the activation of NF-κB and the subsequent production of pro-
inflammatory cytokines.  On the other hand, in vitro studies have shown that 
phytoestrogens modulate osteoprotegerin (OPG)-receptor activator of nucle-
ar factor κB ligand (RANKL) system which indicates the vital role it plays in 
the process of bone remodeling (Yamagishi et al., 2001, Viereck et al., 2002).  
Isoflavones treatment have been shown to decrease the concentration of se-
rum cytokines such as IL-6 and TNF-α, known to be the main protein factors 
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responsive to the body’s immune system to regulate bone metabolism and 
play a key role in the maturation and differentiation of osteoblasts as well as 
the activation of osteoclasts.  These effects are worth same attention as 
treating bone disorders in post-menopausal women (Chi and Zhang 2013).   
In summary, during the manifestation of postmenopausal osteoporosis, the 
interaction of estrogen with bone cells has the ability to adjust the cytokine 
network, which regulates the formation of bone.  The sufficiency of estrogen 
limits the production of cytokines and maintains normal bone formation how-
ever, decreased levels of estrogen result in the loss of balance which not on-
ly leads to increased secretion of TNF-α and IL-6 in the bone marrow but al-
so disrupt the synergy between cell factors and therefore, result in the dis-
turbance of balance between osteoblasts and osteoclasts (Delmas et al., 
2000).  Furthermore, studies conducted suggest that the administration of 90 
mg/day isoflavone for a period of 6 months was correlated with decreased IL-
6 and TNF-α serum levels which suggests that soy isoflavone can prevent 
osteoporosis by decreasing IL-6 and TNF-α levels in the serum.  The cyto-
kine IL-6 is thought to be a prominent factor that contributes to bone loss in 
osteoporosis and structural damage in rheumatoid arthritis (Terauchi 2011., 
Jilka et al, 1992).  As a result, this has led to the development of anti-IL-6 re-
ceptor agents such as tocilizumab, which has been effectively used in pa-
tients suffering with moderate to severe rheumatoid arthritis (Agarwal 2011).  
In addition, it has been well established that the osteocytes play a critical role 
in bone remodeling.  Similarly, to osteoblasts, osteocytes are known to pro-
duce IL-6, however, higher levels of IL-6 are observed with apoptotic osteo-
cytes.  The production of IL-6 from apoptotic osteocytes is key step in the ini-
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tiation of bone remodeling by facilitating osteoclast precursors adhesion to 
endothelial cells (Cheung et al., 2012).  Moreover, previous studies showed, 
co-culture of MLO-Y4 cells with spleen or bone marrow derived precursor 
cells also promoted osteoclastogenesis in-vitro.  However, the effects seen 
were secondary to RANKL and M-CSF production (Zhao et al., 2002).  
Therefore, it is likely that the process of osteoclastogenesis is regulated by 
osteocytes via multiple pathways of which IL-6 plays a prominent role (Pe-
ruzzi et al., 2012).  Osteoclast activity is thought to be suppressed by both 
Genistein and Diadzein through a number of possible mechanisms such as 
induction of apoptosis, activation of protein tyrosine phosphatase, inhibition 
of cytokines, changes in intracellular Ca++, and membrane depolarization 
(Okamoto et al., 2001, Gao and Yamaguchi et al., 2000).  The mechanism 
through which PEs reduce cytokines expression is not known and could po-
tentially be meditated through several effects.  It could be caused by the anti-
oxidant action of PEs, which could modify the redox status and inhibit TNF-α 
secretion.  The effect of Genistein could also be mediated through its ability 
to suppress tyrosine kinase signalling which plays an important role in in-
flammation (Duan et al., 2003).  
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CHAPTER SEVEN: GENERAL DISCUSSION 
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7.1 Discussion 
Bone is a dynamic tissue that constantly maintains its integrity through bone 
remodelling cycle in response to changes in mechanical loading, serum cal-
cium and micro-damage.  Bone remodelling is dependent on the balanced 
activity of osteoclasts, osteoblasts and osteocytes.  Local and systemic fac-
tors orchestrate a balance between bone formation and resorption during 
normal remodelling (Weitzmann and Pacifici, 2005).  This balance is disrupt-
ed in many skeletal diseases including post-menopausal osteoporosis due to 
a decrease in the level of circulating E2, which is associated with decreased 
bone mass, and increased fracture risk.  E2 has been shown to regulate 
bone remodelling through several mechanisms, it can directly modify osteo-
clast life span via the modification of cytokine production by osteoblasts and 
immune cells can stimulate osteoclast formation and activity (Weitzmann and 
Pacifici  2006a).  
Several therapeutic agents have been developed to limit bone resorption in 
women after menopause such as HRT, which lowers the risk of vertebral and 
hip fracture in women (Barrett-Connor 1998) and decreases incidence of 
cardiovascular diseases (Collins 2002).  However, other studies suggested 
that HRT treatment has been shown to be associated with cardiovascular 
disease and cancer risk (Chlebowski et al., 2010).  PEs have been used as 
an alternative for HRT with fewer side effects and have beneficial effect on 
bone mass.  This was observed in Asian women with high consumption of 
PEs in comparison to Western populations, and have lower incidence of frac-
tures, breast cancer and cardiovascular disease (Peeters et al., 2003).  Epi-
demiological studies and associated meta-analyses strongly suggest that 
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long-term consumption of diets rich in plant polyphenols offer protection 
against development of numerous diseases including osteoporosis (Graf et 
al., 2005).  The positive action of PEs has been thought to be via the activity 
of different bone cells such as inhibition of osteocyte and osteoblast apopto-
sis and inhibition of osteoclast differentiation.  However, the molecular mech-
anism through which PEs act is not clear.  One potential mechanism is pro-
tecting osteocyte cells from oxidative stress through inhibition of ROS gener-
ation. 
 Chapter three results provide evidence that PEs directly suppress oxidative 
stress in MLO-Y4 cells induced by H2O2.  The data demonstrate that treat-
ment of MLO-Y4 cells with H2O2 induced oxidative stress resulted in cell 
death with morphological characteristics of apoptosis at a concentration of 
0.4mM.  Treatment of MLO-Y4 cells with E2 blocked H2O2 effects of apopto-
sis and reduced the level of apoptosis to that of control.  Previous studies 
have shown that, treatment of MLO-Y4 with H2O2 induced apoptotic cell 
death which was inhibited after pre-treatment with 17-estradiol at near physi-
ological concentrations 10nM ( Mann et al., 2007).  Estradiol is important in 
preventing the increase in osteocyte apoptosis engendered by OVX 
(Collishaw et al., 2004).  Similarly treatment of MLO-Y4 cells with Genistein, 
Daidzein and Resveratrol at a concentration of 10nM were found to block ox-
idant induced apoptosis with H2O2, which was evidenced by a range of 
methods such as morphology characterisation evidenced by DAPI staining 
and caspase activation.  Caspase activation is the common feature of apop-
tosis and this study, has shown that PEs influence caspase-3,-7 activation 
and the percentage of caspase positive cells was decreased significantly af-
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ter treatment with PEs in presence of H2O2.  It has been demonstrated that 
using pan-caspase inhibitor in vivo prevented both, the osteocyte apoptosis 
and the activation of new bone remodelling.  Therefore, osteocyte apoptosis 
plays a direct, and controlling role in the activation and targeting of a micro-
damage remodelling response  (Cardoso et al., 2009).   The identification of 
ROS in MLO-Y4 cells which was evidenced by the free radical indicator 
H2DCF-DA, has demonstrated that PEs were capable of blocking ROS gen-
erated in cells by H2O2.  Therefore, the effects of PEs were tested on ROS 
generation in MLO-Y4 cells and were found to inhibit ROS generation in 
these cells.  A range of PEs (Genistein, Daidzein and Resveratrol) were 
used which were able to reduce free radical production in MLO-Y4 as in the 
last decade, there has been much interest in the potential health benefits of 
these dietary PEs as antioxidant therapy.  In this study  knowledge about the 
effects of other polyphenols are presented in the context of relevance to hu-
man health e.g. Fucosterol and 6-gingerol.  There is less knowledge about 
these two phytomolecules in regard to their protective effects as antioxidants 
in MLO-Y4 cells. 
Osteoblast and osteoclast activity is tightly coupled during remodelling, such 
that bone resorption is linked to a subsequent formative phase. This coupling 
is lost in post-menopausal women, which contributes to bone loss.  This 
study examined the effect of PEs on osteoblast apoptosis induced by H2O2.  
Genistein, Daidzein and Resverartrol have the ability to inhibit apoptosis in-
duced by oxidative stress in osteoblast cells MC3T3-E1 evidenced with DAPI 
staining and assessment of ROS generation.  The effects of PES on osteo-
clast differentiation were investigated to establish their anti-osteoporotic ac-
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tivity.  Osteoclast differentiation from murine macrophage RAW 264.7 cells 
was induced by RANKL and M-CSF, which are essential for the differentia-
tion of monocytes/macrophages into osteoclasts. TRAP- 
positive multinucleated osteoclasts were visualized by light microscopy. 
RANKL treatment increased the induced osteoclast formation from RAW 
264.7 and increased TRAP positive cells, while treatment with PEs reduced 
the number of TRAP positive cells.  This result is consistent with previous 
studies which suggest that Soy phytoestrogen Genistein has been shown to 
enhance osteoblast differentiation and maturation and also inhibit osteoclast 
formation and bone resorption through inducing osteoclastogenic inhibitor 
OPG and blocking NF-kappaB signaling, whilst these effects are probably not 
mediated via estrogen receptors (Ming et al., 2013).  Resveratrol is also re-
ported as a potent inhibitor of osteoclast differentiation through controlling 
ROS generation (He et al., 2010).  
These results strengthen the data for the use of PEs as agents in the treat-
ment of post-menopausal bone loss and inflammatory osteolytic diseases 
where they may suppress RANKL-induced osteoclast formation. 
The mechanism of action of PEs on MLO-Y4 cells was investigated as to 
whether it had direct action or was directed via ER.  ERs inhibitor ICI 182780 
was used prior to treatment with PEs (Genistein, Daidzein and Resveratrol) 
and H2O2 to induce apoptosis.  Pre-treatment of MLO-Y4 cells with ICI 
182780 did not block the protective effect of PEs, which indicates that the ef-
fect of PEs is ER independent.  However, the incubation of cells with estro-
gen antagonist ICI 182780 alone also prevented apoptosis induced by H2O2. 
This study provided evidence that the ability of PEs to inhibit oxidant induced 
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apoptosis in HEK293 cell line which is negative for ER-α and ER-β indicated 
an estrogen receptor- independent mechanism of apoptosis blockade in cells 
exposed to oxidant attack.  
Regulation of antioxidant enzyme in cells is an important process that bal-
ances the generation and the abolition of reactive oxygen species.  Among 
the antioxidant enzymes, catalase is more important and eliminates hydrogen 
peroxide directly.  According to the results, catalase activity was higher in the 
H2O2 group, compared to the control group.  Treatment with PEs decreased 
the catalase activity, indicating a reduction in reactive oxygen species.  The 
prevention of oxidative stress induced apoptosis is thought to be through its 
direct activity and is related to the presence of C3-OH group.  Hence, the role 
of OH group on saving effect of PEs was investigated by modifying their 
structure, namely removing these groups,  to test their effect on oxidative 
stress induced by H2O2.   
The presence of free hydroxyl groups on the aromatic ring of Daidzein and 
Genistein was assumed to play significant roles in the antioxidant activity of 
PEs, owed to their ability in scavenging ROS.  Modification of the hydroxyl 
groups at positions 5 and 7 for Genisten or all the hydroxyl groups, endorsed 
the significant structural relationship and the activities of those functional 
groups within the biological system. The fluorescence intensity of H2DCFDA 
probe correlated negatively with the intensity of the ROS quenching by the 
hydroxyl groups.  The cellular fluorescence production of H2DCFDA gave 
clear evidence for the reduced capacity of the modified hydroxyl groups in 
ROS scavenging in MLO-Y4 cell line, as compared to original un-modified 
counterparts.  Modified Daidzein and Genistein did not protect MLO-Y4 cells 
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against apoptosis caused by H2O2 when they were compared with cells pre-
treated with H2O2, suggesting the important role of the hydroxyl groups in the 
protection of the cells from oxidative stress. This result is consistent with pre-
vious study which has reported that in most polyphenolic antioxidants, the 
number of OH groups substantially influence several mechanism of antioxi-
dant activity (Burda et al., 2001). 
ROS is assumed to mediate the activation of NF-κB and the subsequent pro-
duction of pro-inflammatory cytokines (RANKL, IL-6 and TNF- α).  Therefore, 
the level of these cytokines which have been thought to contribute to bone 
resorption were measured.  The results show that treatment with H2O2 in-
creased the level of RANKL, IL-6 and TNF- α in MLO-Y4 cells.  Treatment 
with E2 decreased the production of these cytokines, which was correlated 
with previous study that estrogen has been shown to modulate pro-
inflammatory cytokine activity (Pfeilschifter et al., 2002).  Withdrawal of es-
trogen is associated with increases in cytokine activity which support a link 
between the increased state of pro-inflammatory cytokine activity and post-
menopausal bone loss (Mundy 2007).  Earlier studies indicated that the pro-
inflammatory cytokines IL-6 and TNF-α are important regulators of bone re-
sorption and may play an important role in age- and estrogen deficiency-
related bone loss (McLean 2009).  Estrogen, as well as modulating the pro-
duction of pro-inflammatory cytokines known to stimulate osteoclastogenesis, 
also down-regulate RANKL-induced JNK activation (Srivastava et al., 2001). 
Therefore, the effect of PEs on cytokines release in MLO-Y4 cells was test-
ed.  E2, Genistein, Daidzein and Resveratrol significantly decreased the pro-
duction RANKL at 2,4 and 24 hours when compared with treatment with 
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H2O2, also decreasing the level of IL-6 production at 2, 4 and 24 hours.  TNF- 
α production was also decreased after treatment with PEs at 2, 4 and 24 
hours. 
In summary, this study has demonstrated that H2O2 induces production of cy-
tokines.  These responses together with recent knowledge on the connection 
between the saving effect of PEs on osteocyte apoptosis and initiation of 
bone resorption make it reasonable to suggest better treatment to control os-
teocytes apoptosis in diseases such as osteoporosis.  Genistein and Daidze-
in have been shown to protect bone in ovariectomized rodent models, and 
most likely have a similar effects in other mammalian species (Anderson and 
Garner 1998).  It has been reported that Genistein prevent loss of BMD in the 
rat model of ovaridectomy (Hooshmand et al.2010).  Isoflavone-containing 
soy intake was found to protect againt osteoporosis in addition to their pro-
tective effect against breast cancer and cardiovascular disease (Zittermann 
et al., 2004) 
In conclusion, this study provides important results regarding the mecha-
nisms by which PEs regulate bone cell activity and suggest that PEs-rich di-
ets may assist in the treatment of hormone-dependent disease.  They directly 
inhibit osteocyte and osteoblast apoptosis and also have an inhibitory effect 
on osteoclast formation.  Furthermore, PEs suppressed cytokine release in 
osteocyte cells in response to oxidative stress.  These results suggest that 
PEs may have a beneficial effect on skeletal health in post-menopausal os-
teoporosis and osteolytic inflammatory disorders such as rheumatoid arthritis.  
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7.2 Future work 
Several areas still need further investigation to elucidate the accurate effect 
of PEs on bone cell. PEs have multiple activities, therefore their beneficial 
effect is not completely understood. The most discussed side effect of HRT is 
the risk of developing breast cancer, therefore it would be  beneficial to inves-
tigate the effect of PEs on cancer cells to evaluate the effect of PEs on can-
cer cells proliferation.  The antioxidant activity of PEs could be identified by 
investigating the protein content of mitochondrial antioxidant enzymes, SODs 
and GPX.  Due to estrogen withdrawal, women are more prone to to develop 
neurodegenerative disorders such as Alzheimer’s disease, hence the possi-
ble beneficial effect of PEs on brain cells apoptosis and Caspase 3 activation 
could be investigated. 
 In-vivo mouse models of bone loss would increase the strength of the data 
and provide further enhancement of doses necessary to alter osteocytes and 
osteoblasts activity during normal and diseases-induced remodelling.  
The mechanism of action for isoflavones is still being investigated; it is clear 
from the many lines of evidence that there are probably multiple pathways, 
direct and indirect, that preserve the integrity and activity of bone cells to 
maintain stable bone mass in adults. As we found that the effect of PEs is ER 
independent, therefore it would be interesting to utilise ERα and ERβ-
knockout mice to confirm the mechanism of action of PEs. The presence of 
estrogen receptors in bone and the wide-ranging biological properties of 
these non-steroidal dietary estrogens provide a good foundation for thinking 
that dietary phytoestrogens could play a role in bone remodelling. 
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The immune system has an important role in post-menopausal and inflam-
matory bone loss and in this study, PEs have been found to reduce cytokines 
such as RANKL, IL-6 and TNF-α. Therefore, it would be interesting to inves-
tigate the effect of PEs on circulating levels of inflammatory cytokine produc-
tion in animal models of osteoporosis to identify the role of PEs on bone 
cells. 
In conclusion, further experiments to test for the potential beneficial effect of 
PEs on bone and immune cells are needed to understand the precise effect 
of these compounds on bone health,establish effective concentration ranges 
in-vivo and determine any risks associated with long-term use. 
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